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   Avant-propos
The DANONE INSTITUTE is an association of scientists, who are specialists in the 
field of nutrition.
Its objectives are as follows:
– to encourage research in the field of nutrition,
–  and to inform professionals in the areas of health and education about all matters 
related to foodstuffs.
The DANONE CHAIR contributes to this second objective, as it aims to highlight 
recent developments in the area of human nutrition. The chair was created in 1994 
and every year it is awarded to both a Flemish-language university and a French-
language university. Under their patronage, they organise instruction by Belgian or 
non-Belgian scholars. This course of instruction, which is aimed at nutrition specialists 
from a multidisciplinary background, comprises an introductory lecture followed by 
fifteen hours of course work. All conferences are contained in an integrated publication 
in a series of monographs, which are edited by the DANONE INSTITUTE.
Professor Philip CALDER of the Institute of Human Nutrition, School of Medicine 
of the University of Southampton (UK) was the holder of the Danone Chair awarded 
to the Université Libre de Bruxelles for the academic year 2003-2004. Inspired by his 
teaching, the work “Omega-3 Fatty Acids: The Good Oil?” complements the Danone 
Chair’s collection of monographs.
The DANONE INSTITUTE wishes to express its sincere gratitude to Professor Philip 
CALDER. The quality of the series of conferences was confirmed by the attendance of an 
attentive and enthusiastic audience. The monograph which was produced as a result 
of this will certainly answer many readers’ questions. The Institute would also like to 
express its gratitude to Ms Micheline POPULER for her valuable contribution to the 
compilation of this publication. Lastly, the DANONE INSTITUTE expresses its deep gratitude 
to the staff of the Université Libre de Bruxelles, and especially to Professor Yvon 
CARPENTIER.
Prof. Dr. Eng. Greet VANSANT   Dr. Daniel BRASSEUR
President of the     President of the
Scientific Council    Board of Directors
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   Foreword
XI
The Belgian Danone Institute has established since more than a decade 
what has already become an annual tradition, namely the organisation of two 
Chairs dispensed in Universities of the country. The purpose of the lessons 
given by a well recognized authority in the field of nutrition is to facilitate 
contacts between researchers, to educate students and update or brief future 
and active health care professionals. The Chair has indeed as main objective 
to contribute and facilitate the large diffusion of scientific knowledge amongst 
interested parties. Since nutrition covers a large domain of activities, the 
different Chairs have been focusing in the recent past on both fundamental 
aspects and practical approaches in a number of complementary fields such as 
microbiology, human physiology, clinical feeding techniques, food technology, 
human behaviour, consumer habits, malnutrition and other food related 
disorders…
During the academic year 2003-2004, the ‘Université Libre de Bruxelles’ 
was in charge of organising the Chair and setting up lessons proposed to 
potential participants.
Professor Philip Calder was nominated by the Faculty of Medicine for his 
impressive contributions and publications in nutrition. The work of PC Calder 
raised huge interest more particularly for his original approach in the domain 
of lipid disorders and immunomodulation. 
PC Calder was able to convincingly demonstrate that the impacts of 
different types of fatty acids influencing the immune responses in the body and 
several inflammatory reactions have important implications for the prevention 
and treatment of disease. 
Omega 3 polyunsaturated fatty acids (PUFA) eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) are found in high proportions in oily 
fish and fish oils. Typically, human inflammatory cells contain high proportions 
of the omega 6 PUFA arachidonic acid and low proportions of omega 3 PUFA. 
Feeding on fish oil results in the partial replacement of arachidonic acid in 
inflammatory cell membranes by EPA. This change leads to a decreased 
production of arachidonic acid-derived mediators. This response alone is a 
potentially beneficial anti-inflammatory effect of omega 3 PUFA. However, PC 
Calder was able to show in his work that omega 3 PUFA have a number of other 
effects which might occur downstream of altered eicosanoid production or 
might be independent of this activity. Fish oil feeding improves the symptoms 
in some animal models of chronic inflammatory disease and protects against 
the effects of endotoxin and similar inflammatory challenges. Clinical studies 
have reported that oral fish oil supplementation has interesting effects in 
rheumatoid arthritis and among some patients with asthma, supporting the 
idea that the omega 3 PUFA in fish oil are anti-inflammatory. Further there 
are indications that the inclusion of omega 3 PUFA in enteral formulas and 
parenteral solutions might be beneficial to patients in intensive care or post-
surgery.
This monograph offers a comprehensive summary of a number of 
studies conducted by PC Calder including core work performed by other 
authors allowing a larger understanding of human diseases and their potential 
relationships with food and feeding habits.
The author of this monograph has really been successful in summing up 
in a very understandable text what appears to be a complex field of ongoing 
investigations. The Danone Institute would like to express a special thank to 
PC Calder for accepting to draft and write this overview. 
Professor Yvon Carpentier as the local organizer of the Chair in Brussels 
is also warmly thanked for his kind collaboration and continuous support: 
he contributed to making a success of this Chair and to consolidating the 
recognition of the Institute in a field of excellence.
Last but not least the input of the team from the Institute Danone and 
the particular tribute of Mrs Fabienne Trinon should be acknowledged.
Many thanks to all and congratulation for the performance.
I am convinced that the readers will appreciate reading this 
monograph!
 
Daniel Brasseur
Chair, Management Board
Danone Institute Belgium
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   Summary
Fatty acids are the major component of dietary fat. Although dietary fat 
has long been considered as deleterious to human health, fatty acids play vital 
biochemical and physiological roles and some of the most important fatty 
acids must be obtained from the diet. Amongst these are the simplest 
polyunsaturated fatty acids (PUFAs), linoleic and α-linolenic, which cannot be 
synthesised by mammalian cells. Linoleic acid is an omega-6 (or n-6) PUFA and 
α-linolenic acid is an omega-3 (or n-3) PUFA. These two fatty acids and their 
derivatives play vital roles in cell membrane structure, integrity and function. 
In the absence of sufficient dietary intake of linoleic and α-linolenic acids 
deficiency symptoms occur, and so these two fatty acids are classed as 
essential fatty acids. However, it appears that at least some of the essential 
functions of linoleic acid and perhaps all of the essential functions of α-linoleic 
acid are due to their derivatives. These are synthesized by a series of fatty acid 
chain elongations and insertions of further double bonds (desaturations) that 
occur mainly in the liver. The major biologically important derivative of 
linoleic acid is arachidonic acid. The major biologically important derivatives 
of α-linolenic acid are eicosapentaenoic and docosahexaenoic acids (EPA and 
DHA, respectively). There is competition between linoleic and α-linolenic 
acids for metabolism to their longer chain, more unsaturated derivatives. 
Since most Western diets contain more linoleic acid than α-linolenic acid, the 
metabolism of the former predominates. Thus cell membranes typically 
contain a fairly high proportion of arachidonic acid (10 to 25% of fatty acids). 
One of its principal roles is to serve as a precursor of a family of bioactive 
mediators termed eicosanoids. Examples of these are prostaglandins, 
thromboxanes and leukotrienes. This family of mediators serves to regulate 
gastric acid secretion, smooth muscle contraction, body temperature, renal 
function, platelet aggregation, and inflammation amongst other responses. 
The main dietary source of the long chain n-3 PUFAs is oily fish and few other 
food sources contain substantial amounts of these fatty acids. Thus, in the 
absence of oily fish consumption, the amounts of EPA and DHA in cell 
membranes are relatively low and this is compounded by the limited 
conversion of α-linolenic acid. One functional effect of long chain n-3 PUFAs 
in cell membranes is that they limit metabolism of arachidonic acid to 
eicosanoids. It seems that having a relative imbalance of arachidonic acid and 
long chain n-3 PUFAs in cell membranes is not an ideal situation and may 
XV
result in a prothrombotic and proinflammatory state. Consumption of EPA 
and DHA from fish or from dietary supplements such as fish oils results in the 
appearance of those fatty acids in cell membranes in a time- and dose-
dependent manner. This results in modulation of those cell and tissue 
responses regulated by arachidonic acid-derived eicosanoids. Long chain n-3 
PUFAs have other effects on cellular function such as altering the activity of 
membrane receptors and transporters and altering gene expression. Through 
these effects these fatty acids alter the activity of cells, tissues and organs in a 
way that appears to result in improvement in human health. In accordance 
with this, low intake or low status of long chain n-3 PUFAs is associated with 
increased risk of cardiovascular disease and of some cancers, and perhaps of 
childhood developmental disorders, adult psychiatric and psychological 
disorders, and neurodegenerative diseases of ageing. It is clear that, via effects 
on a range of risk factors, consumption of long chain n-3 PUFAs lowers the 
likelihood of developing cardiovascular disease and protects against mortality 
from myocardial infarction. These fatty acids also exert anti-inflammatory 
actions that make them useful as therapeutic agents in diseases with an 
inflammatory component. They seem to be very efficacious in rheumatoid 
arthritis. An emerging role of long chain n-3 PUFAs is in patients receiving 
artificial nutrition because of surgery or critical illness, where they appear to 
modulate the metabolic, inflammatory and immune responses that are 
associated with poor outcome in some patients. Long chain n-3 fatty acids 
have special roles in the brain and visual systems. There is a very high content 
of DHA in grey matter of the brain and in the outer segment of the retinal 
rods. DHA is accumulated into these regions early in life and a supply from the 
mother in utero and during the suckling period appears to be very important 
in determining optimal DHA accumulation and optimal brain and visual 
function. Inclusion of DHA in formula for pre-term infants has been shown to 
result in better visual function. The same may be true for term infants but the 
evidence is less clear. There is some evidence that early supply of DHA 
improves cognitive and intellectual development in children, although the 
effects may not be long lasting. Emerging data suggests that long chain n-3 
PUFAs may be beneficial in childhood developmental disorders, adult 
psychiatric and psychological disorders and neurodegenerative diseases of 
ageing. Thus, long chain n-3 PUFAs appear to be associated with improved 
health and well-being right across the life cycle. Although it is evident that 
increased intake of these fatty acids should be encouraged in various 
population groups, it is clear that greater scientific evidence of protective 
effects is required in a number of conditions. 
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 1 –    Fatty acids: Structure, 
nomenclature,    
biosynthesis, sources, 
intakes
1-1  Fatty acids
- structure and nomenclature
The general structure of a fatty acid is a hydrocarbon chain with a carboxyl 
group at one end and a methyl group at the other (Figure 1.1). The carboxyl group is 
reactive and readily forms ester links with alcohol groups for example those 
on glycerol or cholesterol, in turn forming acylglycerols (e.g. triacylglycerols,
1
Figure 1.1  —  General features of fatty acid structure.
H3C
COOH
phospholipids), and cholesteryl esters (Figure 1.2). Traditionally, the carbon of 
the carboxyl group is called carbon 1 with carbon 2 being referred to as the α 
carbon and the methyl terminal carbon as the ω (sometimes called n) carbon 
(Figure 1.1). The most abundant fatty acids have straight chains of an even 
number of carbon atoms, although branched chain, odd-numbered and 
substituted fatty acids do exist.  Fatty acid chain lengths vary from 2 to 30 
carbons or more and the chain may contain double bonds. Fatty acids 
containing double bonds in the acyl chain are referred to as unsaturated fatty 
acids; a fatty acid containing two or more double bonds is called a 
polyunsaturated fatty acid (PUFA). Saturated fatty acids do not contain double 
bonds in the acyl chain. 
The systematic name for a fatty acid is determined simply by the number of 
carbons in the acyl chain. For example an eight carbon fatty acid (with no double 
bonds in the acyl chain) is termed octanoic acid while an eighteen carbon fatty acid 
(with no double bonds in the acyl chain) is termed octadecanoic acid. However, 
complications arise for the naming of unsaturated fatty acids. This is because there 
are multiple possibilities for the position of double bonds within the hydrocarbon 
chain and because each double bond may be in the cis or trans configuration. 
Therefore, when naming an unsaturated fatty acid it is important that the exact 2
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Figure 1.2  —   Structures of triacylglycerols, phospholipids and cholesteryl esters.
R, R1, R2 and R3 signify fatty acyl chains.
positions of double bonds and their configurations be clearly identified. Traditionally, 
the position of double bonds was identified by naming the carbon number (from 
carbon 1 (the carboxyl carbon)) on which each double bond occurs. Thus, 
octadecadienoic acid, an 18-carbon fatty acid with cis double bonds between 
carbons 9 and 10 and carbons 12 and 13 is correctly denoted as cis 9, cis 
12-octadecadienoic acid or as cis, cis, 9,12-octadecadienoic acid. More recently, an 
alternative shorthand notation for fatty acids has come into frequent use. This relies 
upon identifying the number of carbon atoms in the chain, the number of double 
bonds and their position. Thus, octadecanoic acid is notated as 18:0, indicating that 
it has an acyl chain of 18 carbons and does not contain any double bonds. 
Unsaturated fatty acids are named simply by identifying the number of double 
bonds and the position of the first double bond counted from the methyl terminus 
(with the methyl, or ω, carbon as number 1) of the acyl chain. The way the first 
double bond is identified is as ω-x, where x is the carbon number on which the 
double bond occurs. Therefore cis, cis, 9,12-octadecadienoic acid is also known as 
18:2ω-6. The ω-x nomenclature is sometimes referred to as omega x (e.g. 18:2 omega 
6) or n-x (e.g. 18:2n-6). In addition to these nomenclatures, fatty acids are often 
described by their common names. Table 1.1 lists a range of fatty acids and shows 
the different ways in which they are named. In most PUFAs the double bonds are 
separated by a methylene (-CH2-) group. Figure 1.3 shows the structure of several 3
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Figure 1.3  —  Structures and naming of a selection of 18 carbon fatty acids.
Octadecanoic acid 18:0
Stearic
cis 9, cis 12, cis 15-Octadecatrienoic acid
Δ9, 12, 15-Octadecatrienoic acid 18:3n-3
α-Linolenic acid
cis 9, cis 12-Octadecadienoic acid
Δ9, 12-Octadecadienoic acid  18:2n-6
Linolenic acid
cis 9-Octadecenoic acid
Δ9-Octadecenoic acid  18:1n-9
Oleic acid
18-carbon fatty acids indicating the position of the double bonds in the chain and 
how this is reflected in their naming. Note that most common unsaturated fatty 
acids contain cis rather than trans double bonds. Cis, but not trans, double bonds 
produce a kink in the molecule so that the molecular shape of unsaturated fatty 
acids containing cis double bonds is distinct from that of saturated fatty acids. 
4
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Table 1.1  —   Fatty acid nomenclature. 
Systematic name Trivial name Shorthand Melting 
  notation point (oC) 
Ethanoic Acetic 2:0  
Propanoic Propionic 3:0  
Butanoic Butyric 4:0  
Hexanoic Caproic 6:0 -8 
Octanoic Caprylic 8:0 13 
Decanoic Capric 10:0 30 
Dodecanoic Lauric 12:0 42 
Tetradecanoic Myrsitic 14:0 52 
Hexadecanoic Palmitic 16:0 61 
Octadecanoic Stearic 18:0 70 
cis 9-Hexadecenoic Palmitoleic 16:1n-7  
cis 9-Octadecenoic Oleic 18:1n-9 16 
cis 9, cis 12 -Octadecadienoic Linoleic 18:2n-6 -5 
All cis 9, 12, 15 -Octadecatrienoic α-Linolenic 18:3n-3 -11
All cis 6, 9, 12 -Octadecatrienoic γ-Linolenic 18:3n-6
All cis 11, 14, 17 -Eicosatrienoic Mead 20:3n-9
All cis 8, 11, 14 -Eicosatrienoic Dihomo-γ-linolenic 20:3n-6
All cis 5, 8, 11,
14 -Eicosatetraenoic Arachidonic 20:4n-6 -50
All cis 5, 8, 11, 14,
17-Eicosapentaenoic Eicosapentaenoic 20:5n-3 -54 
All cis 7, 10, 13, 16,
19-Docosapentaenoic Docosapentaenoic 22:5n-3
All cis 4, 7, 10, 13, 16, 19
-Docosahexaenoic Docosahexaenoic 22:6n-3 -44
The chain length and degree of unsaturation of a fatty acid are what 
determines its melting point. Increasing chain length tends to increase 
melting point while increasing unsaturation decreases it (Table 1.1). It is the 
nature of the constituent fatty acids that gives fat its physical properties. Thus, 
fats that are rich in saturated fatty acids (e.g. butter, lard) are solid at room 
temperature, whereas fats that are rich in unsaturated fatty acids (e.g. olive oil, 
sunflower oil) are liquid at room temperature.
1-2 Fatty acid biosynthesis 
Saturated fatty acids are built up by successive addition of 2-carbon units to a 
growing acyl chain [GURR et al., 2002]. The principal product of fatty acid synthesis (i.e. 
the fatty acid that is finally released from the growing acyl chain) is generally 
considered to be palmitic acid (16:0). Longer chain fatty acids are formed from palmitic 
acid by elongation reactions (the enzymes catalysing these are termed elongases). 
Elongation converts palmitic acid to stearic acid (18:0). The endoplasmic reticulum is 
a site for introduction of double bonds («desaturation») into fatty acids. Insertion of a 
cis double bond between carbons 9 and 10 of stearic acid (18:0) results in oleic 
acid (18:1n-9). Because the double bond is inserted between carbons 9 and 10 
counting from the carboxyl end of the acyl chain, the desaturase enzyme is 
known as delta-9 desaturase (Δ9-desaturase), although sometimes this enzyme 
is referred to as stearoyl CoA desaturase because the substrate is the 
coenzyme A ester of stearic acid. 
Further desaturation of oleic acid produces PUFAs. Plant enzymes 
normally introduce a new double bond between an existing double bond and 
the terminal methyl group, whereas animal enzymes normally introduce a 
new double bond between an existing double bond and the carboxyl group. 
Insertion of a double bond between carbons 12 and 13 (counted from the 
carboxyl carbon) of oleic acid yields linoleic acid (18:2n-6). The enzyme that 
catalyses this reaction is called Δ12-desaturase (Figure 1.4). Linoleic acid can 
be further desaturated by insertion of a double bond between carbons 15 and 
16 (counted from the carboxyl carbon) by Δ15-desaturase to yield α-linolenic 
acid (18:3n-3) (Figure 1.4). Linoleic and α-linolenic acids are the simplest 
members of the n-6 and n-3 families of fatty acids, respectively. As indicated 
above, mammals lack the enzymes that introduce double bonds at carbon 
atoms beyond carbon 9 in the acyl chain (counting from the carboxyl carbon). 
Because these include the Δ12-and Δ15-desaturases, this means that mammals 
cannot synthesise linoleic and α-linolenic acids. Since these fatty acids are 
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required by mammalian cells, they are termed essential fatty acids, and there 
is a need for their consumption in the diet. 
Although mammalian cells cannot synthesise linoleic and α-linolenic 
acids, they can metabolise them by further desaturation and elongation; 
desaturation occurs at carbon atoms below carbon number 9 (counting from 
the carboxyl carbon). Linoleic acid can be converted to γ-linolenic (18:3n-6) by 
Δ6-desaturase and then γ-linolenic can be elongated to dihomo-γ-linolenic 
(20:3n-6) acid (Figure 1.5). Dihomo-γ-linolenic can be further desaturated by 
Δ5-desaturase to yield arachidonic acid (20:4n-6). Using the same series of 
enzymes as used to metabolise n-6 PUFA, α-linolenic acid is converted to 
eicosapentaenoic acid (20:5n-3; EPA). In mammals the pathway of desaturation 
and elongation occurs mainly in the liver.
It is evident from the pathway shown in Figure 1.5 that there is competition 
between the n-6 and n-3 fatty acid families for metabolism. The Δ6-desaturase 
reaction is rate limiting in this pathway [SPRECHER, 2000]. The preferred substrate for 
Δ6-desaturase is α-linolenic acid [SPRECHER, 2000]. However, because linoleic acid is 
much more prevalent in most human diets than α-linolenic acid (see section 1-4), 
metabolism of n-6 fatty acids is quantitatively the more important. In the absence of 
6
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Figure 1.4  —  Pathway of conversion of oleic acid to linoleic and α-linolenic acids.
H3C COOH
H3C
COOH
H3C COOH
Oleic acid (18:1 n-9)
Linoleic acid (18:2 n-6)
α-Linolenic acid (18:3 n-3)
Δ12-desaturase
Δ15-desaturase
intake of linoleic and α-linolenic acids, metabolism of oleic acid by this pathway is 
enhanced resulting in accumulation of mead acid (20:3n-9), which is normally only 
found in tissues in trace amounts. Appearance and accumulation of mead acid is 
taken to indicate dietary essential fatty acid deficiency. The activities of Δ6- and 
Δ5-desaturases are regulated by nutritional status, hormones and by feedback 
inhibition by end products [British Nutrition Foundation, 1992].
A pathway for further conversion of EPA to docosahexaenoic acid 
(22:6n-3; DHA) exists and this involves addition of 2 carbons to form 
docosapentaenoic acid (22:5n-3), 2 further carbons to produce 24:5n-3 and 
desaturation at the Δ6 position to form 24:6n-3 [SPRECHER, 2000, 2002] (Figure 1.5). 
It is unclear whether the same enzyme is responsible for the initial, rate-
limiting desaturation at the Δ6 position and for the synthesis of 24:6n-3 [HARMON 
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Figure 1.5  –   Pathway of conversion of linoleic and α-linolenic acids to longer chain, more 
unsaturated fatty acids.
et al., 2003], although enzyme preparations with both activities have been 
reported [DE ANTUENO et al., 2001; D’ANDREA et al., 2002]. 24:6n-3 is translocated 
from the endoplasmic reticulum to peroxisomes where 2 carbons are removed 
by limited β-oxidation to yield DHA. Subsequent incorporation of DHA into 
complex lipids such as triacylglycerols and phospholipids requires transfer of 
DHA back to the endoplasmic reticulum. It has been suggested that the 
complex series of fatty acid translocation and β-oxidation steps may act as loci 
of metabolic control facilitating regulation of DHA synthesis independent from 
the up-stream activity of the pathway [SPRECHER, 2000, 2002]. EPA and DPA can 
also be synthesised from DHA by retro-conversion due to limited peroxisomal 
β-oxidation. Arachidonic acid can be metabolised by the same series of 
enzymes to yield, in turn, 22:4n-6, 24:4n-6, 24:5n-6 and 22:5n-6.
1-3  Dietary sources of fatty acids 
Fatty acids in fats, oils and foodstuffs are mainly esterified to glycerol, as 
triacylglycerols, although some are present as esterified components of 
phospholipids, glycolipids, and other lipids. The fatty acid composition of cow’s, 
sheep’s, and goat’s milks is typically characterised by relatively high proportions of 
short and medium chain saturated and monounsaturated fatty acids and low 
proportions of PUFAs. Ruminant milks also contain small quantities of a variety of 
trans, branched, or odd-numbered fatty acids. The proportions of different fatty 
acids in milks can be affected by the nature of the feed. While eggs are rich in 
palmitic and oleic acids, the phospholipid fraction of yolk provides linoleic acid and 
other PUFAs. Again different feeding regimens alter the fatty acid composition of 
eggs. Animal and poultry storage fats tend to be rich in saturated and monounsaturated 
fatty acids, but the muscle (i.e. meat) contains significant proportions of PUFAs. 
The fatty acid composition of lipids in plant membranes varies little between 
different types of leaves. Five fatty acids generally account for > 90% of total fatty 
acids: palmitic (ca. 13%), palmitoleic (ca. 3%), oleic (ca. 7%), linoleic (ca.16%) and 
α-linolenic (ca. 56%). Thus, green leaves are an important source of the essential 
fatty acid, α-linolenic acid. In contrast to the uniformity of the fatty acid composition 
of plant leaves, seed oils exhibit a wide range of fatty acid compositions (Table 1.2). 
Interestingly, in seed oils, one fatty acid often predominates, and seed oils are 
important sources of essential fatty acids. Some seed oils contain moderate to high 
proportions of relatively unusual fatty acids. For example, borage (starflower) and 
evening primrose oil contain γ-linolenic acid, and echium oil contains stearidonic 
8
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acid (18:4n-3). Older varieties of rapeseed oil contained nearly 60% erucic acid 
(22:1n-9) which was reported to be toxic. New varieties of rapeseed oil have had the 
erucic acid replaced by oleic acid through breeding. 
Fish can be classified into lean fish that store lipid as triacylglycerols in 
the liver (e.g. cod) or «fatty» («oily») fish that store lipid as triacylglycerols in 
the flesh (e.g. mackerel, herring, salmon, tuna). Compared with other 
foodstuffs, fish and other seafood are good sources of long chain n-3 PUFAs. 
However different types of fish contain different amounts of these fatty acids. 
This is partly dependent upon the metabolic characteristics of the fish and 
also upon their diet, water temperature, season etc. Recent studies have 
investigated the effect of changing the type of dietary oil fed to farmed salmon 
[BELL et al., 2001, 2002, 2003] and identify significant effects of this on long chain 
n-3 PUFA content of the flesh. 
The oil obtained from fatty fish flesh or lean fish livers is termed «fish 
oil» and it has the distinctive characteristic of being rich in long chain n-3 
PUFAs. Since different oily fish contain different amounts of n-3 PUFAs then so 
do fish oils. Note too that it is not only the amount of n-3 PUFAs that can vary 
between fish and fish oils, but also the relative proportions of the individual 
long chain n-3 PUFAs (EPA, DPA and DHA). EPA and DHA comprise 20% to 30% 
of the fatty acids in a typical preparation of fish oil, which means that a one 
gram fish oil capsule can provide 200 to 300 mg of EPA plus DHA. It should also 
be mentioned that fish oils contain fairly high proportions of palmitic and 
palmitoleic acids, and contain some arachidonic acid.    
1-4 Intakes of fatty acids by humans
Most fat consumed in the human diet (90 to 95%) is in the form of 
triacylglycerols, although the diet also contains phospholipids, glycolipids, other 
complex lipids, and cholesterol. Fatty acids are components of each of these 
structures apart from cholesterol, and so fatty acids form quantitatively the bulk of 
dietary fat. There are large differences in fat intake between countries with average 
intakes among adults varying from < 20 g/day in some developing countries to > 150 
g/day in some developed countries. The mix of fatty acids consumed also varies in 
accordance with the fatty acid compositions of the fats and oils used in food 
preparation and of the foodstuffs eaten. Average fat consumption has changed over 
time and continues to do so. These time trends differ between countries. In many 
developing countries fat intake is increasing, while in developed countries fat intake 
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has tended to decline over the last 40 years or so. For example, the average 
consumption of fat in United Kingdom fell from 110 to 86 g per person per day 
between 1959 and 1990 [British Nutrition Foundation, 1992]. The type of fat consumed 
has also changed over time, meaning that the fatty acid composition of the human 
diet has changed. For example, in the United Kingdom the consumption of saturated 
fatty acids as a percentage of food energy decreased from 20.3% in 1975 to 16.6% in 
1990 and to 13% in 2000 [Brit. Nutr. Found., 1992; HENDERSON et al., 2003]. In contrast 
the intake of PUFAs, especially linoleic acid, increased over this period [Brit. Nutr. 
Found., 1992; HENDERSON et al., 2003]. Much of this change has been brought about 
by a change in consumption from butter to margarine and from animal fats to 
vegetable oils. As a result the ratio of PUFAs to saturated fatty acids in the average 
United Kingdom diet has increased substantially over the last 40 years, more than 
doubling from 1970 (ratio = 0.2) and 2000 (ratio = 0.44). The main PUFA in the diet is 
linoleic acid followed by α-linolenic acid. On average, adult men in the United 
Kingdom consume about 13 and 2 g linoleic and α-linolenic acids, respectively, per 
day [HENDERSON et al., 2003]. Adult women in the United Kingdom consume about 9.5 
11
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Table 1.3  —   Consumption of linoleic and α-linolenic acids among adults in selected Western 
countries.
Fatty acid intake (g per day)
 Linoleic acid α-Linolenic acid
 Men Women Men Women
UK 13.0 9.5 2.0 1.5
Belgium 16.6 12.8 1.7 1.4
Denmark 12.0 9.0 2.2 2.1
France 8.3 6.8 0.6 0.5 
Germany 9.3 8.0 0.9 0.7 
Netherlands 19.0 13.2 1.7 1.2 
Italy* 14.5 0.8 
Spain* 21.6 0.8 
Australia* 9.9 1.2 
USA 16.0 11.0 2.0 1.0 
Canada - 11.2** - 1.6** 
*    Separate data are not available for men and women.
** Pregnant women.
Data for UK from HENDERSON et al., 2003; data for Australia from OLLIS et al., 1999; data for USA 
from KRIS-ETHERTON et al., 2000; data for Canada from INNIS, ELIAS, 2003; other data from HULSOF 
et al., 1999.
and 1.5 g linoleic and α-linolenic acids, respectively, per day [HENDERSON et al., 2003]. 
Table 1.3 provides details of intakes of linoleic and α-linolenic acids among seventeen 
Western countries and demonstrates that the ratio of linoleic to α-linolenic acids 
varies from between 5 to greater than 20 amongst these countries. 
Longer chain PUFAs are consumed in much lower amounts than linoleic 
and α-linolenic acids. However, intakes of longer chain PUFAs are difficult to 
identify precisely because these fatty acids are found in low amounts in many 
foods and because food composition databases frequently contain inadequate 
information about these fatty acids. Estimates of the intake of arachidonic acid 
intakes in Western populations vary between 50 and 300 mg/day for adults 
[SINCLAIR, O’DEA, 1993; JONNALAGADDA et al., 1995; MANN et al., 1995]. In the 
12
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 20:5n-3 22:5n-3 22:6n-3 Average  Total
    portion size long chain
    in UK n-3 PUFAs  
     per portion
Seafood or meat  g/100 g food  g g
Cod 0.08 0.01 0.16 120 0.30
Haddock 0.05 0.01 0.10 120 0.19
Plaice 0.16 0.04 0.10 130 0.39
Herring 0.51 0.11 0.69 120 1.56
Mackerel 0.71 0.12 1.10 160 3.09
Kippers 1.15 0.10 1.34 130 3.37
Salmon 0.50 0.40 1.30 100 2.20
Trout 0.23 0.09 0.83 230 2.65
Canned crab 0.47 0.08 0.45 85 0.85
Prawns 0.06 trace 0.04 60 0.06
Mussels 0.41 0.02 0.16 40 0.24
Roast beef 0.02 0.02 0 90 0.04
Roast lamb 0.03 0.04 0.02 90 0.08
Roast pork 0.01 0.02 0.01 90 0.04
Roast chicken 0.01 0.02 0.03 100 0.06
(light meat)
Venison 0.04 0.09 0 120 0.16
Data are from British Nutrition Foundation [1999].
Table 1.4  —  Intakes of long chain n-3 PUFAs from a single portion of seafood or meat.
absence of fatty fish or fish oil consumption, α-linolenic acid is by far the 
principal dietary n-3 PUFA. Table 1.4 gives data on the approximate intakes of 
long chain n-3 PUFAs from fish and some other foods available in the United 
Kingdom. The latest estimate for fish consumption among adults in the United 
Kingdom is approximately 100 g lean fish and approximately 50 g oily fish per 
week [Sci. Adv. Com. Nutr., 2004]. The most recent estimate for average intake 
of long chain n-3 PUFAs by adults in the United Kingdom is about 200 mg/day 
[Sci. Adv. Comm. Nutr., 2004].
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 2  –  Polyunsaturated fatty 
acids and cell membranes
2-1  Fatty acids
as membrane components 
Fatty acids have important roles in membrane structure and there are several 
ways by which fatty acids within cell membranes can potentially influence the 
functions of membrane proteins (and indeed some intracellular proteins). The fluid 
mosaic model of membrane structure describes biological membranes as dynamic 
bilayer structures involving lipids and proteins [SINGER, NICHOLSON, 1972] (Figure 2.1).
15
Figure 2.1  —  Cell membrane structure according to the “fluid mosaic model”.
It is now also recognized that domains exist in membranes, where lipid-protein and 
lipid-lipid interactions may be highly specific (see Section 2-2). There is great variety 
in the lipid content and constituents of membranes (Table 2.1). This is not surprising 
since different membranes perform different functions and so will require different 
structural characteristics. Glycerolipids are the most widespread of membrane lipids. 
In higher animals phosphoglycerides (these are usually called phospholipids) 
predominate. Phospholipids and glycosylglycerides both contain fatty acids esterified 
at the sn-1 and sn-2 positions of the glycerol backbone. In some membrane lipids fatty 
acids may be attached by ether, rather than ester, links. These so-called plasmalogens 
are especially abundant in nervous tissue, white blood cells and platelets. Membranes 
also contain sphingolipids, which are based on sphingosine rather than glycerol, and 
these also contain fatty acids or fatty acid derivatives as side chains. Examples of such 
structures are sphingomyelin and ceramide. Membranes are asymmetric i.e. the two 
layers of the bilayer differ from one another structurally. For example, in erythrocyte 
and hepatocyte membranes 80% of the phosphatidylcholine but < 15% of the 
phosphatidylethanolanine is in the outer leaflet [MATHEWS, VAN HOLDE, 1990].
The fatty acid compositions of membrane lipids are usually characteristic 
for the cell [GIBNEY, HUNTER, 1993], membrane type [STUBBS, SMITH, 1984] and 
also for the type of phospholipid [SPERLING et al., 1993]. However, the fatty acid 
16
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Table 2.1  —  Typical compositions of selected membranes.
Composition Erythrocyte Myelin Mitochondria
Component (% by weight)
Protein 49 18 52
Lipid 43 79 48
Component (% by weight of lipids)
Phosphatidylcholine 19 10 39
Phosphatidylethanolamine 18 20 27
Phosphatidylserine 8 8 < 1
Phosphatidylinositol 1 1 7
Sphingomyelin 18 9 0
Glycolipids 10 26 0
Cholesterol 25 26 3
Data are from MATHEWS, VAN HOLDE, 1990.
composition may change with the cell cycle, with age, or in response or to 
stimuli, to changes in the environment [STUBBS, SMITH, 1984] or diet (see 
Section 2-5). It is thought that these changes may have functional consequences 
(Figure 2.2). As many as 40 different fatty acids can be incorporated into the 
sn-1 or sn-2 positions of a phospholipid, but measurement of specific 
functional changes relating to such a diverse array of structural constituents is 
difficult and many measurements instead rely on bulk changes in membrane 
lipid structure and/or membrane function. Under normal conditions the 
membrane bilayer is in a «fluid» state, meaning that membrane proteins and 
lipids can migrate within the plane of the membrane [STUBBS, SMITH, 1984; 
BRENNER, 1984]. The fluidity of a membrane is strongly influenced by the fatty 
acid composition of its constituent lipids [STUBBS, SMITH, 1984; BRENNER, 1984; 
CALDER et al. 1994] (Figure 2.3). In turn, membrane fluidity may affect cell 
function [STUBBS, SMITH, 1984; BRENNER, 1984; CALDER et al. 1990, 1994]. This may 
be because fluidity, and hence protein movement, is required to establish 
appropriate interactions between proteins or between proteins and lipids. 
Often functional proteins require a specific lipid to provide a specific 
17
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Figure 2.2  —   General scheme of the interacting mechanisms whereby fatty acids might 
influence cell function.
microenvironment around hydrophobic regions. A number of membrane-
bound enzymes, transporters and receptors have been shown to be particularly 
sensitive to their fatty acid environments; these include adenylate cyclase, 5’ 
nucleotidase, the Na+/K+ ATPase, and the insulin receptor [see STUBBS, SMITH, 
1984; BRENNER, 1984; MURPHY, 1990 for reviews]. These observations suggest that 
changing the fatty acid composition of cell membranes may alter the function 
of membrane proteins and so may affect cell functions (Figure 2.2). 
18
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Figure 2.3  —   The relationship between fatty acid composition and membrane fluidity.
Rat T lymphocytes were cultured in the presence of various fatty acids. The fatty 
acid composition of the cell phospholipids was determined by gas chromatography 
and is summarised as “index of unsaturation”. The fluidity of the cells was 
determined by electron spin resonance (ESR) spectroscopy using a suitable spin-
labelled probe and is expressed as the order parameter. Data are from 
CALDER et al. [1994].
2-2 Fatty acylation of proteins
In addition to the non-covalent interactions between membrane lipids and 
proteins (see Section 2-1), proteins may be anchored into membranes via covalent 
attachment to lipids. If the lipids involved are fatty acids, this process is termed protein 
acylation (there are other types of lipid anchoring including prenylation and anchoring 
via glycosyl phosphatidylinositol). Myristic and palmitic acids are the predominant 
fatty acids found attached to proteins in eukaryotic cells [see SCHMIDT, 1989; MCILHINNEY, 
1990 for reviews]. Myristic acid is normally found attached to proteins by an amide 
bond to an N-terminal glycine and this attachment takes place as the protein is being 
synthesized. Generally, the attached myristic acid is stable and has a half-life similar to 
that of the protein to which it is bound. This contrasts with palmitic acid, which is 
attached to the protein post-translationally via an ester (usually thioester) linkage; 
palmitic acid can turn over much faster than the protein to which it is attached. The 
addition of myristic acid to a protein is catalyzed by a transferase enzyme (myristoyl-
CoA:protein N-myristoyl transferase) which exhibits a high level of specificity for 
myristoyl-CoA; in contrast the enzyme(s) which attaches palmitic acid to proteins is 
less specific and may also add myristic, stearic and oleic acids. Myristic and palmitic 
acids are attached to very distinct classes of protein, including protein kinases, 
receptors, G proteins and a number of oncogene products. These proteins appear 
targeted or anchored to specific regions of the plasma membrane, termed rafts. Rafts 
have a composition that is different from other regions of the membrane: they contain 
more lipid, more phospholipid and more cholesterol than the bulk plasma membrane 
[PIKE et al., 2002]. Rafts seem to function as foci for the generation of intracellular 
signals in response to extracellular stimuli. Lipid rafts are rich in unsaturated fatty 
acids, especially arachidonic acid and DHA [PIKE et al., 2002], and they are considered 
to be more fluid than other regions of the membrane. Many proteins involved 
in cell signalling are located in lipid rafts [see BOWN, LONDON, 1998; SIMONS, 
TOMRE, 2000; PIKE, 2003 for reviews]. In simple terms, rafts can be viewed as 
signalling platforms that serve to co-localize the requisite components 
facilitating their interaction. Thus, receptors, coupling factors, effector 
enzymes and substrates are co-localized within a single raft. Signal transduction 
would occur rapidly and efficiently because of the spatial proximity of the 
various components involved. PIKE [2003] has recently reviewed current views 
of the structure, organization and function of rafts. 
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2-3 Fatty acids as eicosanoid 
precursors
One of the key functional roles of PUFAs is as precursors to eicosanoids. 
Eicosanoids are a family of bioactive mediators that are oxygenated derivatives of the 
20-carbon PUFAs dihomo-γ-linolenic, arachidonic and eicosapentaenoic acids. 
Eicosanoids include prostaglandins (PG) and thromboxanes (TX), which together are 
termed prostanoids, and leukotrienes (LT), lipoxins (LX), hydroperoxyeicosatetraenoic 
acids (HPETE) and hydroxyeicosatetraenoic acids (HETE). In most conditions the principal 
precursor for these compounds is arachidonic acid and the eicosanoids produced from 
arachidonic acid frequently have more potent biological functions than those produced 
from dihomo-γ-linolenic or eicosapentaenoic acids. The precursor PUFA is released from 
membrane phosphatidylcholine (PC) by the action of phospholipase A2 or from 
membrane phosphatidylinositol-4,5-bisphosphate (PIP2) by the actions of phospholipase 
C and a diacylglycerol (DAG) lipase (Figure 2.4). 
The pathways of eicosanoid synthesis begin with prostaglandin endoperoxide 
synthase, commonly known as cyclooxygenase (COX), which ultimately yields the PGs 
and TXs, or with the 5-, 12- or 15-lipoxygenases (LOX), which yield the LTs, HPETEs, 
HETEs and LXs (Figure 2.5). The amount and type of eicosanoids synthesized are 
determined by the availability of arachidonic acid and other precursors, by the 
activities of phospholipase A2 and phospholipase C, and by the activities of COX and 
LOX enzymes. 
COX enzymes have been found in every animal tissue and cell type 
examined with the exception of mature erythrocytes. Together with the 
hydroperoxidase which catalyses the next step in the pathway of prostanoid 
synthesis (Figure 2.5), COX forms part of the enzyme known as PGG/PGH 
synthase. There are two isoforms of COX: COX-1 is a constitutive enzyme and 
COX-2 is induced in cells as a result of stimulation (for example with inflammatory 
cytokines and growth factors) and is responsible for the markedly elevated 
production of prostanoids that occurs upon cellular activation. COX enzymes are 
localized in both the endoplasmic reticulum and the nuclear envelope. The major 
biologically active products of COX metabolism of arachidonic acid are considered 
to be PGD2, PGE2, PGI2 (prostacyclin), PGF2α and TXA2 (Table 2.2), although these 
are produced in a cell-specific manner. For example, platelets form mainly TXA2 
while endothelial cells form mainly PGI2. These compounds usually have a short 
half-life (of the order of seconds) and act locally to the cell from which they are 
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produced. Their production is initiated by a stimulus and, once produced, they 
themselves are able to modify the response to the stimulus. Different prostanoids 
have different, sometimes opposite, effects; for example, TXA2 increases platelet 
aggregation whereas PGI2 inhibits platelet aggregation (see Section 3-2-4). PGs are 
associated with the inflammatory response (see Section 5-2) and COX inhibitors 
include aspirin and related non-steroidal anti-inflammatory drugs. For a recent 
review of prostanoids see NICOLAOU [2004].
It appears that each of the LOX enzymes has a particular cellular distribution: 
5-LOX is found in mast cells, monocytes, macrophages and granulocytes, 12-LOX is 
found in platelets and some epithelial cells and 15-LOX is found in young myeloid 
cells and some epithelial cells. LTA4 is formed by 5-LOX activity on 5-HPETE (Figure 
2.5). Further metabolism (hydrolysis) of LTA4 yields LTB4. LTA4 is also metabolized to 
LTC4 via addition of a glutathione moiety. LTD4 and LTE4 are products of further 
metabolism of this glutathione moiety. Thus LTC4, D4 and E4 are known as the 
cysteinyl LTs. They are also collectively referred to as slow-reacting substance, the 
mediator of the slow but sustained contractile response in airways and gastrointestinal 
smooth muscle; this and other effects of LTs are listed in table 2.3. For a recent 
review of lipoxygenase metabolites see FIORE [2004].
Dihomo-γ-linolenic acid competes with arachidonic acid for COX and 
therefore decreases the production of COX products from arachidonic acid, 
whilst favoring the production of the 1-series PGs and TXs for which it is the 
precursor (e.g. PGE1 and TXA1; there is no PGI2 analogue formed from dihomo-
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Table 2.2  —  Actions of arachidonic acid-derived prostanoids.
 Regulates Receptor involved
PGD2 Sleep-wake cycle; Pain responses; Vasodilation; DP
 Vasoconstriction
PGE2 Gastric acid secretion; Vasoconstriction; EP1, EP2, EP3, EP4
 Vasodilation; Bronchiole relaxation;
 Uterine implantation; Uterine contraction;
 Pain responses; Temperature regulation;
 Inflammatory cytokine production;
 Immune function 
PGI2 Platelet aggregation; Vasodilation IP
PGF2α  FP
TXA2 Platelet aggregation; Smooth muscle contraction; TP
 Smooth muscle proliferation  
γ-linolenic acid). The prostanoids generated from dihomo-γ-linolenic acid 
have different (less potent) functional properties from those generated from 
arachidonic acid [HORROBIN, MANKU, 1990]. Dihomo-γ-linolenic acid is converted 
by 15-LOX to 15-hydroxy-dihomo-γ-linolenic acid, which can inhibit the 5-LOX 
activity. 
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Table 2.3  —  Actions of arachidonic acid-derived leukotrienes.
 LTB4 LTC4, D4 and E4
Produced by Neutrophils, macrophages Mast cells, basophils, eosinophils
Increases Leukocyte chemotaxis Vascular permeability
 Leukocyte adhesion Mucus secretion
 Leukocyte degranulation Smooth muscle proliferation
 Leukocyte oxidative burst Vasodilatation
 Inflammatory cytokine Vasoconstriction
 production 
  
Smooth muscle contraction
  (bronchospasm)
EPA competes with arachidonic acid for COX and LOX and therefore 
decreases the production of COX products from arachidonic acid, whilst 
favoring the production of the 3-series PGs and TXs and 5-series LTs for 
which it is the precursor (Figure 2.6). The prostanoids generated from EPA 
frequently have different (less potent) functional properties from those 
generated from arachidonic acid (see Sections 3-2-4 and 5-3). 
2-4 Fatty acids and cell signalling
In addition to their roles as precursors of regulatory eicosanoids, in 
membrane structure/fluidity/function and in the acylation of proteins involved 
in intracellular signalling, fatty acids may have other roles in signal transduction. 
Many lipids are involved directly in signalling pathways; for example hydrolysis 
of membrane phospholipids such as PIP2 and PC by phospholipases C and D 
generates second messengers such as DAG and phosphatidic acid (Figures 2.7 
and 2.8). Other phospholipids have roles in activating or stabilizing enzymes 
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Figure 2.7  —   Sites of action of phospholipase enzymes.
PL, phospholipase.
Figure 2.8  —   Generation of signalling molecules from membrane phospholipids.
IP3, inositol-2,4,5-trisphosphate; PC, phosphatidylcholine;
PIP2, phosphatidylinositol-4,5-bisphosphate; SM, sphingomyelin.
involved in intracellular signalling; for example phosphatidylserine (PS) is 
required for protein kinase C (PKC) activation. Since PIP2, PC, PS, phosphatidic 
acid and DAG all contain fatty acyl chains attached to the sn-1 and sn-2 positions 
of the glycerol moiety, it is conceivable that changing the type of fatty acid 
present may alter the precise properties of these compounds with regard to 
their functions in signal transduction. Indeed, KISHIMOTO et al. [1980] reported 
that PKC was more active with dioleoylglycerol and diarachidonoylglycerol than 
with diacylglycerols containing two saturated fatty acids or one saturated and 
one unsaturated fatty acid. BELL and SARGENT [1987] showed that the activity of rat 
spleen PKC differed in the presence of different combinations of PS and DAG 
each with differing fatty acid compositions. These observations suggest that the 
fatty acid composition of PS and DAG may affect the activity of PKC. In addition 
to the effects of fatty acids on intracellular signalling mechanisms due to 
changes in the fatty acid composition of the phospholipids which are involved, 
it has been proposed that fatty acids themselves may have a direct effect. This 
direct modulatory effect of fatty acids has been fairly extensively documented 
in relation to PKC, which has been shown to be regulated by oleic, linoleic, 
γ-linolenic, arachidonic, eicosapentaenoic and docosahexaenoic acids in 
different ways according to the precise environment [e.g. SPEIZER et al., 1991]. 
These observations are indicative that changes in fatty acid availability can affect 
the activity of cell signalling enzymes. More recently studies have shown that 
n-6 and n-3 PUFAs can differentially alter the expression and/or activities of 
other protein kinases involved in cell signalling pathways [e.g. LO et al., 2000; 
DENYS et al., 2001, 2002], and that this influences the activity of transcription 
factors such as nuclear factor κB (see Section 5-5). This is one mechanism by 
which these fatty acids can alter gene expression in various cell types.
In addition to influencing signalling pathways that converge on transcription 
factor activation, fatty acids appear to more directly affect the activity of a family of 
transcription factors called the peroxisomal proliferator-activated receptors (PPARs). 
PPARs belong to the steroid hormone receptor family. There are several isoforms of 
PPARs (Table 2.4). PPARs act by forming a heterodimer with the retinoic-X-
receptor (RXR), the ligand for which is cis-9-retinoic acid (Figure 2.9). PPAR-α 
is expressed mainly in the liver, and is involved in regulating hepatic responses 
to the availability of certain fatty acids, fatty acid metabolites and other 
peroxisome proliferators. Several key enzymes of β-oxidation and of 
lipoprotein metabolism have been shown to have PPAR-α-response elements 
in the 5’-upstream regulatory regions of their genes (Table 2.4) [SCHOONJANS et 
al., 1996]. Thus, a role for activation of PPAR-α may be to partition fatty acids 
towards hepatic oxidation. PPAR-γ is expressed mainly in adipose tissue and is 
involved in regulating adipocyte differentiation and in the regulating metabolic 
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responses of adipocytes. PPAR-γ is also expressed in inflammatory cells, and 
appears to be involved in regulation of production of inflammatory mediators 
(see Section 5-5). As with other steroid hormone receptors, PPARs are activated 
by non-covalent binding of ligands which promote alterations in transcription 
of genes containing PPAR response elements (Figure 2.9). An arachidonic acid 
derivative, 15-deoxy-Δ12,14-PGJ2, is a ligand for PPAR-γ [FORMAN et al., 1995; 
KLEIWER et al., 1995]. A number of years ago relatively high concentrations of 
several fatty acids including lauric, oleic, elaidic, linoleic, α-linolenic and 
arachidonic acids were shown to activate PPAR-α [GOTTLICHER et al., 1992], 
although it was not clear whether they did so by binding directly to PPAR or 
by being metabolized to one or more common ligands. More recent studies 
have demonstrated that certain fatty acids are ligands for PPARs. For example, 
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Table 2.4  —  Distribution and targets of PPAR isoforms.
Receptor Tissue distribution Target genes
PPAR-α Liver; Also kidney, heart, muscle, K Apo AI, Apo AII,
 brown adipose tissue Enzymes of peroxisomal
  fatty acid oxidation,
  Carnitine palmitoyl
  transferase,
  Enzymes of mitochondrial
  fatty acid oxidation,
  Liver FABP
  L Apo CII
PPAR-δ Widespread ?
(also known as 
PPAR-β
and FAAR)
PPAR-γ1 Widespread ?
PPAR-γ2 Adipose tissue K Factors involved
  in adipocyte differentiation,
  adipose tissue FABP
  (also known as aP2),
  lipoprotein lipase, FAT,
  acyl CoA synthase, GLUT4,
  phosphoenolpyruvate
  carboxykinase
  L Leptin  
Apo, apolipoprotein; FAAR, fatty acid activated receptor; FABP, fatty acid binding protein; 
FAT, fatty acid transporter; GLUT4, glucose transporter 4; PPAR, peroxisome proliferator-
activated receptor.
FORMAN et al. [1997] demonstrated that linoleic, α-linolenic, γ-linolenic, 
arachidonic, eicosapentaenoic and docosahexaenoic acids were ligands (and 
activators) of PPAR-α and -δ. In contrast, saturated fatty acids did not bind or 
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Figure 2.9  —   Generalised scheme for the mechanism of action of peroxisome proliferator 
activated receptors.
PPAR, peroxisome proliferator activated receptor; PPRE, PPAR response element; 
RXR, retinoic-X-receptor.
activate PPAR-α or -δ. Although FORMAN et al. [1997] reported that PUFAs were 
poor activators of PPAR-γ, another study found that oleic, linoleic, α-linolenic 
and arachidonic acids were effective ligands and activators for both PPAR-α 
and -γ [KLEIWER et al., 1997]. Thus, through activation of PPARs, fatty acids are 
able to regulate metabolism and other cell and tissue responses. This 
mechanism of action might explain some of physiological actions of certain 
fatty acids. For example, activation of PPAR-α by long chain n-3 PUFAs might 
explain the ability of these fatty acids to lower fasting plasma triacylglycerol 
concentrations (see Section 3-2-2), since this would partition fatty acids 
towards oxidation and away from incorporation into triacylglycerols. 
2-5  Fatty acid composition changes
as a result of increased intake
of long chain n-3 PUFAs 
Changes in the fatty acid composition of cultured cells according to the 
fatty acids to which they are exposed are readily demonstrated [ROSENTHAL, 
1987]. Such studies show that EPA and DHA are fairly easily incorporated into 
mammalian cells, at least in culture, and that their incorporation is partly at 
the expense of arachidonic acid [e.g. CALDER et al., 1990, 1994]. Feeding studies 
in laboratory animals confirm that long chain n-3 PUFAs are readily incorporated 
from the diet (e.g. from fish oil) into various cells and tissues and that this 
incorporation is associated with a reduction in arachidonic acid levels [e.g. 
YAQOOB et al., 1995a, 1995b]. Increased consumption of long chain n-3 PUFAs 
by humans results in appearance of those fatty acids in plasma lipids [1], 
platelets [2], erythrocytes [3], leukocytes [4], cardiac cells [HARRIS et al., 2004] 
and most likely in many other cell types [HOFFMAN et al., 1999; LUND et al., 1999; CONNOR 
et al., 2001]. Some studies report that EPA is preferentially incorporated into 
phosphatidylethanolamine and phosphatidylcholine in platelets and 
erythrocytes, with little incorporation into phosphatidylserine or 
phosphatidylinositol [GALLOWAY et al., 1985; VON SCHACKY et al., 1985; POPP-
SNIJDERS et al., 1986]. The incorporation of long chain n-3 PUFAs occurs in a 
dose-response fashion. For example, studies using a range of EPA+DHA 
intakes from 1 to 5 g/day reported near linear relationships between EPA 
intake and the EPA content of plasma phospholipids [HARRIS et al., 1991; MARSEN 
et al., 1992], while BLONK et al. [1990] reported linear relationships between 
intakes of EPA and DHA at 1.5, 3 and 6 g/day and the proportions of those fatty 
acids in plasma phospholipids in male volunteers. SANDERS and ROSHANAI [1983] 
demonstrated dose-dependent incorporation of EPA and DHA into platelet 
phospholipids in men consuming between 1.6 and 6.5 g EPA+DHA/day for 3 
weeks. In another study incorporation of EPA and DHA into neutrophils in 
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[1] VON SCHACKY et al., 1985; BLONK et al., 1990; HARRIS et al., 1991; MARSEN et al., 1992; KATAN et al., 1997; 
YAQOOB et al., 2000; OTTO et al., 2000.
[2] GOODNIGHT et al., 1981; SANDERS et al., 1981; GALLOWAY et al., 1985; VON SCHACKY et al., 1985.
[3] VON SCHACKY et al., 1985; POPP-SNIJDERS et al., 1986; KATAN et al., 1997; OTTO et al., 2000; YAQOOB et al., 2000; 
TREBBLE et al., 2003.
[4] LEE et al., 1985; ENDRES et al., 1989; GIBNEY, HUNTER, 1993; SPERLING et al., 1993; CAUGHEY et al., 1996; HEALY 
et al., 2000; YAQOOB et al., 2000. 
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Figure 2.10  —   Dose-dependent incorporation of eicosapentaenoic and docosahexaenoic 
acids into human neutrophils. 
Healthy young males supplemented their diet with differing amounts of EPA 
and DHA from tuna oil (in capsules) for a period of 12 weeks. Blood neutrophil 
phospholipids (PL) were isolated and their fatty acid composition determined 
by gas chromatography. Data are mean ± SEM from 8 subjects per dose, and are 
from HEALY et al. [2000].
healthy young males occurred in a linear dose response manner (Figure 2.10). 
In an elegant study combining dose-response and time-course over 12 months 
in older male subjects KATAN et al. [1997] reported the fatty acid compositions 
of serum cholesteryl esters, erythrocytes and adipose tissue. The results for 
EPA incorporation into serum cholesteryl esters and erythrocytes are shown 
in figure 2.11. This study confirmed that EPA and DHA are incorporated into 
circulating lipid pools and into erythrocytes when their intakes are increased. 
It also demonstrated EPA and DHA incorporation into adipose tissue, a storage 
pool, when their intake is increased. However it also clearly shows that 
incorporation into different pools occurs at different rates and to differing 
extents (i.e. with different efficiencies) and may not be related to intake in a 
strictly linear fashion, at least over the intakes studied. The study of KATAN et 
al. [1997] shows that near-maximal incorporation of EPA and DHA into serum 
cholesteryl esters occurs within 30 days of beginning supplementation, 
whereas maximal incorporation into erythrocytes does not occur until 
sometime between 56 and 182 days. YAQOOB et al. [2000] reported the time 
dependent incorporation of EPA and DHA into peripheral blood mononuclear 
cells, a mixture of lymphocytes and monocytes; incorporation of both fatty 
acids was near-maximal after 4 weeks of supplementation (Figure 2.12). Upon 
cessation of supplementation EPA in mononuclear cells returned to starting 
levels within 8 weeks, while the cells appeared to retain DHA (Figure 2.12). 
This is similar to the findings of POPP-SNIJDERS et al. [1986], who observed that 
erythrocyte EPA content returned to basal values eight weeks after stopping 
fish oil supplementation, whereas DHA remained elevated. The same 
observations of loss of EPA and selective retention of DHA upon cessation of 
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Figure 2.11  —   Dose- and time-dependent incorporation of eicosapentaenoic acid into human 
serum cholesteryl esters and erythrocytes. 
Healthy male subjects supplemented their diet with control capsules (no n-3 
fatty acids) or with fish oil capsules providing different amounts of EPA + DHA 
(1.35, 2.25 and 3.2 g/day) for a period of 12 months. Serum cholesteryl 
esters and erythrocytes were isolated and their fatty acid composition 
determined by gas chromatography. Data are mean values from 14 or 15 
subjects per dose and are from KATAN et al. [1997]. ■ indicates highest 
dose (2.5 g EPA + 0.7 g DHA/day), ▲ indicates medium dose (1.75 g EPA 
+ 0.5 g DHA/day); ● indicates lowest dose (1 g EPA + 0.35 g DHA/day);
❒ indicates control.
fish oil supplementation have been made for platelets [VON SCHACKY et al., 
1985]. Thus, a significant body of literature reports that EPA and DHA are 
incorporated into blood, cell and tissue lipids when their intake is increased. 
Given the roles of PUFAs in determining membrane structure and in regulating 
membrane protein-mediated responses, eicosanoid generation, cell signalling 
and transcription factor activity (Figure 2.2), it seems likely that increased 
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Figure 2.12  —   Time course of incorporation of eicosapentaenoic and docosahexaenoic acids 
into human mononuclear cells. 
Healthy subjects supplemented their diet with fish oil capsules providing 2.1 g 
EPA plus 1.1 g DHA per day for a period of 12 weeks (indicated by bar). Blood 
mononuclear cell phospholipids (PL) were isolated and their fatty acid 
composition determined by gas chromatography. Data are mean + SEM from 8 
subjects and are from YAQOOB et al. [2000].
incorporation of long chain n-3 PUFAs into cell membranes will impact on 
cellular responses (Figure 2.13) and thus on cell, tissue and organ responses 
in a way that influences human health (Figure 2.14).
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Figure 2.13  —   Representation of the mechanisms by which an increased supply of n-3 
polyunsaturated fatty acids could affect cell responses. 
NFκB, nuclear factor κB; PPAR, peroxisome proliferator activated receptors; 
PUFAs, polyunsaturated fatty acids; SREBP, sterol receptor element binding 
protein.
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 3  –  Long chain
n-3 fatty acids and   
 cardiovascular disease
3-1  Overview - atherosclerosis, 
cardiovascular disease,
and risk factors
Cardiovascular disease (CVD) includes:
– coronary heart disease (CHD), which may manifest itself clinically as stable angina, 
unstable angina, myocardial infarction (“heart attack”) or sudden death;
– stroke, which may be thrombotic or haemorrhagic;
– peripheral vascular disease, which occurs in the aorta, and the iliac and leg, 
but rarely the arm, arteries, and which may manifest itself as leg pain, 
especially, but not exclusively on effort.
CVD is the major cause of death in Western countries. In the United 
Kingdom in 1990, CHD accounted for 30% of male deaths and 23% of female 
deaths. Stroke accounted for a further 15% of female deaths and 9% of male 
deaths. Table 3.1 shows the age standardised mortality from CHD and stroke 
in European countries, the United States and Australia in 1989.  In addition to 
being the major cause of death, morbidity from CVD (incapacitation due to 
myocardial infarction, stroke or peripheral vascular disease, amputation of the 
lower limbs due to peripheral vascular disease etc.) and the need for surgical 
interventions (coronary artery bypass grafts, aortic aneurysm repair, carotid 
endarterectomy) and pharmacological interventions (aspirin, ACE inhibitors, 
β-blockers, statins) place an enormous burden on sufferers, their families, 
health services and society at large.
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The underlying basis of CVD is the combination of atherosclerosis and 
thrombosis. Atherosclerosis is the thickening of the arterial wall as the result of 
the accumulation of lipid, calcium, connective tissue and cellular material in the 
form of plaques. The plaques, or lesions as they are sometimes called, may occur 
throughout the vasculature, their presence being determined by blood flow 
characteristics and by stress to the vascular wall. They are commonly found at 
bends or branches in the vasculature. The series of events leading to atherosclerosis 
is still not fully known. Fatty streaks, containing lipid-filled macrophages within 
the artery wall, have been identified in children and are likely to be the precursors 
of mature atherosclerotic plaques. A key event leading to formation of fatty 
streaks and plaques is the entry of low density lipoprotein (LDL) into the arterial 
intima and its subsequent modification, usually oxidation, and recognition by 
scavenger receptors on macrophages [STEINBERG et al., 1989; WITZTUM, STEINBERG, 
1991]. The modified LDL is then taken up by the macrophages in an apparently 
poorly regulated process that results in the macrophages becoming lipid-laden 
[STEINBERG et al., 1989; WITZTUM, STEINBERG, 1991]. These lipid-laden macrophages are 
termed foam cells and their formation represents the sequestration of LDL lipids 
within the arterial wall. Oxidised LDL also acts as a chemoattractant for monocytes 
[BERLINER et al., 1990], which are not usually found in high numbers within the 
normal intima. These monocytes are the precursors of the differentiated 
macrophages involved in LDL modification and uptake (Figure 3.1). The 
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Table 3.1  —   Age-standardised mortality from coronary heart disease and stroke in various 
countries in 1989.
Country Mortality from CHD* Mortality from stroke*
Belgium 115 185
Denmark 250 180
France 170 165
Greece 100 140
Ireland 270 105
Italy 105 100
Luxembourg 130 120
Netherlands 140 180
Portugal 180 210
Spain 175 115
United Kingdom 225 100
Germany (West) 160 100
Australia 200 170
United States 180 150
*  standardized death rate per 100,000 population. Data are from Department of Health 
[1994].
development of the atherosclerotic plaque is characterised by the migration of 
smooth muscle cells from the media layer of the artery into the intima, or 
subendothelial space (Figure 3.2). Intimal smooth muscle cells may proliferate 
and can take up modified LDL. They also synthesise the extracellular matrix 
proteins that lead to development of the fibrous cap. Interactions between 
monocyte/macrophages and T-cells are also important in plaque development 
(Figure 3.2). Both necrosis and rupture occur within regions of the plaque as it 
grows, and the latter may serve as foci for thrombus formation, suggesting that 
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Figure 3.1  —   Initiating events in atherosclerosis. 
Low density lipoproteins (LDL) are subject to oxidative modifications in the 
subendothelial space, progressing from minimally modified LDL (mmLDL) to 
extensively oxidised LDL (oxLDL). Monocytes attach to endothelial cells that 
have been induced to express adhesion molecules by mmLDL and inflammatory 
cytokines. Adherent monocytes migrate into the subendothelial space and 
differentiate into macrophages. Uptake of oxLDL via scavenger receptors leads 
to foam cell formation. 
Reprinted from Cell, 2001; 104: 503-516, CK GLASS, JL WITZTUM, Atherosclerosis: The 
road ahead. Copyright, with permission from Elsevier.
cycles of rupture and healing thrombosis occur as plaques grow. Acute, 
unexpected and life-threatening coronary events (e.g. myocardial infarction) are 
characterised by acute thrombosis usually resulting from plaque rupture (Figure 
3.3). Such rupture exposes the plaque contents to the pro-thrombotic vessel 
lumen. Characteristics that make a plaque more vulnerable to rupture are a thin 
“cap”, which can be easily disrupted, and a heavy infiltration with macrophages 
[PLUTZKY, 1999; GLASS, WITZTUM, 2001]. Most strokes are due either to thrombosis or 
to thrombotic emboli arising from elsewhere (e.g. from a myocardial infarction or 
from rupture of plaques within neck arteries).
44
OMEGA-3 FATTY ACIDS: THE GOOD OIL?
Figure 3.2  —   Progression of the atherosclerotic lesion. 
Interactions between macrophage foam cells and helper T lymphocytes (Th1 
and Th2) establish a chronic inflammatory process within the vascular wall. 
Cytokines secreted by lymphocytes and macrophages exert pro-and anti-
atherogenic effects on endothelial and smooth muscle cells. Smooth muscle 
cells migrate from the media into the intima where they proliferate and secrete 
intracellular matrix proteins that form the fibrous plaque. Reprinted from 
Cell, 2001; 104: 503-516, CK GLASS, JL WITZTUM, Atherosclerosis: The road ahead. 
Copyright, with permission from Elsevier.
A number of modifiable and non-modifiable risk factors for CVD have 
been identified (Table 3.2). Some of these (e.g. hypercholesterolemia, 
smoking) have been known for many years, but in recent years new risk 
factors, such as inflammation [PLUTZKY, 1999; GLASS, WITZTUM, 2001], have been 
identified. 
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Figure 3.3  —   Plaque rupture and thrombosis. 
Necrosis of macrophages and smooth muscle cell (SMC) derived foam cells leads 
to formation of a necrotic core and accumulation of extracellular cholesterol. 
Macrophage secretion of matrix metalloproteinases (MMPs) weakens the fibrous 
cap. Plaque rupture exposes blood components to tissue factor initiating 
coagulation, recruitment of platelets and thrombus formation. 
Reprinted from Cell, 2001; 104: 503-516, CK GLASS, JL WITZTUM, Atherosclerosis: The 
road ahead. Copyright, with permission from Elsevier.
3-2  Long chain n-3 PUFAs
and selected CVD risk factors
3-2-1  Hypercholesterolemia
Between country, within country, and migrant studies indicate a strong 
positive relationship between serum or plasma cholesterol concentration and 
incidence of coronary heart disease [see Department of Health, 2004 for 
references], with much of the risk lying with LDL cholesterol. Since movement 
of LDL cholesterol into the intima and its subsequent modification are 
necessary for foam cell formation and lipid deposition within the vessel wall, 
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Table 3.2  —   Risk factors for cardiovascular disease.
Non-modifiable risk factors:
 Age
 Male gender
 Genetics
Modifiable risk factors:
 Low socioeconomic status
 Smoking
 Lack of physical activity
 Alcohol consumption
 Hypercholesterolaemia*
 Hypertriglyceridaemia (Fasting or post-prandial)*
 Hypertension*
 Vascular dysfunction*
 Diabetes*
 Obesity*?
 Propensity towards thrombosis*
 Inflammation*
 Hyperhomocysteinaemia
*indicates may be influenced by the fatty acid composition of the diet.
it is clear why an elevated LDL cholesterol concentration is a risk factor for 
CVD. Thus, cholesterol, especially LDL-cholesterol, lowering is related to 
reduced risk of CVD. It is estimated that a 1% reduction in serum/plasma 
cholesterol concentration is associated with a 2.5% reduction in risk of an 
acute coronary event [see Dept. of Health, 2004]. LDL cholesterol lowering is 
associated with a lower rate of progression of atherosclerosis. High density 
lipoprotein (HDL)-cholesterol concentration has been inversely associated 
with CVD risk. 
Numerous studies have shown that serum/plasma cholesterol 
concentrations are influenced by the types of fatty acids in the human diet 
[see KATAN et al., 1995 for a review, and British Nutrition Found., 1992; 
Department of Health, 1994 for further references]. Detailed discussion of 
these studies is not necessary here but they can be summarised as follows:
– in general, saturated fatty acids increase and “polyunsaturated fatty acids 
(PUFAs)” (mainly linoleic acid) decrease serum cholesterol concentration, 
with equations being developed to predict the relationship between the 
change in serum cholesterol and the change in intake of saturated and 
polyunsaturated fatty acids; 
– not all saturated fatty acids are equally potent in raising serum cholesterol 
concentrations. Lauric, myristic and palmitic acids are all cholesterol 
raising, while stearic acid and fatty acids with 10 or less carbon atoms do 
not appear to affect serum cholesterol concentrations. The cholesterol 
raising potency appears to be lauric < palmitic < myristic;
– replacement of either saturated fatty acids or carbohydrate with oleic acid 
decreases total and LDL cholesterol with a small HDL raising effect; 
– substituting saturated fatty acids or carbohydrate with linoleic acid 
decreases total and LDL cholesterol concentrations;
– elaidic acid (trans-18:1n-9) increases total and LDL cholesterol and decreases 
HDL cholesterol concentrations. 
Numerous studies have examined the effect of long chain n-3 PUFAs on 
blood cholesterol, LDL and HDL concentrations; these have been reviewed by 
HARRIS [1996]. He identified 72 placebo-controlled studies of fish oil of more 
than 2 weeks duration in humans looking at circulating cholesterol 
concentrations and concluded that long chain n-3 PUFAs have a small 
cholesterol RAISING effect; overall there was a 3% increase in total cholesterol, 
a 4.5% increase in LDL cholesterol and a 4% increase in HDL concentration. 
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3-2-2  Hypertriacylglycerolemia in combination
with a low HDL cholesterol concentration
Epidemiological data suggest that fasting triacylglycerol (TAG) concentrations 
are associated with increased CVD risk, probably in combination with decreased 
HDL cholesterol and the presence of small-dense LDL. Meta-analysis revealed a 
30% increase in risk for each 1 mM increase in fasting TAG concentration in men 
(75% in women) [HOKANSON, AUSTIN, 1996]. When HDL cholesterol concentration 
was adjusted for, the risk was decreased (to 14% and 37%, respectively), but 
remained significant [HOKANSON, AUSTIN, 1996]. Thus, fasting TAG concentration is 
a risk factor independent of HDL cholesterol. Small-dense LDL is a risk factor 
because it is pro-atherogenic since it can cross the endothelium easily, and has 
great susceptibility to oxidation. TAG and small-dense LDL are related to one-
another since TAG is a major determinant of small-dense LDL [GRIFFIN, 1997].
Long chain n-3 PUFAs exert a hypotriacylglycerolemic effect. A review of 72 
placebo-controlled human studies which provided 1 to 7 g eicosapentaenoic acid 
(EPA) + docosahexaenoic acid (DHA)/day for at least two weeks, demonstrated a 
25 to 30% lowering in plasma TAG concentration [HARRIS, 1996]. The effect is dose-
dependent [e.g. SANDERS et al., 1981; BLONK et al., 1990; SCHMIDT et al., 1990]. Using a 
selection of studies providing 1 to 9 g EPA+DHA/day for 4 to 12 weeks, ROCHE 
[1999] derived a predictive equation for the relationship between altered fasting 
TAG concentration and altered intake of long chain n-3 PUFAs: 
[ΔTAG (% change) = -7.67-3.05(Δn-3 PUFA in g/day)]
Data from HARRIS [1996] and from ROCHE [1999] are indicative that a 20 to 
30% lowering of fasting triglyceride concentrations could be expected from 
an intake of more than 2 g EPA+DHA per day. However, low doses of long 
chain n-3 PUFAs provided for an extended duration can induce the same TAG-
lowering effect as higher doses given for a short time [ROCHE, GIBNEY, 1996].
Although there has been some focus on fasting plasma TAG concentrations, 
it is now recognised that the post-prandial TAG response may also be important 
as a risk factor, probably because of the relationship between TAG and 
cholesterol-rich lipoproteins [see WILLIAMS, 1997 for references]. In brief this can 
be explained as follows: an exaggerated or prolonged post-prandial response to 
fat provides greater opportunity for formation of cholesterol-rich chylomicron 
remnants and small-dense LDL particles [see WILLIAMS, 1997 for a detailed 
explanation]. The post-prandial response is examined by providing a meal 
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containing a known amount of fat to a fasting subject and taking a series of 
blood samples at times thereafter; typically both concentration and area-under-
the-concentration-curve (AUC) are used as outcomes. ZAMPELAS et al. [1994] 
showed that including fish oil in the test meal resulted in lower plasma 
chylomicron and total TAG AUC than if an oil mix not including n-3 PUFAs was 
used. Compared with controls of olive oil or mixed oils, consumption of long 
chain n-3 PUFAs (1.6 to 9 g/day) for a period of time (4 to 42 days) resulted in 
lower peak TAG concentrations and lower chylomicron or TAG AUC when a 
saturated fatty acid rich test meal was consumed [see WILLIAMS, 1997 for 
references]; the reductions were between 28 and 46%. Typically a 30% reduction 
occurs at an intake of 1.6 to 2.8 g EPA+DHA/day.  However some lower dose 
studies (< 1.7 g EPA+DHA/day) have failed to show an effect of long chain n-3 
PUFAs on post-prandial lipemia [LOVEGROVE et al., 1997; FINNEGAN et al., 2003].
The lowering of plasma TAG concentrations either in the fasting or post-
prandial state may relate to decreased entry of TAG-rich lipoproteins into the 
circulation or to their increased clearance from it. TAG clearance from the 
circulation is the result of the activity of lipoprotein lipase. Lipoprotein lipase 
mRNA levels were higher in adipose tissue of rats fed fish oil compared with other 
oils [MURPHY et al., 1993]. However, human studies do not show enhanced 
lipoprotein lipase activity after chronic n-3 PUFA consumption. Fasting TAG and 
TAG appearing in the circulation in the late post-prandial state originate in the 
liver. Thus, hepatic actions of long chain n-3 PUFAs might explain the TAG lowering 
effect. These actions may relate to enhanced activation of PPAR-α, which increases 
the expression of enzymes involved in peroxisomal and mitochondrial fatty acid 
oxidation and decreases expression of some apolipoprotein genes [e.g. BERTHOU 
et al., 1995; see SCHOONJANS et al., 1996 for a review]. These actions would have the 
effect of partitioning fatty acids towards β-oxidation and away from TAG synthesis 
and of decreasing VLDL assembly, respectively.
3-2-3 Hypertension and endothelial responsiveness
Systolic and diastolic blood pressure are directly related to risk of CHD 
and stroke [STAMLER et al., 1989], possibly because of the damaging effects of 
pressure on the vessel wall that can create foci for plaque formation. A 7.5 mm 
Hg difference in diastolic pressure within the range 70 to 110 mm Hg is 
accompanied by a 29% difference in CHD risk and a 46% difference in risk of 
stroke irrespective of age, gender or ethnicity [MACMAHON et al., 1990]. A mean 
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reduction of diastolic blood pressure of 4 mm Hg reduces risk of stroke by at 
least 34% [MACMAHON et al., 1990; COLLINS et al., 1990] and of CHD by 14% 
[COLLINS et al., 1990].
A large number of studies have examined the effect of long chain n-3 PUFAs 
in the form of fish oil on blood pressure in both normotensive and hypertensive 
individuals. A number of reviews and meta-analyses of these studies exist [BONAA, 
1989; RADACK, DACK, 1989; APPEL et al., 1993; MORRIS et al., 1993]. MORRIS et al. [1993] 
examined 31 placebo controlled trials using an average dose of 4.8 g EPA+DHA per 
day. The overall effects observed were reductions of 3 mm Hg in systolic and of 1.5 
mm Hg in diastolic blood pressure. Effects were seen in hypertensive but not 
normotensive populations. A further meta-analysis of 36 trials, including 22 double 
blind, placebo controlled trials, involving over 2100 subjects was recently published 
[GELEIJNSE et al., 2002]. The doses of fish oil used ranged from 0.2 to 15 g/day with an 
average dose of 3.7 g/day. Duration ranged from 3 to 52 weeks with a mean of about 
12 weeks. The overall effects observed were reductions of 2.3 mm Hg in systolic and 
of 1.5 mm Hg in diastolic blood pressure. Effects were greater in older compared 
with younger populations and in hypertensive compared with normotensive 
populations. The data also suggested a greater effect in women than men. 
The arachidonic acid derivative TXA2 is a potent vasoconstrictor via its action 
on smooth muscle cells while PGI2 is a vasodilator (Table 2.2). One of the 
characteristic features of increased availability of long chain n-3 fatty acids, especially 
EPA, is a reduction in the content of arachidonic acid in cell membrane phospholipids, 
thus decreasing the amount of substrate available for eicosanoid synthesis. 
Therefore, n-3 fatty acids are associated with a decrease in production of TXA2 and 
PGI2 (see below). As a result of incorporation of EPA into cell membrane 
phospholipids there is increased capacity to produce TXA3 and PGI3. TXA3 is only 
weakly vasoconstrictive, while PGI3 is vasodilatory. Thus, long chain n-3 PUFAs from 
fish oil might lower blood pressure by inducing vasodilation due to decreased TXA2 
and increased PGI3 production. Alternatively they may act at the level of the kidney. 
Renal prostaglandins (PGE2 and PGF2) stimulate renin release, and renin promotes 
angiotensin formation causing the kidneys to retain salt and water, thus increasing 
extracellular fluid volume and increasing blood pressure. EPA-derived prostaglandins 
do not stimulate renin production [WEBER et al., 1976; GERKENS et al., 1981] and so fish 
oil may decrease blood pressure by decreasing renin activity. 
There is a close relationship between blood pressure and endothelial 
responsiveness to vasodilators. A healthy endothelium modulates the activity of 
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vascular smooth muscle cells while damage to the endothelium decreases the 
vasodilatory response to acetylcholine and other substances. The effect of 
acetylcholine is mediated by nitric oxide produced by endothelial nitric oxide 
synthase. Damage to the endothelium results in decreased nitric oxide production 
and so an impaired response to acetylcholine. The impaired endothelial response 
may be secondary to atherosclerotic damage or a consequence of raised blood 
pressure and will act to increase blood pressure further. SHIMOKAWA et al. [1987, 
1988] demonstrated that feeding cod liver oil to pigs increased nitric oxide release 
from coronary arteries in response to bradykinin, serotonin and thrombin, and that 
this was associated with an improvement in endothelium-dependent vascular 
relaxation. HARRIS et al. [1997] reported that fish oil providing 2 g EPA + 1 g DHA/day 
for 3 weeks resulted in a 43% increase in the concentration of nitric oxide 
metabolites in human urine, reflecting increased whole body nitric oxide production 
in humans. Interestingly 2.73 g EPA/day had no effect, suggesting that DHA may be 
the n-3 PUFA involved in regulating endothelial nitric oxide production. Several 
studies in humans now report improved nitric oxide-dependent and -independent 
endothelial relaxation and improved arterial compliance after chronic fish oil 
supplementation [CHIN et al., 1993; MCVEIGH et al., 1994; GOODE et al., 1997; TAGAWA et 
al., 1999; GOODFELLOW et al., 2000; NESTEL et al., 2002].
3-2-4 Propensity towards thrombosis
As indicated above thrombosis is involved in the cycle of events that 
build up an atherosclerotic plaque and also is the ultimate cause of vessel 
occlusion during an acute cardiovascular event. The local responses at the 
vessel wall that play a role in thrombosis involve three main components: 
platelets, coagulation factors and fibrinolytic factors. 
• Platelet aggregation
Cellular adhesive reactions lead to attachment of platelets to a damaged 
endothelial surface and their subsequent activation and aggregation. Arachidonic 
acid typically comprises 20 to 30% of the fatty acids in human platelet 
phospholipids. Platelet adhesion activates phospholipase enzymes, particularly 
PLA2, releasing arachidonic acid. The released arachidonic acid is metabolised 
via COX (Figure 2.5) and then to TXA2 a potent inducer of platelet degranulation 
(with the release of many factors including adenosine diphosphate (ADP), 
platelet-derived growth factor, fibrinogen, von Willebrand’s factor, tissue 
plasminogen activator (tPA), plasminogen activator inhibitor (PAI)-1 and 
plasminogen) and aggregation (triggered in part via ADP release). Inhibitors of 
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platelet aggregation include adenosine, PGD2 and PGI2. PGI2 is synthesised by 
activated endothelial cells and inhibits both platelet TXA2 synthesis and 
aggregation. Nitric oxide generated from endothelial cells is also an inhibitor of 
platelet aggregation. Thus, TXA2 and PGI2/nitric oxide act as opposing factors 
controlling platelet aggregation (and smooth muscle contraction) (Figure 3.4).
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Figure 3.4  —   The balance in production of cyclooxygenase products from arachidonic acid 
controls platelet aggregation and smooth muscle contraction. 
PG, prostaglandin; TX, thromboxane.
• Coagulation and fibrinolysis
Injury to the vascular endothelium can expose a cell membrane protein 
called tissue factor, which combines with circulating coagulant factor VII. The 
tissue factor/factor VII complex initiates a cascade of reactions (the coagulation 
pathway) that culminates in the generation of thrombin from prothrombin 
and the deposition of an insoluble fibrin network at the site of injury. The rate 
of coagulation is regulated by an anticoagulant pathway but this may be 
overwhelmed after injury. High levels of factor VII activity and of fibrinogen 
may predispose the blood to clotting (a hypercoagulable state) and are 
predictive of CHD [see British Nutrition Foundation, 1992 for references]. 
Disruption of the vessel wall can trigger massive deposition of platelets and 
fibrin (thrombosis), which may be sufficiently large to occlude the vessel 
lumen. There is a fibrinolytic system to protect against this [see British 
Nutrition Foundation, 1992]. It involves the generation of plasmin, which can 
degrade fibrin in a thrombus, from plasminogen. Plasminogen is converted to 
plasmin via the action of tPA. tPA is inhibited by plasminogen activator 
inhibitor type 1 (PAI-1).
• Long chain n-3 PUFAs and platelet aggregation
Comparison between Inuits and Danes and between inhabitants of 
Japanese fishing and farming villages showed that populations consuming 
high amounts of long chain n-3 PUFAs had decreased platelet aggregation and 
increased bleeding time [DYERBERG, BANG, 1979; HIRAI et al., 1982]. One of the 
characteristic features of increased availability of long chain n-3 fatty acids, 
especially EPA, is a reduction in the content of arachidonic acid in membrane 
phospholipids in platelets [SIESS et al., 1980; SANDERS et al., 1981; GOODKNIGHT et 
al., 1981; THORNGREN et al., 1984; VON SCHACKY et al., 1985] and presumably also 
endothelial cells, thus decreasing the amount of substrate available for 
eicosanoid synthesis. Therefore, n-3 fatty acids are associated with a decrease 
in production of TXA2 and PGI2 [GOODKNIGHT et al., 1981; THORNGREN et al., 1984; 
VON SCHACKY et al., 1985; KNAPP et al., 1986; KNAPP,FITZGERALD, 1989] (Figure 3.5). 
EPA is readily incorporated in a dose-dependent manner into platelet (and 
presumably endothelial) membrane phospholipids [SIESS et al., 1980; 
GOODKNIGHT et al., 1981, SANDERS et al., 1981; THORNGREN et al., 1984; KNAPP, 
FITZGERALD, 1989]. EPA is released upon platelet and endothelial activation by 
the action of phospholipase A2 and acts as a substrate for COX (Figure 2.6). The 
products produced (e.g. TXA3 and PGI3) have a different potency from those 
produced from arachidonic acid: TXA3 has a weaker pro-aggregatory effect 
than does TXA2, while PGI2 and PGI3 have similar anti-aggregatory potencies 
[NEEDLEMAN et al., 1979; 1980; FISHER, WEBER, 1984]. Therefore, the effect of long 
chain n-3 fatty acids is to decrease platelet aggregation in response to collagen 
[1] or ADP [2] and increase the time taken for blood to clot (i.e. bleeding time) 
[e.g. 3]. Increases of bleeding time of 20 to 100% are reported, the extent of 
the effect being largely related to dose of long chain n-3 PUFAs. It is unlikely 
that low-to-modest doses of long chain n-3 PUFAs will dramatically affect 
bleeding time.
• Long chain n-3 PUFAs and coagulation factors
Incubation of a monocytic cell line with EPA or DHA did not affect basal 
expression of tissue factor but decreased by more than 50% the induction of 
tissue factor by endotoxin [CHU et al., 1999]. Supplementing the diet of dogs 
with fish oil did not affect basal monocyte procoagulant activity, which is 
largely due to tissue factor expression, but significantly decreased the activity 
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[2] THORNGREN, GUSTAFSON, 1981; THORNGREN et al., 1984; FREESE, MUTANEN, 1997.
[3] GOODKNIGHT et al., 1981; THORNGREN, GUSTAFSON, 1981; SANDERS, ROSHANAI, 1983; STEINBERG et al., 1989.
induced by endotoxin [CHU et al., 1997]. HANSEN et al. [1989] showed that tissue 
factor expression on unstimulated and endotoxin-stimulated mononuclear 
cells was decreased by consumption of cod liver oil (25 ml/day for 8 weeks) by 
healthy adults. Similarly ABBATE et al. [1996] and TREMOLI et al. [1994] reported 
that 3.0 or 3.4 g EPA+DHA/day for 18 weeks decreased monocyte procoagulant 
activity (both unstimulated and endotoxin stimulated) by over 60%. One 
cross-sectional study revealed significant negative associations between fish 
or n-3 PUFA intake and concentrations of fibrinogen, factor VIII, and von 
Willibrand factor, but no association with factor VII [SHAHAR et al., 1993]. 
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Figure 3.5  —   Effect of long chain n-3 polyunsaturated fatty acids on platelet fatty acid 
composition and production of eicosanoids involved in regulation of platelet 
aggregation. 
Healthy volunteers consumed 10 ml cod liver oil/day for 4 weeks, then 20 ml/day 
for 4 weeks, and then 40 ml/day for 4 weeks. Platelet EPA (    ), DHA (    ) 
and arachidonic acid (     ) contents were determined by gas chromato gra-
phy (A). Production of TXA2 by clotting blood (    ) and the urinary appea-
rance of PGI2 (     ) and PGI3 (     ) were determined (B). Data are from VON 
SCHACKY et al., 1985.
Another study revealed no association between fish, EPA or DHA intake and 
concentrations of fibrinogen, factor VII, factor VIII or von Willebrand factor 
[ARCHER et al., 1998]. Several studies report no effect of fish oil, even at fairly 
high doses, on factor VII concentration or coagulant activity [see British 
Nutrition Foundation, 1992; NETTLETON, 1995 for references]. YAHIA and SANDERS 
[1997] reviewed nine studies of fish oil and two of oily fish that provided 
between 1.3 and 9 g EPA+DHA/day for between 10 days and 9 months and 
identified only two studies that reported effects (both increases) on Factor VII 
coagulant activity.  A number of studies report no effect of fish oil (providing 
1.6 to 5.1 g EPA+DHA/day) on fibrinogen concentration, although some studies 
using high doses (> 4.5 g EPA+DHA/day) or long durations report decreases 
[see British Nutrition Foundation, 1992; NETTLETON, 1995 for references]. 
• Long chain n-3 PUFAs and fibrinolytic factors
Some studies have reported an increase in PAI-1 activity after fish oil 
supplementation, whereas others report a decrease or no effect [see 
NETTLETON, 1995]. In most studies fish oil did not affect tPA concentrations, 
although some studies have reported an increase or a reduction [see British 
Nutrition Foundation, 1992]. 
3-2-5 Inflammation
Atherosclerosis is now considered to be an inflammatory disease resulting 
from interaction between modified lipoproteins, monocyte-derived macrophages, 
T cells and the normal cellular elements of the vessel wall [ROSS, 1993; 1999; BLAKE, 
RIDKER, 2001; GLASS, WITZTUM, 2001] (Figures 3.1 and 3.2). The earliest lesions, fatty 
streaks, are pure inflammatory lesions consisting only of monocyte-derived 
macrophages and T lymphocytes. Endothelial injury increases the adhesiveness 
of the endothelium to leukocytes (and platelets) by upregulating expression of 
adhesion molecules as well as its permeability. Mice deficient in intercellular 
adhesion molecule 1 (ICAM-1), E-selectin or P-selectin show less atherosclerosis 
when fed an atherosclerotic diet [see GLASS, WITZTUM, 2001; BLAKE, RIDKER, 2001], 
indicating the importance of endothelial-leukocyte adhesive interactions in the 
atherosclerotic process. The injured endothelium also produces vasoactive 
molecules, cytokines and growth factors. Some of these molecules such as 
monocyte chemoattractant protein 1 (MCP-1), act as chemoattractants attracting 
monocytes and T cells to the vessel wall (Figures 3.1 and 3.2). The resulting 
inflammatory response stimulates migration and proliferation of smooth muscle 
cells that become mixed into the area of inflammation (Figure 3.2). The 
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inflammatory response within the vascular wall is mediated by monocyte-derived 
macrophages and T cells [see ROSS, 1993; 1999; GLASS, WITZTUM, 2001]. Continued 
inflammation results in increased numbers of inflammatory cells that migrate 
from the bloodstream and proliferate within the lesion. Activation of these cells 
leads to release of enzymes, cytokines, chemokines, eicosanoids and growth 
factors continuing the inflammatory process and contributing to the build up of 
the plaque. C reactive protein (CRP) is an acute phase protein produced by the 
liver; interleukin (IL)-6 is the major inducer of CRP synthesis. CRP has been 
considered to be simply a marker of inflammation. However more recent studies 
have indicated that CRP may play an active role in inflammation by stimulating 
monocytes to release inflammatory cytokines and by increasing upregulation of 
adhesion molecule expression and MCP-1 synthesis by endothelial cells [see 
BLAKE, RIDKER, 2001 for references]. 
In accord with the proposed central role of inflammation in development 
of the atherosclerotic plaque, several inflammatory markers present in the 
serum or plasma are associated with cardiovascular disease risk. Soluble 
P-selectin was identified as an independent predictor of future CVD risk in the 
Women’s Health Study [RIDKER et al., 2001]. sICAM-1 concentration was shown to 
be an independent predictor of CHD risk [HWANE et al., 1997; RIDKER et al., 1998]. 
Serum IL-6 concentrations may also be predictive [RIDKER et al., 2000]. However, 
of the inflammatory markers, CRP has been most investigated, and has been 
found to be predictive of future myocardial infarction, stroke, peripheral 
vascular disease and CVD mortality [see BLAKE, RIDKER, 2001 for references]. CRP 
has been compared with other inflammatory and lipid risk factors and found to 
be the most powerful predictor of risk [see BLAKE, RIDKER, 2001]. 
Long chain n-3 fatty acids decrease production of some chemoattractants 
including LTB4 and MCP-1 [LEE et al., 1985; SPERLING et al., 1993; WALLACE et al., 1995; 
BAUMANN et al., 1999] and growth factors including platelet derived growth factor 
[WALLACE et al., 1995; BAUMANN et al., 1999] and the expression of some adhesion 
molecules on endothelial cells and leukocytes [HUGHES et al., 1996; see also 
Section 5-4-2]. Thus long chain n-3 PUFAs could down-regulate processes 
leading to leukocyte and smooth muscle migration into the vessel wall intima. 
Long chain n-3 fatty acids are also anti-inflammatory exerting effects on the 
production of inflammatory eicosanoids and cytokines (see Sections 5-3 and 
5-4-1) and so they could decrease inflammatory processes within the vessel 
wall, which are now recognised to be a major contributory factor in the 
atherosclerosis. Long chain n-3 PUFAs have been reported to decrease plasma 
concentrations of some adhesion molecules [see MILES et al., 2001]. 
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3-3  Long chain n-3 PUFAs
and cardiovascular risk:  
evidence from ecological, 
epidemiological and
case-control studies
As indicated in Section 3-2, long chain n-3 fatty acids favorably affect a 
number of risk factors involved in the development of atherosclerosis (Table 3.3), 
indicating that they will most likely slow the progression of the disease. Indeed, 
including long chain n-3 PUFAs in the diet has been demonstrated to decrease 
atherosclerosis in a variety of animal models [LANDYMORE et al., 1985; WEINER et al., 
1986; DAVIS et al., 1987; CAHILL et al., 1988; RENIER et al., 1993; MORTENSEN et al., 
1998]. 
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Table 3.3  —   Effects of long chain n-3 PUFAs on selected cardiovascular risk factors. 
Risk factor  Effect of long chain n-3 PUFAs
Hypercholesterolaemia -/K
Fasting hypertriglyceridaemia  L
Post-prandial hypertriglyceridaemia  L
Hypertension  L
Vascular dysfunction  L
Propensity towards thrombosis L
Inflammation  L
If long chain n-3 PUFAs do slow atherosclerosis, they might be expected 
to decrease risk of CVD mortality. It has been known for many years that Inuit 
populations in Greenland, Northern Canada and Alaska consuming their 
traditional diet had much lower cardiovascular mortality than predicted 
[DYERBERG et al., 1978; KROMANN, GREEN, 1980; BJERREGAARD, DYERBERG, 1988; 
NEWMAN et al., 1993]. Typically the rate of cardiovascular mortality was < 10% of 
that predicted [e.g. KROMANN, GREEN, 1980]. This was surprising since these 
populations consumed a high fat diet. The protective component was 
suggested to be the long chain n-3 fatty acids consumed in very high amounts 
as a result of the regular intake of seal and whale meat and whale blubber 
[BANG et al., 1976, 1980]. Intake of these fatty acids was estimated to average as 
much as 5 to 15 g/day amongst such populations [BANG et al., 1976, 1980]. The 
Japanese also exhibit a low cardiovascular mortality [YANO et al., 1988] and the 
traditional Japanese diet is rich in seafood including oily fish, which contain 
significant amounts of EPA and DHA. CVD mortality was different between 
Japanese fishing and farming villages [TOSHIMA et al., 1995], supporting a 
protective role of fish. Substantial evidence from epidemiological and case-
control studies has now accumulated indicating that consumption of fish or 
of long-chain n-3 fatty acids reduces the risk of cardiovascular mortality in 
Western populations [1]; [see CALDER, 2004 for details] and elsewhere [YUAN et 
al., 2001]. KROMHOUT et al. [1985] demonstrated a significant effect of consuming 
fish with a 40% lower 20-year coronary heart disease mortality among men in 
The Netherlands who ate 1 to 14 g fish/day in 1960 compared with those men 
who did not eat fish at all in 1960. Men who consumed more than 30 g fish/day 
had a 60% lower risk of 20-year mortality from coronary heart disease 
compared with non-fish eaters. DAVIGLUS et al. [1997] reported a dose-
dependent effect of fish consumption upon 30-year mortality among men in 
the USA. Men who ate 1 to 17 g fish/day in 1957 had a 10% lower risk of death 
from coronary heart disease or myocardial infarction compared with those 
who did not eat fish. Men who ate more than 34 g fish/day had a 40% lower 
risk of mortality from coronary heart disease or myocardial infarction 
compared with those who did not eat fish [DAVIGLUS et al., 1997]. Although not 
all studies agree [e.g. ASCHERIO et al., 1995], the protective effects of the fish 
and/or long chain n-3 fatty acids have been confirmed by a number of recent 
studies [ISO et al., 2001; TAVANI et al., 2001; ALBERT et al., 2002; HE et al., 2002; 
GUALLAR et al., 2002; ERKKILA et al., 2003; LEMAITRE et al., 2003; MOZAFFARIAN et al., 
2003]. Data from the Nurses’ Health Study revealed that fish and long chain n-3 
PUFA intake decreased risk of coronary heart disease, fatal coronary heart 
disease and non-fatal myocardial infarction [HU et al., 2002]. In an Italian study, 
fish and long chain n-3 PUFA intake were lower in patients who suffered a 
non-fatal myocardial infarction compared with age- and gender-matched 
controls [TAVANI et al., 2001]. Data from the Physicians’ Health Study showed 
that the long chain n-3 PUFA status of whole blood at study entry was strongly 
inversely related to the risk of sudden death over the follow-up period of 0.7 
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to 16.9 (mean 8.7) years [ALBERT et al., 2002]. The relative risk of sudden death 
was lower by about 50% in those men in the second quartile of whole blood 
total long chain n-3 PUFA content compared with those in the lowest quartile. 
The relative risk of sudden death in the highest quartile of blood long chain 
n-3 PUFA content was 70 to 90% lower (depending upon adjustment for other 
factors) than in the lowest quartile [ALBERT et al., 2002].  A European multi-
centre study identified that adipose tissue DHA content, a marker of DHA 
intake, was inversely associated with risk of first myocardial infarction, even 
when toenail mercury level (associated with increased risk) was adjusted for 
[GUALLAR et al., 2002]. The relative risk of first myocardial infarction was 40% 
lower in men in the highest quintile of adipose tissue DHA content compared 
with those in the lowest quintile [GUALLAR et al., 2002]. In another study, the 
combined EPA and DHA content of plasma phospholipids was lower in cases 
of fatal coronary heart disease than in matched controls [LEMAITRE et al., 2003]. 
The authors identified that the odds ratio for fatal coronary heart disease was 
decreased by 70% with a one standard deviation increase in plasma 
phospholipid EPA plus DHA content.
3-4  Secondary prevention studies
in post-MI patients
A secondary prevention study providing long chain n-3 fatty acids in the 
form of oily fish or fish oil capsules to patients who had already suffered a 
myocardial infarction demonstrated a significant reduction (29%) in mortality 
compared with the control group [BURR et al., 1989]. More recently the GISSI 
Prevenzione study investigated the effect of n-3 fatty acids (0.885 g EPA plus 
DHA/day in the form of Omacor, a pharmaceutical-grade preparation of long 
chain n-3 PUFAs) on 3.5-year mortality outcomes in post-myocardial infarction 
patients in a placebo-controlled study also investigating vitamin E and 
involving approximately 11,000 patients in Italy. The major findings are shown 
in table 3.4, the most remarkable of which is the approximately 45% reduction 
in risk of sudden death. The effects observed occurred in the absence of lipid 
lowering [GISSI Prevenzione, 1999] and occurred in a relatively short period 
of time after starting supplementation. The reduction in risk of sudden death 
at 3.5 years in those patients consuming long chain n-3 fatty acids was already 
apparent at 4 months and the reductions in risk of cardiovascular mortality 
and coronary heart disease mortality were apparent within 6 to 8 months of 
initiating n-3 fatty acid treatment [MARCHIOLI et al., 2002]. 
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Despite the potential for protection against atherosclerosis (Sections 
3-2 and 3-3), much interest has been focused on the potent protective effect 
of n-3 fatty acids towards fatal myocardial infarction [BUUR et al., 1989; SISCOVICK 
et al., 1995;  DAVIGLUS et al., 1997; GISSI Prevenzione, 1999], and particularly 
towards sudden death [ALBERT et al., 1998, 1999; GISSI Prevenzione, 1999; HU et 
al., 2002], suggesting that they influence acute events. Several studies also 
report protection against non-fatal myocardial infarction [SISCOVICK et al., 1995; 
PEDERSEN et al., 2000; HU et al., 2002; LEMAITRE et al., 2003], which is consistent with 
a lowered risk of acute events be they non-fatal or fatal.
Two mechanisms have been proposed to contribute to the strong 
protective effect of long chain n-3 fatty acids towards acute cardiovascular 
events, especially those that are fatal. The first is the anti-thrombotic effect of 
long chain n-3 fatty acids already described in Section 3-2. However, some 
acute damage to the endothelium must occur to precipitate the thrombosis 
and so some other event must precede thrombosis (Figure 3.3).
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 Table 3.4  —   Summary of the findings of the GISSI Prevenzione study [1999].
 Control  n-3 PUFA Risk P
 group (%) group (%) reduction (%)
Primary outcomes
All cause mortality, 14.8 12.6 16 0.02
non-fatal MI and
non-fatal stroke
Cardiovascular mortality, 11.7 9.4 20 0.006
non-fatal MI and
non-fatal stroke
Secondary outcomes
All cause mortality 10.6 8.4 21 0.0004
Cardiovascular death 7.2 5.1 30 < 0.001
Cardiac death 6.1 4.0 35 < 0.001
Coronary death 5.2 3.6 32 < 0.01
Sudden death 3.3 1.8 44 0.0006
Non-fatal  4.9 4.9 2 NS
cardiovascular events
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Electrical impulses in the heart can become rapid (ventricular tachycardia) 
or chaotic (ventricular fibrillation) or both. The resulting irregular heart rhythm 
(arrhythmia) can cause the heart to suddenly stop beating, causing an infarction 
frequently in the form of sudden death (Figure 3.6). Studies in rats, pigs, dogs and 
marmosets suggest that long chain n-3 fatty acids from fish oil have anti-arrhythmic 
effects [e.g. MCLENNAN et al., 1988; 1990; MCLENNAN, 1993] and so would act to 
counter this cause of sudden death. NAIR et al. [1997] reviewed 20 dietary studies 
with fish oil in animal models, almost all of which demonstrate benefits on 
outcomes such as ventricular fibrillation and ventricular tachycardia. These 
effects of dietary fish oil can be mimicked in cultured cardiomyocytes exposed to 
EPA or DHA [KANG, LEAF, 1994; LEAF, XIAO, 2001]. The presence of n-3 fatty acids in 
cardiomyocyte membrane phospholipids decreases electrical excitability and 
modulates the activity of ion (e.g. sodium, potassium, calcium) channels [XIAO et 
al., 1997; 1998], effects that are claimed to promote electrical stability in the cell 
and prevent arrhythmias. SELLMAYER et al. [1995] reported that 2.4 g EPA+DHA/day 
decreased by 48% the frequency of premature ventricular complexes after 16 
weeks in patients who experienced frequent but not life threatening ventricular 
arrhythmias. A recent study has indicated that long chain n-3 fatty acids may be 
able to alter arrhythmias acutely. In the study, patients with ventricular tachycardia 
Figure 3.6  —   Model linking inflammation, plaque rupture and thrombosis and arrhythmia to 
sudden death and other cardiovascular (CV) events.
and with implanted defibrillators were infused with an emulsion containing 3.8 g 
long chain n-3 fatty acids [SCHREPF et al., 2004].  The infusion rendered five out of 
seven patients in this uncontrolled and unblinded study non-responsive to the 
induction of sustained monomorphic ventricular tachycardia. 
In addition to possible anti-arrhythmic actions due to their effects on ion 
channels, long chain n-3 fatty acids might influence heart rate variability (low 
heart rate variability is believed to be associated with increased mortality post-
myocardial infarction [TSUJI et al., 1996; HUIKURI et al., 1998]), and this might have an 
anti-arrhythmic effect via the autonomic nervous system (Figure 3.6). CHRISTENSEN 
et al. [2001] reported a positive correlation between the n-3 fatty acid content of 
platelets and heart rate variability in patients with type-1 diabetes mellitus. 
BROUWER et al. [2002] reported a significant positive association between the DHA, 
but not EPA, content of serum cholesteryl esters and heart rate variability in 
healthy subjects, although there was no association with the so-called QT interval 
(corrected for heart rate). CHRISTENSEN et al. [1996] reported increased heart rate 
variability in myocardial infarction survivors given 5.2 g EPA + DHA/day for 12 
weeks. However, GEELEN et al. [2002] found no effect of 1.5 g EPA+DHA/day for 12 
weeks on QT interval (corrected for heart rate) or on other electrocardiographic 
characteristics in healthy elderly subjects. This may be because of the lower dose 
of EPA+DHA used. These studies are suggestive of two potential ways by which 
long chain n-3 fatty acids could affect cardiac arrhythmias: via modulation of ion 
channels and by increased heart rate variability (Figure 3.6). However, it is still 
unclear whether moderate intakes of long chain n-3 PUFAs do affect arrhythmias 
and so the results of new and ongoing studies are eagerly awaited.
An additional third mechanism may play an important role in the protective 
effects of long chain n-3 fatty acids towards acute cardiovascular events: the well-
documented anti-inflammatory effects of long chain n-3 fatty acids may be 
important (Figure 3.6). The rupture of an atherosclerotic plaque, which is the acute 
event that exposes the plaque contents to the highly pro-thrombotic environment 
of the vessel lumen, is, essentially, an inflammatory event [PLUTZKY, 1999; GLASS, 
WITZTUM, 2001] (Figure 3.3). The characteristics of an atherosclerotic plaque that 
make it vulnerable to rupture include a thin fibrous cap and increased numbers of 
inflammatory cells such as macrophages [STARY et al., 1995; FELTON et al., 1997; PLUTZKY, 
1999; GLASS, WITZTUM, 2001]. Long chain n-3 fatty acids might act to stabilize 
atherosclerotic plaques by decreasing infiltration of inflammatory and immune 
cells (e.g. monocyte/macrophages and lymphocytes) into the plaques and/or by 
decreasing the activity of those cells once in the plaque. Unstable regions of 
plaques have a lower n-3 PUFA content, and a higher n-6 PUFA content, than stable 
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areas [FELTON et al., 1991]. RAPP et al. [1991] showed that high dose fish oil 
supplementation resulted in higher EPA and DHA contents of plaques in various 
sites of the vasculature than seen in the absence of supplementation. A recent 
study confirmed that long chain n-3 fatty acids are readily incorporated from dietary 
fish oil supplements (providing 1.4 g EPA+DHA/day) into advanced atherosclerotic 
plaques and showed that this incorporation is associated with structural changes 
consistent with increased plaque stability [THIES et al., 2003] (Table 3.5). The 
 EPA in                Plaque morphology                 Macrophage staining
 carotid Type IV Type V Moderate Heavy
 plaque (% of (% of (% of (% of
 phospholipids plaques) plaques) plaques) plaques)
 (% of total FAs)* 
Placebo group 0.6 ± 0.4 59.6 29.8 13.2 84.2 
Fish oil group 1.1 ± 0.6 71.7 15.1 38.1 61.9 
Significance of
difference
between
groups (P) < 0.0001 0.041 0.027 0.011 0.026 
*mean ± SD; FAs=Fatty acids
Table 3.5  —   Summary of the findings of the study of THIES et al. [2003].
morphology of carotid plaque sections was characterized according to the 
American Heart Association (AHA) classification [STARY et al., 1995]. Plaques from 
patients treated with fish oil were more likely to be Type IV (fibrous cap atheromas: 
well-formed necrotic core with an overlaying thick fibrous cap) than those from the 
placebo group (odds ratio 1.19; Table 3.5). Conversely, plaques from patients treated 
with fish oil were less likely to be Type V (thin fibrous cap atheromas – thin fibrous 
cap infiltrated by macrophages and lymphocytes) than those from the placebo 
group (odds ratio 0.52). Thus, there were more plaques with a well formed fibrous 
cap, rather than a thin inflamed cap, in the fish oil group. Infiltration by macrophages 
was investigated using immunohistochemistry. It was found that plaques from 
patients given fish oil were more likely to be less heavily infiltrated with macrophages 
than those in the placebo group (Table 3.5). Since it is the vulnerability of the plaque 
to rupture rather than the degree of atherosclerosis that is the primary determinant 
of thrombosis-mediated acute cardiovascular events, it is likely that the findings of 
THIES et al. [2003] are clinically relevant. If carotid plaques really are stabilized by fish 
oil, then the risk of neurological events in patients with advanced carotid 
atherosclerosis may be reduced. If a similar stabilizing effect of n-3 PUFAs occurs in 
coronary plaques then these too might be stabilized. This might explain the 
significant protective effects of n-3 PUFAs towards both fatal and non-fatal 
cardiovascular events [see earlier], which are so far not fully explained.
3-5 Conclusions
Cardiovascular disease is accompanied by significant morbidity and 
remains the biggest cause of mortality in Western populations. Some of the 
risk factors involved were known many years ago, but in recent times new risk 
factors have been identified. Many of these risk factors are related to, or can 
be influenced by, diet. There is considerable evidence from ecological, 
epidemiological and case control studies that consumption of fish, oily fish or 
long chain n-3 PUFAs decreases risk of cardiovascular events and of 
cardiovascular mortality. Secondary prevention trials in survivors of myocardial 
infarction have shown that long chain n-3 PUFAs decrease mortality with a 
particularly potent effect on sudden death. Studies in experimental animals 
and in humans have demonstrated beneficial effects of long chain n-3 PUFAs 
on cardiovascular risk factors including hypertriacylglycerolemia, post-
prandial hypertriacylglycerolemia, hypertension, vascular dysfunction, 
thrombosis and inflammation. Since these are involved in initiating and 
progressing atherosclerosis (i.e. the buildup of the fibrous plaque in the 
vessel wall), the reduction in risk factor burden may explain the benefits of 
long chain n-3 PUFA consumption. However, effects on sudden death and 
sudden death mortality suggest effects on cardiovascular events and on event 
severity even in subjects with advanced atherosclerosis. Anti-thrombotic 
effects of long chain n-3 PUFAs may decrease event severity, and so decrease 
the likelihood of dying. Anti-arrhythmic actions are believed by many to 
decrease the likelihood and severity of myocardial infarction particularly of 
the type that leads to sudden death. In vitro and animal studies and a limited 
number of human studies support this mechanism of action. Finally, the anti-
inflammatory actions of long chain n-3 PUFAs may be important in maintaining 
the stability of advanced plaques, so preventing their rupture. In reality all of 
these mechanisms may operate in concert.
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  4 –  Long chain n-3 fatty 
acids and the brain
4-1  The relationship between
maternal and fetal 
docosahexaenoic acid status
4-1-1  Fetal and infant brain growth creates
a demand for DHA
More than 50% of the dry weight of the brain is lipid, particularly 
structural lipid (i.e. phospholipids). The most abundant fatty acids in the brain 
are docosahexaenoic acid (DHA), arachidonic acid and adrenic acid [O’BRIEN, 
SAMPSON, 1965; CRAWFORD et al., 1976]. The human brain and retina contain an 
especially high proportion of DHA relative to other tissues and little 
eicosapentaenoic acid (EPA) [O’BRIEN, SAMPSON, 1965; ANDERSON, 1970; CRAWFORD 
et al., 1976]. Grey matter phosphatidylethanolamine contains 24% of fatty acids 
as DHA while grey matter phosphatidylserine contains 37% fatty acids as DHA 
[O’BRIEN, SAMPSON, 1965; CRAWFORD et al., 1976]. DHA contributes 50 to 70% of 
the fatty acids present in the rod outer segments of the retina [ANDERSON, 
1970]. These rod outer segments contain the eyes’ photoreceptors. The human 
brain growth spurt occurs from approximately the beginning of the third 
trimester of pregnancy to 18 months after birth [MARTINEZ, 1992]. The amount 
of DHA in the brain increases dramatically during the brain growth spurt 
(Figure 4.1). In humans, brain weight increases from about 100 g at 30 weeks 
of gestation to about 1100 g at 18 months of age [DOBBING, SANDS, 1973]. Over 
this period the DHA content of the brain increases from 900 μg/g (90 mg in 
total) to 3,000 μg/g (3,300 mg total) [CUNNANE et al., 2000; see also MARTINEZ, 
MOUGAN, 1998; LAURITZEN et al., 2001]. This represents a 35-fold increase in total 
brain DHA. The estimated rate of accretion of DHA into the human brain in 
the last trimester of pregnancy is 15 to 22 mg/week [CLANDININ et al., 1980]. This 
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is also the most active period of brain cell division. Thus it is believed that an 
adequate supply of DHA during this period is essential for normal growth, 
neurological development and function, and learning behaviour.
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Figure 4.1  —   Accumulation of docosahexaenoic acid (DHA) by the human cerebellum during 
the period before and soon after birth. 
Drawn by Dr G.C. BURDGE using data from MARTINEZ, MOUGAN [1998].
4-1-2  Maternal supply of DHA to the fetus
during pregnancy 
There is a significant linear relationship between the DHA contents of 
maternal and umbilical cord plasma phospholipids (Figure 4.2). This suggests 
that maternal plasma phospholipids are an important source of DHA for the 
fetus and that maternal plasma phospholipid DHA concentration determines 
DHA supply to the fetus. A model for supply of fatty acids from mother to 
fetus is shown in figure 4.3. An increase in maternal plasma DHA concentration 
occurs during pregnancy and this increase precedes the increase in DHA 
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Figure 4.2  —   The relationship between the docosahexaenoic acid contents of maternal and 
umbilical cord blood phospholipids. 
Drawn by Dr. G.C. BURDGE using data from SHERMAN et al. [2001].
Figure 4.3  —   General model for the transfer of nutrients from mother to fetus. 
Drawn by Dr G.C. BURDGE. 
accretion by the brain. The extent of the increase differs among pregnant 
women in different countries [OTTO et al., 1997], perhaps indicating dietary 
differences during the pre-pregnancy period. AL et al. [1997] reported that 
maternal plasma phospholipid DHA content was lower in women who had 
had multiple pregnancies than in those in their first pregnancy. This may 
indicate that maternal body stores are important in maintaining plasma DHA 
status but that these may be eroded by multiple pregnancies. 
4-1-3 Maternal supply of DHA to the infant after birth
Human breast milk contains DHA, although the amount differs among 
populations and sub-groups of the population, one important influence being 
diet (Table 4.1) [see LAURITZEN et al., 2001 for a discussion]. However, a typical breast 
milk DHA concentration in Western populations is 0.2 to 0.3% of fatty acids or 
about 0.02% of milk. Note that Inuit women have a much higher breast milk DHA 
content than women consuming a typical Western diet (Table 4.1). Breast milk 
DHA content decreases with duration of lactation [see LAURITZEN et al., 2001]. 
4-2  DHA plays special roles in brain
and eye development (and function)
Studies in rats, mice, guinea-pigs, cats, pigs and monkeys demonstrate 
that maternal deprivation of n-3 fatty acids results in decreased accumulation of 
DHA into the brain and eye, and in reduced visual responses and discrimination 
[WHEELER et al., 1975; FRANÇOIS et al., 1980; NEURINGER et al., 1984; 1986; 1988; REISBICK 
et al., 1990; WEISINGER et al., 1996] and in impaired learning [LAMTEY, WALKER, 1976; 
YAMAMOTO et al., 1988]. Some studies demonstrated that supplementation with 
DHA or fish oil after birth could restore the abnormalities [CONNOR, NEURINGER, 
1988]. A study in monkeys showed that maternal deprivation of n-3 PUFAs also 
resulted in behavioural deficits in the offspring such as increased drinking 
frequency, increased anxiety, depression and impaired socialisation [REISBICK et 
al., 1992]. Thus, an adequate supply of n-3 PUFAs, and perhaps DHA in particular, 
appears essential for visual, neural and behavioural development to occur in an 
appropriate way. In humans, maternal dietary intake of DHA (and also of 
arachidonic acid) is related to head circumference at birth [CRAWFORD et al., 1986; 
DOYLE et al., 1990; KOLETZKO, BRUNN, 1991], indicating the importance of DHA 
supply to the fetus to in utero brain growth.
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n-3 PUFAs, most likely DHA, appear to be required for several aspects of 
normal brain development and function. During the structural development 
of the brain neurones develop by outgrowth of extensions called neurites and 
by establishing connections between neurites. Nerve growth factor (NGF) 
promotes the differentiation of neurones. Deficiency of n-3 PUFAs in pregnant 
rats has been demonstrated to decrease the NGF concentration in the brain 
of the offspring [IKEMOTO et al., 2000] and to decrease neurone length in the 
hippocampus and cortex, although not in the hypothalamus, of the offspring 
at 6 weeks of age [IKEMOTO et al., 1997; AHMAD et al., 2002], suggesting an 
impairment of neurite outgrowth. DHA deficiency also results in impaired 
dopaminergic and serotoninergic neurotransmission [ZIMMER et al., 2000] and 
decreased neuronal Na+/K+ ATPase activity [BOWEN, CLANDININ, 2002]. 
The role of DHA in the eye appears to be related to providing an 
environment that allows the protein rhodopsin to undergo conformational 
changes necessary for signal transduction [VAIDYANATHAN et al., 1994] (Figure 4.4). 
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Figure 4.4  —   Model of the role of docosahexaenoic acid (DHA) in the membrane of retinal rod 
outer segments in allowing metarhodopsin (MR) to respond to visual signals. 
The structure of DHA allows phospholipids containing two DHA moieties to act 
like a spring enabling metarhodopsin to change conformation upon receipt of a 
visual stimulus. The conformational change initiates the signaling 
events. 
Drawn by Dr G.C. BURDGE. 
Signal
Studies with rhodopsin imbedded in artificial membrane bilayers demonstrate 
that phospholipids containing two DHA molecules are superior to phospholipids 
containing one or no DHA molecules [MITCHELL, LITMAN, 1998].
4-3 DHA and visual function 
4-3-1 Pre-term human infants
Pre-term birth results in interruption of DHA supply from the mother and 
so the infant is at great risk of decreased DHA status. Supply of human breast 
milk, which contains long chain PUFAs including DHA, results in improved visual 
development in preterm infants compared with feeding formula that does not 
contain long chain PUFAs [UAUY et al., 1990; BIRCH DG et al., 1992; BIRCH EE et al., 
1992]. A number of studies reported that addition of DHA to pre-term formulas 
resulted in improved visual acuity [UAUY et al., 1990; BIRCH DG et al., 1992; BIRCH EE 
et al., 1992; CARLSON et al., 1993; 1996; CARLSON, WERKMAN, 1996; WERKMAN, CARLSON, 
1996; FALDELLA et al., 1996; O’CONNOR et al., 2001] compared with infants receiving 
standard formula, although one study was negative [VAN WEZEL-MEIJLER et al., 2002] 
and the positive effects on visual acuity eventually diminished [CARLSON et al., 
1993; CARLSON, WERKMAN, 1996; WERKMAN, CARLSON, 1996]. A meta-analysis including 
studies published up to 1996 (4 studies) showed differences between DHA-
supplemented formula and standard formula in visual acuity at 2 and 4 months of 
age; improvement with DHA containing formula was roughly 23 and 14% at 2 and 
4 months, respectively. It was concluded that DHA is efficacious with respect to 
early visual system development, but whether this advantage is maintained 
remains to be determined [SANGIOVANNI et al., 2000].
4-3-2 Term infants
WILLIAMS et al. [2001] observed that children whose mothers ate oily fish 
during pregnancy tended to have better visual acuity at 3.5 years than children 
whose mothers did not. JORGENSEN et al. [2001] observed a positive association 
between DHA intake from breast milk and visual acuity at 4 months of age. 
Some studies show better visual acuity in term infants fed breast milk than in 
those fed standard formula [MAKRIDES et al., 1995; 2000; JORGENSEN et al., 1996; 
BIRCH et al., 1998; HOFFMAN et al., 2000]. Other studies show better visual acuity 
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in infants fed milk formula supplemented with DHA than without DHA 
[MAKRIDES et al., 1995; 2000; CARLSON et al., 1996; BIRCH et al., 1998; HOFFMAN et al., 
2000], although some studies do not show such differences [JORGENSEN et al., 
1996; AUESTAD et al., 1997; 2001; 2003; MAKRIDES et al., 2000]. These data have been 
subjected to meta-analysis. One meta-analysis concluded that DHA-containing 
formula results in better visual acuity at 2 months, and perhaps 4 months, of 
age than seen with non-DHA containing formulas [SANGIOVANNI et al., 2000]. 
However a second meta-analysis concluded that there is little evidence in 
favour of benefit for visual development of term infants [SKIMMER, 2001].
4-4 DHA and cognitive development
4-4-1 Pre-term infants
LUCAS et al. [1992] reported that pre-term infants who had received breast 
milk for one month post-partum had a significantly higher IQ at 8 years of age 
than infants who received standard formulas. They speculated that the difference 
may be due to the presence of long chain PUFAs, including DHA, in breast milk 
but not formula. However, a later study by the same researchers found that breast 
milk was not superior to standard formula with respect to Bayley Mental 
Development Index at 1 or 1.7 years of age [LUCAS et al., 2001], although FEWTRELL et 
al. [2002] did show such superiority of breast milk at the same ages. 
4-4-2 Term infants
DANIELS et al. [2004] reported that children of mothers who ate fish four 
times per week during pregnancy had higher developmental scores at 18 months 
than children of mothers who did not eat fish. HELLAND et al. [2003] supplemented 
the diet of pregnant women with 2.4 g/day long chain n-3 PUFAs (including 1.2 g/
day DHA) from week 18 of pregnancy until 3 months post-partum. They assessed 
the intelligence and achievement of the children born to these mothers at 4 years 
of age using the Kaufman Assessment Battery for Children. This has four 
components: sequential processing, simultaneous processing, achievement, 
non-verbal abilities. The authors combined results from the first two components 
to give a “mental processing score” which is indicative of intelligence. Children of 
mothers in the control group scored 102.3 + 11.3 while those of mothers in the 
fish oil group scored 106.4 + 7.4, the difference between the two groups being 
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significant (P = 0.049). Thus, in this study early exposure to long chain n-3 PUFAs 
augmented children’s intelligence at 4 years of age.
Consistent with the idea that early DHA supply promotes cognitive and 
intellectual development, GIBSON et al. [1997] reported significant correlations 
between breast milk or infant cord blood erythrocyte DHA contents and mental 
development at one year of age as assessed by the Bayley Mental Development 
Index. Breast feeding or long chain PUFA supplemented formula was shown to 
promote cognitive development at 4 months of age [AGOSTONI et al., 1995] but not 
at 2 years [AGOSTONI et al., 1997]. WILLATTS et al. [1998] reported that a DHA 
containing formula given from birth to 4 months of age improved problem 
solving at 10 months. However, two studies found no relationship between 
umbilical cord plasma DHA levels and cognitive function in 4 [GHYS et al., 2002] or 
7 [BAKKER et al., 2003] year olds, and several studies fail to show effects of breast 
feeding or long chain PUFA containing formula on measures of cognitive 
development assessed at between 2 and 4 years of age [SCOTT et al., 1998; MAKRIDES 
et al., 2000; AUESTAD et al., 2001; 2003; GHYS et al., 2002; BAKKER et al., 2003].
4-5  Dietary strategies to increase 
maternal DHA status
With the recognition that maternal supply of DHA to the fetus is important 
(Section 4-1) and that fetal and infant DHA status is important for optimal visual 
and brain development and function (Sections 4-2, 4-3, 4-4), attempts to increase 
maternal DHA status have been made. Clearly the simplest way to do this would 
be to increase maternal DHA intake from fish or from fish oils or from other long 
chain n-3 PUFA rich oils (e.g. algal oil rich in DHA). Regular consumption of oily 
fish results in higher maternal erythrocyte DHA content [OLSEN et al., 1991; 
SANJURJO et al., 1995]. CONNOR et al. [1996] reported that consumption of sardines 
and fish oil by women from week 30 of pregnancy resulted in higher DHA 
contents of maternal plasma and erythrocytes 4 weeks later than observed in 
women taking placebo. In that study a total of 3 g long chain n-3 PUFAs including 
1.1 g DHA were supplied per day. A similar intake of long chain n-3 PUFAs (2.7 g/
day) and of DHA (1.1 g/day) provided as fish oil from week 30 of pregnancy 
resulted in higher DHA contents of maternal plasma phospholipids and of 
umbilical cord vein and artery at birth [VAN HOUWELINGEN et al., 1995].  Fish oil 
providing 3.3 g/day long chain n-3 PUFAs (2.2 g/day as DHA) from week 20 of 
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pregnancy resulted in higher DHA contents of maternal erythrocytes at weeks 30 
and 37 of pregnancy and at 6 weeks post-partum [DUNSTAN et al., 2004]. Furthermore 
the DHA content of cord blood erythrocytes was 40% higher than in the placebo 
group [DUNSTAN et al., 2004]. A much lower intake of DHA (200 mg/day) from week 
15 of pregnancy resulted in higher DHA content of maternal plasma erythrocytes 
at week 28 of pregnancy and at birth, although there was no effect on DHA 
content of cord blood plasma or erythrocytes [MONTGOMERY et al., 2003].  
Breast milk DHA content can be increased by maternal supplementation 
with fish oil [HARRIS et al., 1984], DHA-rich oil [JENSEN et al., 2000; HAWKES et al., 
2002] or long chain n-3 PUFA rich eggs [JENSEN et al., 2000]. HARRIS et al. [1984] 
gave lactating women 5 g/day fish oil for 28 days or 10 g/day fish oil for 14 days 
or 47 g/day fish oil for 8 days.  Levels of DHA in breast milk were 0.1% of total 
fatty acids at baseline and 0.5, 0.8 and 4.8% of fatty acids after 5, 10 and 47 g/
day fish oil, respectively. HAWKES et al. [2002] gave lactating women placebo, 
“low” dose DHA (300 mg/day) or “high” dose DHA (600 mg/day) from day 3 
post-partum for 4 weeks. They found that the DHA content of maternal 
plasma, maternal mononuclear cells, breast milk and breast milk cells 
increased in relation to DHA intake. In another low dose approach, JENSEN et 
al. [2000] compared fish oil, algal oil and eggs as a source of DHA for 
incorporation into breast milk: lactating women (two weeks after giving birth) 
received about 200 mg/day DHA from the oils or eggs for 4 weeks. This 
resulted in an increase in DHA in maternal plasma phospholipids (from 2.5 to 
about 4% of total fatty acids) and in breast milk (from about 0.2 to about 0.4% 
of total fatty acids). Furthermore infant plasma phospholipid DHA increased 
from about 3.6 to about 5% of total fatty acids. This demonstrates that 
increased consumption of DHA by lactating women results in increased DHA 
in breast milk, subsequently elevating infant DHA status. 
4-6  Long chain n-3 PUFAs and 
childhood developmental disorders
Children with attention deficit hyperactivity disorder (ADHD) or autistic 
spectrum disorders appear to show lower levels of long chain n-3 PUFAs in their 
plasma or erythrocytes than control children [MITCHELL et al., 1987; STEVENS et al., 
1996; BELL et al., 2000; 2004; BURGESS et al., 2000; VANCASSEL et al., 2001], leading to the 
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suggestion that these and other developmental disorders such as dyslexia and 
dyspraxia are related to some sort of fatty acid deficiency state [RICHARDSON, 2004]. 
In one study behavioural and learning problems were greater in boys (a mix of 
controls and those with ADHD) with low levels of long chain n-3 PUFAs in their 
plasma phospholipids [BELL et al., 2000]. Therefore, normalisation of fatty acid 
levels or proportions might lead to clinical benefit. This has been examined in a 
limited number of trials.
A study of 0.345 g DHA/day for four months showed no effect on measures 
of inattention and impulsivity or on parent-rated symptoms among children with 
ADHD aged 6 to 12 years [VOIGT et al., 2001]. Another study using foods providing 
children aged 6 to 12 years with about 0.5 g DHA/day for two months showed no 
improvements in the ADHD outcome measures made [HIRAYMA et al., 2004]. In 
another study 0.56 g/day long chain n-3 PUFAs (mostly in the form of DHA and in 
combination with some γ-linolenic acid and arachidonic acid) resulted in 
improvements in only two out of sixteen outcomes [STEVENS et al., 2003].
One small study of long chain n-3 PUFAs (666 mg/day, mostly as DHA) in 
combination with γ-linolenic acid reported significant beneficial effects after 
12 weeks on 6 out of 14 outcomes in dyslexic children [RICHARDSON, PURI, 2002]. 
RICHARDSON [2004] also discusses data from unpublished studies in dyslexia 
and dyspraxia, which suggest some clinical benefits.
4-7  Long chain n-3 PUFAs and 
psychiatric and psychological 
disorders in adults
RUDIN [1981] was the first to suggest that mental disorders might result 
from a deficiency in n-3 PUFAs and might respond to provision of these fatty 
acids. Schizophrenic patients have lower levels of long chain n-3 PUFAs in 
their erythrocytes than do controls [GLEN et al., 1994; YAO et al., 1994; PEET et al., 
1995; EDWARDS et al., 1998]. In a study of nine countries, HIBBELN [1998] 
demonstrated a significant correlation between high annual fish consumption 
and lower prevalence of major depression, an observation that is compatible 
with a proposed protective effect of long chain n-3 PUFAs. There was also a 
significant correlation between low fish consumption and depressive 
85
4 – LONG CHAIN N-3 FATTY ACIDS AND THE BRAIN
symptoms among Finnish adults [TANSKANEN et al., 2001]. Other studies show 
that fish consumption is associated with lower risk of bipolar disorder 
[NOAGHIUL, HIBBELN, 2003] and homicide [HIBBELN, 2001]. A recent study showed 
that consumption of fish, oily fish or DHA is associated with lower risk of 
hostility in young adults [IRIBARREN et al., 2004].
A small study using a very high dose of long chain n-3 PUFAs (9.6 g/day) 
reported a reduction in depressive symptoms [SU et al., 2003], while a study 
using a lower dose of DHA alone (2 g/day) found no such effect [MARANGELL et 
al., 2003]. Intervention with 6.2 g/day EPA+DHA in patients with bipolar maniac 
depression resulted in significant improvements in nearly all outcomes, 
especially with respect to depressive symptoms, after 4 months [STOLL et al., 
1999]. Likewise, 2 g/day EPA as the ethyl ester improved symptoms in patients 
with unipolar depressive disorder after 4 weeks [NEMETS et al., 2002]. The first 
trial of long chain n-3 PUFAs in schizophrenia identified clinical improvement 
with EPA (2 g/day), but not with DHA [PEET et al., 2001]. Subsequently, trials have 
examined the effect of EPA as an ethyl ester using doses of 1, 2 [PEET, HORROBIN, 
2002], 3 [FENTON et al., 2001; EMSLEY et al., 2002] or 4 [PEET, HORROBIN, 2002] g/day. 
Two of these studies [PEET, HORROBIN, 2002; EMSLEY et al., 2002] demonstrated 
clinical improvement with EPA. Although these findings are encouraging, a 
Cochrane review concluded that long chain n-3 PUFAs should be regarded 
only as an experimental treatment for schizophrenia at this stage [JOY et al., 
2003]. One study reported significant benefit from 1 g/day EPA in borderline 
personality disorder [ZANARINI, FRANKENBURG, 2003], while two studies report 
anti-aggressive effects of DHA [HAMAZAKI et al., 1996; 2002].
4-8  Long chain n-3 PUFAs
and neurodegenerative diseases
of ageing
Fish intake (> 20 g/day) was identified as a protective factor against 
cognitive decline, dementia and Alzheimer’s disease among older Dutch 
subjects [KALMIJN et al., 1997]. A prospective study of elderly subjects found 
that those who ate oily fish at least once per week had a 60% lower risk of 
Alzheimer’s disease over the following 4 years [MORRIS et al., 2003]. DHA rather 
than EPA appeared to be the protective component. Post-mortem studies 
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showed that the brains of Alzheimer’s disease sufferers contain less DHA than 
those without the disease [PRASAD et al., 1998; TULLY et al., 2003]. Some studies 
have linked low plasma long chain n-3 PUFA status to dementia [SODERBERG et 
al., 1991] and cognitive impairment [CONQUER et al., 2000].
4-9 Conclusions
DHA is a key structural component of the brain and retina, where it 
plays particular, unique functional roles. A supply of DHA is very important 
early in life, especially during the fetal and early infant periods when the eye 
and central nervous system are developing. Since the supply must come from 
maternal sources (via the placenta and breast milk), maternal DHA status is 
likely to be important in determining eye and brain development early in life. 
Thus maintenance of maternal DHA status is the key to optimising DHA 
supply to the developing fetus and newborn infant. Animal experiments 
indicate that a lack of n-3 PUFAs in the diet results in poor visual development 
and in learning and behavioural abnormalities. There is evidence that preterm 
infants, in whom this early DHA supply is interrupted, have poorer visual and 
cognitive development than term infants, although the provision of breast 
milk or DHA-supplemented formulas improves these outcomes. Increased 
consumption of DHA during pregnancy or lactation increases the DHA 
content of maternal and cord plasma and of breast milk, indicating a greater 
ability of the mother to supply DHA. There is some evidence for benefits of 
increased DHA supply either through the maternal diet during pregnancy or 
breast feeding or in formulas in term infants, although this is less strong than 
the evidence in pre-term infants. Newly emerging areas of interest relate to 
the influence of long chain n-3 PUFAs on childhood developmental disorders, 
adult psychiatric and psychological disorders, and neurodegenerative diseases 
of ageing. These conditions appear to be associated with a lowered long chain 
n-3 PUFA status. Additionally, there is epidemiological evidence for a lowered 
risk of psychiatric, psychological disorders, and neurodegenerative disorders 
with increased consumption of fish. Intervention studies indicate clinical 
benefit from long chain n-3 PUFAs in childhood developmental and adult 
psychiatric and psychological disorders, although the evidence base is not yet 
sufficiently robust for clear recommendations to be made. Interestingly many 
of these studies are indicative that EPA is more important than DHA, which 
contrasts with the relative roles of the fatty acids in very early brain 
development. 
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  5 –  Long chain n-3 fatty 
acids and inflammation
5-1   Inflammation in health
and disease
Inflammation is the body’s immediate response to infection or injury; 
as such it is a component of the immune response. It is typified by redness, 
swelling, heat and pain. These occur as a result of increased blood flow, 
increased permeability across blood capillaries, which permits large 
molecules (e.g. complement, antibodies, cytokines) to leave the bloodstream 
and cross the endothelial wall, and increased movement of leukocytes from 
the bloodstream into the surrounding tissue. Inflammation functions to 
begin the immunological process of elimination of invading pathogens and 
toxins and to repair damaged tissue. These responses must be ordered and 
controlled. The movement of cells into the inflammatory/infected site is 
induced by the up-regulation of adhesion molecules such as E-selectin, 
intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion 
molecule-1 (VCAM-1) on the surface of endothelial cells allowing leukocyte 
binding and subsequent diapedesis. The earliest cells appearing at inflamed 
sites are granulocytes, with monocyte/macrophages and lymphocytes 
appearing later. Granulocytes and monocyte/macrophages are involved in 
pathogen killing, in clearing up cellular and tissue debris, and in tissue 
repair. The activity of these cells is induced by certain triggers. One 
important exogenous trigger is bacterial endotoxin (also known as 
lipopolysaccharide or LPS), a component of the cell wall of Gram-negative 
bacteria. LPS can trigger complement activation (resulting in vasodilation 
and increased vascular permeability), coagulation, fibrinolysis and the kinin 
cascade. LPS can directly activate monocyte/macrophages inducing them to 
form cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 
and IL-8; eicosanoids, such as prostaglandin (PG) E2; nitric oxide; matrix 
metalloproteinases (MMPs); and other mediators. LPS also induces adhesion 
97
molecule expression on the surface of endothelial cells and leukocytes. The 
cytokines produced by monocyte/macrophages also serve to regulate the 
whole body response to infection and injury (Figure 5.1). Thus, inflammation 
and the inflammatory response are part of the normal, innate immune 
response; inflammatory mediators also provide a link between the innate 
and acquired immune responses (Figure 5.1). However, when inflammation 
occurs in an uncontrolled manner disease ensues. High levels of TNF-α, 
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Figure 5.1  —   The role of inflammation in host defense and in causing tissue damage. Modified 
from P.C. CALDER. Polyunsaturated fatty acids and immunity. Lipids, 2001; 36, 
1007-1024, with permission from the American Oil Chemists’ Society. 
IL-1β and IL-6 are particularly destructive. Chronic overproduction of TNF-α 
and IL-1 may cause muscle wasting and loss of bone mass. TNF-α, IL-1 and 
IL-6 are implicated in causing some of the pathological responses that occur 
in endotoxic shock, in adult respiratory distress syndrome and in chronic 
inflammatory diseases such as rheumatoid arthritis and inflammatory bowel 
disease. It is this highly destructive nature of these and other inflammatory 
mediators that prompted THOMAS [1972] to say «Our arsenals for fighting off 
bacteria are so powerful, and involve so many different defense mechanisms, 
that we are more in danger from them than from the invaders. We live in the 
midst of explosive devices; we are mined».
5-2  Arachidonic acid-derived 
eicosanoids and inflammation
Inflammatory cells typically contain a high proportion of the n-6 
polyunsaturated fatty acid (PUFA) arachidonic acid and low proportions of n-3 
PUFAs especially eicosapentaenoic acid (EPA). The exact proportion of 
arachidonic acid in human inflammatory cells varies according to cell type and 
the lipid fraction examined [DINARELLO et al., 1983; LEWIS et al., 1990]. The 
principal functional role for arachidonic acid is as a substrate for synthesis of 
the eicosanoid family of bioactive mediators according to the metabolic 
processes described in figures 2.4 and 2.5. Eicosanoids are involved in 
modulating the intensity and duration of inflammatory responses [see LEWIS et 
al., 1990; TILLEY et al., 2001 for reviews]. However, these mediators have cell- and 
stimulus-specific sources and frequently have opposing effects. For example, 
PGE2 is produced mainly by monocytes, macrophages and, to a lesser extent, 
neutrophils and inhibits the production of TNF-α and IL-1β [DINARELLO et al., 
1983; KNUDSEN et al., 1986; KUNKEL et al., 1988; MEJA et al., 1997; DOOPER et al., 2002; 
MILES et al., 2002], while leukotriene (LT) B4 is produced mainly by neutrophils, 
other granulocytes and, to a lesser extent, monocytes and macrophages, and 
increases the production of TNF-α and IL-1β [ROLA-PLESZCZYNSKI, LEMAIRE, 1985; 
GAGNON et al., 1989; SCHADE et al., 1989]. Thus, the overall physiological (or 
pathophysiological) outcome will depend upon the cells present, the nature 
of the stimulus, the timing of eicosanoid generation, the concentrations of 
different eicosanoids generated and the sensitivity of target cells and tissues 
to the eicosanoids generated. Recent studies have demonstrated that PGE2 
induces cyclooxygenase (COX)-2 in fibroblasts cells and so upregulates its 
own production [BAGGA et al., 2003], induces production of IL-6 by macrophages 
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[BAGGA et al., 2003], inhibits 5-lipoxygenase (LOX) and so decreases production 
of 4-series LTs [LEVY et al., 2001], and induces 15-LOX so promoting the 
formation of lipoxins [VACHIER et al., 2002] that have been found to have anti-
inflammatory effects [GEWIRTZ et al., 2002; SERHAN et al., 2003].  Thus PGE2 
possesses both pro- and anti-inflammatory actions. 
5-3  Long chain n-3 PUFAs
and inflammatory eicosanoid 
production
Increased consumption of long chain n-3 PUFAs such as EPA and 
docosahexaenoic acid (DHA), results in increased proportions of those fatty 
acids in inflammatory cell phospholipids, partly at the expense of arachidonic 
acid (Figures 2.10 and 5.2). Since significantly increased consumption of fish 
oil results in a decrease in the amount of arachidonic acid in the membranes 
of inflammatory cells, there will be less substrate available for synthesis of 
eicosanoids from arachidonic acid (Figure 5.3). Thus, fish oil supplementation 
of the human diet has been shown to result in decreased production of PGE2 
[ENDRES et al., 1989; MEYDANI et al., 1991; CAUGHEY et al., 1996; TREBBLE et al., 
2003], TXB2 [CAUGHEY et al., 1996], LTB4 and 5-HETE [LEE et al., 1985; SPERLING et 
al., 1993] (Figure 5.4) and LTE4 [VON SCHACKY et al., 1993] by inflammatory cells. 
Since EPA is able to act as a substrate for both COX and 5-LOX (Figure 2.6), 
fish oil supplementation of the human diet has been shown to result in 
increased production of LTB5, LTE5 and 5-HEPE by inflammatory cells [LEE et 
al., 1985, SPERLING et al., 1993; VON SCHACKY et al., 1993] (Figure 5.4), although 
generation of PGE3 has been more difficult to demonstrate [HAWKES et al., 
1991]. The functional significance of this is that the mediators formed from 
EPA are believed to be less potent than those formed from arachidonic acid. 
For example, LTB5 is 10- to 100-fold less potent as a neutrophil chemotactic 
agent than LTB4 [GOLDMAN et al., 1983; LEE et al., 1984]. Recent studies have 
compared the effects of PGE2 and PGE3 upon production of cytokines by 
cells lines and by human cells. BAGGA et al. [2003] reported that PGE3 was a 
less potent inducer of COX-2 gene expression in fibroblasts and of IL-6 
production by macrophages. However, PGE2 and PGE3 had equivalent 
inhibitory effects upon production of TNF-α [DOOPER et al., 2002; MILES et al., 
2002] and IL-1β [MILES et al., 2002] by human mononuclear cells stimulated 
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Figure 5.2  —   Effect of dietary fats on the fatty acid composition of mouse macrophages. Male 
C57Bl6 mice were fed on a low fat (LF; 2.5% by weight mixed oils) diet or on one 
of four high fat (21% by weight fat) diets in which the bulk of the fat was as 
coconut oil, olive oil, safflower oil or fish oil. After 6 weeks the mice received an 
intraperitoneal injection of Brewer’s thioglycollate broth and 4 days later 
peritoneal macrophages were isolated. The fatty acid composition of the 
macrophages was determined by gas chromatography. Data are mean + SEM % 
of arachidonic acid or eicosapentaenoic acid (EPA) from 6 mice per diet and are 
from WALLACE et al. [2000].
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with endotoxin. The reduction in generation of arachidonic acid-derived 
mediators which accompanies fish oil consumption has lead to the idea that 
fish oil is anti-inflammatory (Figure 5.5). 
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Figure 5.3  —   Effect of dietary fats on prostaglandin E2 production by mouse macrophages. 
Male C57Bl6 mice were fed on a low fat (LF; 2.5% by weight mixed oils) diet or 
on one of four high fat (21% by weight fat) diets in which the bulk of the fat 
was as coconut oil (CO), olive oil (OO), safflower oil (SO) or fish oil (FO). After 
8 weeks the mice received an intraperitoneral injection of Brewer’s thioglycollate 
broth and four days later peritoneal macrophages were isolated. Macrophages 
were incubated with bacterial endotoxin and prostaglandin (PG) E2 
concentrations in the culture medium measured 8 hours later. Data are mean 
+ SEM from 3 mice per diet and are from YAQOOB, CALDER [1995].
Figure 5.4  —   Effect of fish oil supplementation on production of lipoxygenase metabolites by human 
neutrophils and monocytes. 
Healthy subjects supplemented their diet of fish oil capsules providing 9.4 g EPA 
plus 5.0 g DHA per day for a period of 10 weeks. Blood neutrophils and monocytes 
were isolated at baseline and after 3 and 10 weeks and stimulated with calcium 
ionophore for 15 minutes. The concentrations of lipoxygenase metabolites of 
arachidonic acid and eicosapentaenoic acid were measured by reverse phase 
HPLC. Data are mean + SEM from 8 subjects and are from SPERLING et al. [1993].  
HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; LT, 
leukotriene.
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Figure 5.5  —   Classic view of the anti-inflammatory actions of long chain n-3 PUFAs. 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) antagonise the 
incorporation of arachidonic acid into inflammatory cell membrane phospholipids 
and inhibit the metabolism of arachidonic acid by cyclooxygenase (COX) and 
lipoxygenase (LOX) enzymes. 
LT, leukotriene; PG, prostaglandin; TX, thromboxane.
In addition to long chain n-3 PUFAs modulating the generation of 
eicosanoids from arachidonic acid and to EPA acting as substrate for the 
generation of alternative eicosanoids, recent studies have identified a novel 
group of mediators, termed E-series resolvins, formed from EPA by COX-2 that 
appear to exert anti-inflammatory actions [SEHRAN et al., 2000a; 2000b; 2002]. In 
addition, DHA-derived mediators termed D-series resolvins, docosatrienes 
and neuroprotectins also produced by COX-2 have been identified and these 
too appear to be anti-inflammatory [HONG et al., 2003; MARCHESELLI et al., 2003; 
MUKHERJEE et al., 2004]. This is an exciting new area of n-3 fatty acids and 
inflammatory mediators and the implications to a variety of conditions may be 
of great importance.
5-4  Anti-inflammatory effects
of long chain n-3 PUFAs
other than altered eicosanoid 
production
Although their action in antagonizing arachidonic acid metabolism is a 
key anti-inflammatory effect of n-3 PUFAs, these fatty acids have a number of 
other anti-inflammatory effects that might occur downstream of altered 
eicosanoid production or might be independent of this. For example, animal 
and human studies have shown that dietary fish oil results in suppressed 
production of pro-inflammatory cytokines and can modulate adhesion 
molecule expression (Table 5.1). 
5-4-1  n-3 PUFAs and inflammatory
cytokine production
Cell culture studies demonstrate that EPA and DHA can inhibit the 
production of IL-1β and TNF-α by monocytes [CHU et al., 1999], and the 
production of IL-6 and IL-8 by venous endothelial cells [DE CATERINA et al., 1994; 
KHALFOUN et al., 1997]. Fish oil feeding decreased ex vivo production of TNF-α, 
IL-1β and IL-6 by rodent macrophages [BILLIAR et al., 1988; RENIER et al., 1993; 
YAQOOB, CALDER, 1995]. Supplementation of the diet of healthy human volunteers 
with fish oil providing more than 2.4 g EPA plus DHA per day decreased 
production of TNF, IL-1 and IL-6 by mononuclear cells [ENDRES et al., 1989; 
MAYDANI et al., 1991; GALLAI et al., 1993; ABBATE et al., 1996; CAUGHEY et al., 1996]. 
CAUGHEY et al. [1996] reported a significant inverse correlation between the EPA 
content of mononuclear cells and the ability of those cells to produce TNF-α 
and IL-1β in response to endotoxin (Figure 5.6). Recent studies have confirmed 
the ability of dietary fish oil to decrease production of TNF α [TREBBLE et al., 2003] 
and IL-6 [TREBBLE et al., 2003; WALLACE et al., 2003] by human mononuclear cells. 
Furthermore these studies provide for the first time information on the dose-
response relationship between dietary intake of long chain n-3 fatty acids and 
production of these cytokines. It should be noted that there are also several 
studies that fail to show effects of dietary long chain n-3 fatty acids on production 
of inflammatory cytokines in humans [see CALDER, 2001 for references]. It is not 
clear what the reason for this is but dose of n-3 fatty acids used and other 
technical factors are likely to be contributing factors.
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Table 5.1  —   Summary of the anti-inflammatory effects of long chain n-3 PUFAs.
Anti-inflammatory effect Mechanism(s) likely to be involved 
Decreased generation of arachidonic Decreased arachidonic acid in cell
acid-derived eicosanoids membrane phospholipids;
(many with inflammatory actions) Inhibition of arachidonic acid metabolism;
 Decreased induction of COX-2,
 5-LOX and 5-LOX activating protein 
Increased generation of Increased cell membrane phospholipid
EPA-derived eicosanoids  content of EPA
(many with less inflammatory and some
with anti-inflammatory actions) 
Increased generation of EPA and Increased cell membrane phospholipid
DHA-derived resolvins (some with content of EPA and DHA
anti-inflammatory actions) 
Decreased generation of inflammatory Decreased activation of NFκB 
cytokines (TNF-α, IL-1β, IL-6, IL-8)  (via decreased phosphorylation of IκB);
 Activation of PPARγ;
 Altered activity of other
 transcription factors;
 Differential effects of arachidonic acid-
 vs. EPA-derived eicosanoids  
Decreased expression of adhesion Decreased activation of NFκB
molecules  (via decreased phosphorylation of IκB);
 Altered activity of other
 transcription factors  
Decreased leukocyte chemotaxis Not clear – perhaps decreased expression
 of receptors for some chemoattractants
Abbreviations used:  COX, cyclooxygenase; DHA, docosahexaenoic acid;
EPA, eicosapentaenoic acid; IκB, inhibitory subunit of NFκB;
IL, interleukin; LOX, lipoxygenase; NFκB, nuclear factor κ B;
PPAR, peroxisome proliferators activated receptor;
TNF, tumour necrosis factor.
5-4-2  n-3 PUFAs and adhesion molecule expression
Although it was shown some years ago that culture of murine macrophages 
with n-3 PUFAs decreased their ability to bind to various surfaces [CALDER et al., 1990], 
the first demonstration that these fatty acids could affect the expression of adhesion 
molecules on the cell surface was by DE CATERINA et al. [1994]. These authors showed 
that culture of human venous endothelial cells with DHA significantly decreased 
cytokine-induced surface expression of E-selectin, ICAM-1 and VCAM-1, and 
impaired the ability of ligand-bearing monocytes to adhere [DE CATERINA et al. 1995]. 
EPA also inhibited LPS-induced expression of these three adhesion molecules on 
human venous endothelial cells, and again this had the functional effect of decreasing 
binding of monocytes [WEBER et al., 1995]. In another cell culture study, EPA decreased 
surface expression of ICAM-1 on monocytes stimulated with interferon (IFN)-γ 
[HUGHES et al., 1996a]. Studies of dietary fatty acids and adhesion molecule expression 
are few. Dietary fish oil decreased expression of ICAM-1 on the surface of murine 
macrophages [MILES et al., 2000]. Supplementing the diet of healthy humans with fish 
oil providing about 1.5 g EPA plus DHA per day resulted in a lower level of expression 
of ICAM-1 on the surface of blood monocytes stimulated ex vivo with IFN-γ [HUGHES 
et al., 1996b]. Recently, dietary fish oil was found to decrease circulating levels of 
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Figure 5.6  —   The inverse relationship between the eicosapentaenoic acid (EPA) content of human 
mononuclear cells and their production of inflammatory cytokines. 
Healthy subjects modified their diet to include increased amounts of α-linolenic acid 
and/or long chain n-3 PUFAs for 4 weeks. Blood mononuclear cells were isolated and 
their fatty acid composition determined by gas chromatography. They were also 
incubated with bacterial endotoxin for 24 hours and the concentrations of tumour 
necrosis factor (TNF)-α and interleukin (IL)-1β measured. 
Reproduced from CAUGHEY et al., 1996 with permission by American Journal of Clinical 
Nutrition © Am J Clin Nutr. American Society for Clinical Nutrition. 
soluble VCAM-1 in elderly subjects [MILES et al., 2001], but it is not clear if this 
represents decreased surface expression of VCAM-1.
5-5  n-3 PUFAs
and inflammatory gene expression
Many of the anti-inflammatory effects of n-3 PUFAs appear to be exerted 
at the level of altered gene expression. However, these effects have been 
demonstrated only a limited number of times and often in artificial in vitro 
settings, and thus the extent of these effects in vivo is not yet clear. Nevertheless, 
cell culture and animal feeding studies indicate potentially very potent effects 
of n-3 PUFAs on expression of a range of inflammatory genes (Table 5.2). 
Culturing bovine chondrocytes with EPA or DHA markedly decreased 
cytokine-mediated induction of expression of the COX-2 (but not COX-1), TNF-α and 
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Table 5.2  —   Inflammatory genes downregulated by long chain n-3 PUFAs.
Gene expression Genes downregulated
Enzymes of eicosanoid metabolism COX-2
 5-LOX
 FLAP
Inflammatory cytokines TNF-α
 IL-1β
 IL-6
 MCP-1
Enzymes of arginine metabolism iNOS
Adhesion molecules VCAM-1
 ICAM-1 
Matrix proteinases Aggrecanase-1
 Aggrecanase-2 
 MMP-2
 MMP-3
 MMP-13   
Abbreviations used:  COX, cyclooxygenase; FLAP, 5-lipoxygenase activating protein; ICAM, 
intercellular adhesion molecule; IL, interleukin; iNOS, inducible nitric 
oxide synthase; LOX, lipoxygenase; MCP, monocyte 
chemoattractant protein; MMP, matrix metalloproteinase; TNF, 
tumor necrosis factor; VCAM, vascular cell adhesion molecule. 
IL-1α genes [CURTIS et al., 2000]. The same study investigated the influence of n-3 
PUFAs upon the expression of aggrecanase-1 and -2 genes. Aggrecanase-1 and -2 
degrade cartilage proteoglycan and their expression in cartilage is upregulated in 
response to the pro-inflammatory cytokines TNF-α and IL-1. n-3 PUFAs, but not other 
fatty acids, inhibited cytokine-mediated upregulation of expression of the 
aggrecanase-1 and aggrecanase-2 genes and of aggrecanase activity [CURTIS et al., 
2000]. This study has been extended by one using cultured explants of human 
osteoarthritic cartilage [CURTIS et al., 2002]. Including EPA or DHA in the culture 
medium markedly decreased the cytokine-induced upregulation of expression of 
the COX-2, IL-1α, IL-1β, TNF-α, 5-LOX, 5-LOX activating protein (FLAP), MMP-3, MMP-
13, and aggrecanase-1 genes in these cells. The n-3 PUFAs did not affect expression of 
the COX-1, 12-LOX or 15-LOX genes, which were not induced by cytokines [CURTIS et 
al., 2002]. Also, there was little effect of n-3 PUFAs on the expression of genes for the 
tissue inhibitor of metalloproteinase (TIMP)-1, -2 or -3, which again were not cytokine-
inducible [CURTIS et al., 2002]. These studies indicate a marked capacity of n-3 PUFAs 
to suppress the expression of inflammatory genes, with little effect on the expression 
of housekeeping (e.g. COX-1) or anti-inflammatory (TIMP) genes. They also indicate 
that one potential contributor to the reduction in generation of arachidonic acid-
derived eicosanoids after fish oil feeding may be decreased expression of the 
enzymes and proteins responsible for producing these mediators (e.g. COX-2, 5-LOX, 
FLAP). In an earlier study, DE CATERINA et al. [1994] had demonstrated that the down-
regulation of VCAM-1 expression on endothelial cells caused by DHA was exerted at 
the level of VCAM-1 gene expression, and that this effect was independent of effects 
on eicosanoid production and on antioxidant status. Furthermore, culture of murine 
peritoneal macrophages with DHA decreased the level of mRNA for inducible nitric 
oxide synthase (iNOS) after stimulation with LPS and IFN-γ [KHAIR-EL-DIN et al., 1996]. 
This effect correlated with decreased production of nitric oxide and was due to 
decreased transcription of the iNOS gene [KHAIR-EL-DIN et al., 1996].
A limited number of feeding studies have demonstrated an effect of dietary 
fish oil on inflammatory gene expression. Inclusion of fish oil in the diet 
completely abolished mRNA for TNF-α, IL-1β and IL-6 in the kidneys of 
autoimmune disease-prone mice [CHANDRASEKAR, FERNANDES, 1994]. Feeding mice a 
fish oil-rich diet significantly decreased the level of IL-1β mRNA in LPS- or phorbol 
ester-stimulated spleen lymphocytes [ROBINSON et al., 1996]; the lower IL-1β mRNA 
level was not due to accelerated degradation but to impaired synthesis. Fish oil 
feeding to mice lowered basal and LPS-stimulated TNF-α mRNA levels in 
peritoneal macrophages [RENIER et al., 1993]. ICAM-1 mRNA levels were lower in 
fresh peritoneal macrophages from mice fed fish oil [MILES et al., 2000].
Since eicosanoids derived from arachidonic regulate inflammatory gene 
expression, the effects of n-3 PUFAs might come about through antagonism of the 
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effects of arachidonic acid-derived mediators. However, at least some (if not all) of 
these effects seem to occur in an eicosanoid-independent manner [e.g. DE CATERINA 
et al., 1994]. It is now emerging that n-3 PUFAs might exert their effects through 
direct actions on the intracellular signalling pathways which lead to activation of 
one or more transcription factors such as nuclear factor kappa B (NFκB). 
NFκB plays a role in inducing a range of inflammatory genes including 
COX-2, ICAM-1, VCAM-1, E-selectin, TNF-α, IL-1β, IL-6, iNOS, acute phase 
proteins and MMPs in response to inflammatory stimuli [CHRISTMAN et al., 1998; 
CHEN et al., 1999] (Figure 5.7). The signalling pathway leading to NFκB activation 
109
5 – LONG CHAIN N-3 FATTY ACIDS AND INFLAMMATION
Figure 5.7  —   Outline of the pathway of upregulation of inflammatory gene expression via nuclear 
factor kappa B. 
CD14, cluster of differentiation 14 (the LPS receptor); COX, cyclooxygenase; ICAM, 
intercellular adhesion molecule; IκB, inhibitory subunit of NFκB; IκK, IκB kinase; IL, 
interleukin; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MCP, 
monocyte chemoattractant protein; MMPs, matrix metalloproteinases; NFκB, nuclear 
factor kappa B; RE, response element; TLR, toll-like receptor; TNF, tumor necrosis factor; 
VCAM, vascular cell adhesion molecule. 
Modified from P.C. CALDER, n-3 polyunsaturated fatty acids and inflammation: from 
molecular biology to the clinic. Lipids, 2003; 38: 342-352, with permission from the 
American Oil Chemists’ Society. 
is becoming better understood [KARIN, BEN-NERIAH, 2000; KARIN, DELHASE, 2000]. 
NFκB exists as an inactive heterotrimer in the cytosol of resting inflammatory 
cells; one of the subunits is called inhibitory subunit of NFκB (IκB). Upon 
stimulation, a signalling cascade activates a protein complex known as IκB 
kinase (IκK). Activated IκK phosphorylates IκB on two N-terminal serine 
residues, thus promoting its dissociation from the rest of the inactive NFκB 
trimer. The remaining NFκB heterodimer is rapidly translocated to the nucleus 
where it binds to response elements in target genes, so regulating their 
transcription. The phosphorylated IκB undergoes polyubiquination, targeting it 
for degradation by the 26S proteasome. Recent studies have shown that n-3 
PUFAs can down-regulate the activity of NFκB. Feeding mice fish oil resulted in 
a lower level of NFκB in the nucleus (i.e. activated NFκB) of LPS-stimulated 
spleen lymphocytes compared with feeding corn oil [XI et al., 2001]. Infecting 
the mice with the murine AIDS virus resulted in increased NFκB in the nucleus, 
but the level was lower in fish oil fed mice [XI et al., 2001]. The mechanism by 
which n-3 PUFAs decrease the activation of NFκB is not clear. However, 
incubating human monocytes with EPA or fish oil decreased LPS-induced 
activation of NFκB [CAMANDOLA et al., 1996; LO et al., 1999; NOVAK et al., 2003; ZHAO 
et al., 2004] and this was associated with decreased phosphorylation of IκB 
[ZHAO et al., 2004]. This suggests an effect of n-3 PUFAs on the signalling process 
leading to activation of IκK. Incubation of a pancreatic cell line with TNF-α 
markedly upregulated degradation of IκB, and this could be totally abolished by 
prior incubation of the cells with EPA [ROSS et al., 1999]. This effect could be due 
to inhibition of phosphorylation of IκB, so preventing it from being targeted for 
degradation, or to inhibition of the degradation process itself.
A second group of transcription factors currently undergoing scrutiny for 
their role in inflammation are the peroxisome proliferator activated receptors 
(PPARs). The main members of this family are PPARα and PPARγ. Although 
PPARα and γ play important roles in liver and adipose tissue, respectively 
[SCHOONJANS et al., 1996], they are also found in inflammatory cells [CHINETTI et 
al., 1998; RICOTE et al., 1998]. PPARs dimerise with the retinoid-X-receptor to 
regulate gene expression, and they can bind, and appear to be regulated by, 
PUFAs and eicosanoids [KLEIWER et al., 1995; DEVCHAND et al., 1996] (see Section 
2-4). PPARα deficient mice have a prolonged response to inflammatory stimuli 
[DEVCHAND et al., 1996], suggesting that PPARα activation might be «anti-
inflammatory». More recently, activators of both PPARα and γ have been shown 
to inhibit the activation of inflammatory genes including TNF-α, IL-1β, IL-6, IL-8, 
COX-2, VCAM-1, iNOS, MMPs and acute phase proteins [RICOTE et al., 1998; JIANG 
et al., 1998; POYNTER, DAYNES, 1998; JACKSON et al., 1999; MARX et al., 1999; TAKANO et 
al., 2000; WANG et al., 2001; XU et al., 2001]. Two mechanisms for the anti-
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inflammatory actions of PPARs have been proposed [see CHINETTI et al., 2000; 
DELEVIRE et al., 2001 for reviews]. The first is that PPARs might stimulate the 
breakdown of inflammatory eicosanoids through induction of peroxisomal 
β-oxidation. The second is that PPARs might interfere with/antagonize the 
activation of other transcription factors, including NFκB. n-3 PUFAs might act by 
increasing the level of these anti-inflammatory transcription factors.
There are a number of other transcription factors that are activated by 
inflammatory signals and which play a role in expression of inflammatory 
genes [see HWANG, RHEE, 1999 for a review]. It is possible that n-3 PUFAs might 
affect the activation of these factors, but this has not been studied to detail. 
However, effects of n-3 PUFAs on signalling processes that lead to activation 
of various transcription factors have been reported. For example, incubation 
of murine macrophages with EPA was found to decrease LPS-induced 
phosphorylation and activation of mitogen-activated protein kinase [LO et al., 
2000]. Thus, various intracellular signalling steps appear to be partly inhibited 
by the presence of increased amounts of n-3 PUFAs in cells.  
5-6  Clinical applications of the anti-
inflammatory effects of n-3 PUFAs
5-6-1  Introductory comments
Although the inflammation may afflict different body compartments, one 
common characteristic of inflammatory conditions and diseases is excessive or 
inappropriate production of inflammatory mediators including eicosanoids and 
cytokines. The roles of n-6 and n-3 PUFAs in shaping and regulating inflammatory 
processes and responses suggest that the balance of these fatty acids might be 
important in determining the development and severity of inflammatory diseases. 
The recognition that the long chain n-3 PUFAs have anti-inflammatory actions has 
led to the idea that supplementation of the diet of patients with inflammatory 
diseases may be of clinical benefit. Possible therapeutic targets for long chain n-3 
PUFAs are listed in table 5.3. Supplementation trials have been conducted in 
many of these diseases. Those dealing with rheumatoid arthritis, inflammatory 
bowel diseases (Crohn’s disease and ulcerative colitis) and asthma will be 
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discussed in some detail here. This is because a larger number of trials have been 
conducted in these diseases than in the others. 
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Table 5.3  —   List of diseases and conditions with an inflammatory component in which long 
chain n-3 PUFAs might be of benefit. 
Disease 
Rheumatoid arthritis
Crohn’s disease
Ulcerative colitis
Systemic lupus erythematosus
Type-1 diabetes
Cystic fibrosis
Childhood asthma
Adult asthma
Allergic disease
Psoriasis
Multiple sclerosis
Atherosclerosis
Acute cardiovascular events
Obesity
Systemic inflammatory response to surgery, trauma and critical illness
5-6-2 Rheumatoid arthritis
Rheumatoid arthritis is a chronic inflammatory disease characterized by 
joint inflammation that manifests as swelling, pain, functional impairment, 
morning stiffness, osteoporosis and muscle wasting. Joint lesions are 
characterized by infiltration of activated macrophages, T lymphocytes and 
plasma cells (antibody producing B lymphocytes) into the synovium (the 
tissue lining the joints) and by proliferation of synovial cells called synoviocytes. 
Synovial biopsies from patients with rheumatoid arthritis contain high levels 
of TNF-α, IL-1β, IL-6, IL-8 and granulocyte/macrophage-colony stimulating 
factor (GM-CSF), and synovial cells cultured ex vivo produce TNF-α, IL-1β, IL-6, 
IL-8 and GM-CSF for extended periods of time without additional stimulus 
[FELDMANN, MAINI, 1999]. COX-2 expression is increased in the synovium of 
rheumatoid arthritis patients, and in the joint tissues in rat models of arthritis 
[SANO et al., 1992]. PGE2, LTB4, 5-hydroxyeicosatetraenoic acid and also platelet 
activating factor are found in the synovial fluid of patients with active 
rheumatoid arthritis [SPERLING, 1995]. The efficacy of non-steroidal anti-
inflammatory drugs in rheumatoid arthritis indicates the importance of pro-
inflammatory COX pathway products in the pathophysiology of the disease. 
Increased expression of E-selectin, VCAM-1 and ICAM-1 is found in patients 
with arthritis, and blocking ICAM-1 or VCAM-1 with antibodies reduces 
leukocyte infiltration into the synovium and synovial inflammation in animal 
models of the disease [see FAULL, 1995 for references].
Dietary fish oil has been shown to have beneficial effects in animal models 
of arthritis. For example, compared with vegetable oil, feeding mice fish oil 
delayed the onset (mean 34 days vs. 25 days) and reduced the incidence (69% vs. 
93%) and severity (mean peak severity score 6.7 vs. 9.8) of type II collagen-induced 
arthritis [LESLIE et al., 1985]. Both EPA and DHA suppressed Streptococcal cell wall-
induced arthritis in rats, but EPA was more effective [VOLKER et al., 2000].
Several studies report anti-inflammatory effects of fish oil in patients with 
rheumatoid arthritis, such as decreased LTB4 production by neutrophils [KREMER 
et al., 1985; 1987; CLELAND et al., 1988; VAN DER TEMPEL et al., 1990] and monocytes 
[CLELAND et al., 1988; TULLEKAN et al., 1990], decreased IL-1 production by 
monocytes [KREMER et al., 1990], decreased plasma IL-1β concentrations [ESPERSON 
et al., 1992], decreased serum C-reactive protein concentrations [KREMER et al., 
1985] and normalization of the neutrophil chemotactic response [SPERLING et al., 
1987]. A number of randomized, placebo-controlled, double-blind studies of 
fish oil in rheumatoid arthritis have been reported. The characteristics and 
findings of these trials are summarized in table 5.4. The dose of long chain n-3 
PUFAs used in these trials was between 2.1 and 7.1 g/day and averaged about 3.9 
g/day. Each of these trials showed some benefit of fish oil. Such benefits include 
reduced duration of morning stiffness, reduced number of tender or swollen 
joints, reduced joint pain, reduced time to fatigue, increased grip strength and 
decreased use of non-steroidal anti-inflammatory drugs. A number of reviews 
of these trials have been published [VOLKER, GARG, 1996; JAMES, CLELAND, 1997; 
GEUSENS, 1998; KREMER, 2000; CALDER, 2001; CALDER, ZURIER, 2001] and each has 
concluded that there is benefit from fish oil, as has a meta-analysis that included 
data from nine trials published between 1985 and 1992 inclusive, and from one 
unpublished trial [FORTIN et al., 1995]. In an editorial commentary discussing the 
use of fish oil in rheumatoid arthritis it was concluded that «the findings of 
benefit from fish oil in rheumatoid arthritis are robust», «dietary fish oil 
supplements in rheumatoid arthritis have treatment efficacy», and «dietary fish 
oil supplements should now be regarded as part of the standard therapy for 
rheumatoid arthritis» [CLELAND, JAMES, 2000].Thus, there is fairly strong evidence 
that long chain n-3 PUFAs have some clinical benefits in rheumatoid arthritis.
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5-6-3 Inflammatory bowel diseases
Ulcerative colitis and Crohn’s disease are chronic inflammatory diseases 
of the alimentary tract. In ulcerative colitis the mucosa of the colon is mainly 
affected, while in Crohn’s Disease any part of the alimentary tract from the 
mouth to the anus can be affected, although it is usually the ileum and colon. 
In both diseases the intestinal mucosa contains elevated levels of inflammatory 
cytokines and eicosanoids such as LTB4 [SHARON, STENSON, 1984]. Dietary fish oil 
has been shown to have beneficial effects in animal models of colitis [WALLACE 
et al., 1989; VILASECA et al., 1990]. Long chain n-3 PUFAs are incorporated into gut 
mucosal tissue of patients with inflammatory bowel disease who supplement 
their diet with fish oil [LORENZ et al., 1989; HILLIER et al., 1991; HAWTHORNE et al., 
1992], and there are reports that this results in anti-inflammatory effects, such as 
decreased LTB4 production by neutrophils [MCCALL et al., 1989; HAWTHORNE et al., 
1992; SHIMIZU et al., 2003] and colonic mucosa [STENSON et al., 1992; SHIMIZU et al., 
2003], decreased PGE2 and TXB2 production by colonic mucosa [HILLIER et al., 
1991] and decreased production of PGE2 by blood mononuclear cells [TREBBLE et 
al., 2004]. Small open-label or pilot studies reported clinical benefit of fish oil 
supplementation in ulcerative colitis [MCCALL et al., 1989; SALOMON et al., 1990]. 
A number of randomized, placebo-controlled, double-blind studies of fish oil 
in inflammatory bowel disease have been reported. The characteristics and 
findings of these trials are summarized in table 5.4. The dose of long chain n-3 
PUFAs used in these trials was between 2.7 and 5.6 g/day and averaged about 4.6 
g/day. Some of these trials indicate benefits of fish oil which include improved 
clinical score, improved gut mucosal histology, improved sigmoidoscopic score, 
lower rate of relapse, and decreased use of corticosteroids. One study of 
special note is that of BELLUZZI et al. [1996] in which patients with Crohn’s disease 
in remission were randomized to receive placebo or 2.7 g long chain n-3 PUFAs/
day from an enterically coated fish oil preparation for one year. The primary 
outcome was relapse. There was a significant difference in the proportion of 
patients who relapsed over 12 months: 11/39 (28%) in the fish oil group vs. 27/39 
(69%) in the placebo group (P < 0.001). Likewise there was a significant difference 
in the proportion of patients who remained in remission at 12 months: 59% in 
the fish oil group vs. 26% in the placebo group (P = 0.003). Several reviews of 
trials of fish oil in inflammatory bowel diseases have been published [RODGERS, 
1998; BELLUZZI, 2000; 2002] and, although these conclude that there is some 
benefit from fish oil, the overall view at the moment must be that there is only 
weak evidence that long chain n-3 PUFAs have clinical benefits in inflammatory 
bowel diseases. However, the apparent ability of long chain n-3 PUFAs to retain 
Crohn’s Disease patients in remission [BELLUZZI et al., 1996] is a striking finding.
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5-6-4 Asthma
Arachidonic acid-derived eicosanoids such as PGD2, LTC4, D4 and E4 are 
produced by the cells that mediate pulmonary inflammation in asthma (e.g. mast 
cells) and are believed to be major mediators of asthmatic bronchoconstriction. 
4-series LT have been detected in the blood, bronchoalveolar lavage fluid and urine 
of asthmatics [HENDERSON, 1994]. In addition to the role of arachidonic acid-derived 
eicosanoids as mediators of asthma, PGE2 is also involved in regulating the 
development of the T helper type 2 phenotype of T lymphocyte that predisposes to 
allergic inflammation [MILES et al., 2003] and promotes the formation of immunoglobulin 
E by B lymphocytes [ROPER, PHIPPS, 1994] (Figure 5.8). Thus a hypothesis has evolved 
that an increased intake of n-6 PUFAs has played a causal role in increased asthma 
incidence [HODGE et al., 1994; BLACK, SHARP, 1997]. There are epidemiologic data 
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Figure 5.8  —   The role of arachidonic acid-derived eicosanoids in allergic inflammation. Several 
arachidonic acid-derived eicosanoids are mediators of allergic inflammation. In 
addition prostaglandin E2 promotes immunoglobulin E production by B lymphocytes 
and inhibits the production of the Th-1 type cytokine interferon-γ, which normally acts 
to down regulate the pro-allergic Th2 type response. 
HETE, hydroxyeicosatetraenoic acid; IFN, interferon; IgE, immunoglobulin E; IL, 
interleukin; LT, leukotriene; PG, prostaglandin. 
Modified from P.C. CALDER, Polyunsaturated fatty acids and immunity. Lipids, 2001, 36, 
1007-1024, with permission from the American Oil Chemists’ Society.
linking high n-6 PUFA or low n-3 PUFA consumption with childhood asthma [HODGE 
et al., 1994; DUNDER et al., 2001]. Early exposure to long chain n-3 PUFAs does appear 
to alter cytokine production by neonatal T cells [DUNSTAN et al., 2003a, 2003b] 
although the longer-term clinical impact of this is not yet clear. Nevertheless, the role 
of arachidonic acid-derived eicosanoids in asthma has prompted a series of studies 
attempting to modify the disease with fish oil treatment. Several studies report anti-
inflammatory effects of fish oil in patients with asthma, such as decreased 4-series LT 
production [PAYAN et al., 1986; ARM et al., 1988; KIRSH et al., 1988], and leukocyte 
chemotaxis [ARM et al., 1988; KIRSH et al., 1988]. Several uncontrolled or open-label 
trials of fish oil reveal clinical benefit of fish oil. However, randomized, placebo-
controlled, double-blind studies of fish oil in asthma (characteristics and findings of 
these trials summarized in table 5.4) reveal little overall benefit. THIEN et al. [2002] 
included eight studies published between 1988 and 2000 in a systematic review, and 
identified “no consistent effect on forced expiratory volume at one second, peak 
flow rate, asthma symptoms, asthma medication use or bronchia hyper-reactivity”. 
They conceded that one study in children showed improved peak flow and reduced 
asthma medication use. However, studies by BROUGHTON et al. [1997] and NAGAKURA 
et al. [2000] indicate that there may be subgroups of asthmatic subjects who may 
benefit greatly from long chain n-3 PUFAs. 
In the study by BROUGHTON et al. [1997], lung function worsened in adult 
asthmatics on low n-3 PUFA intakes, consistent with a protective effect of n-3 
PUFAs (Table 5.5). However, lung function improved in only some (ca. 40%) of 
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Table 5.5  —   Summary of findings from the study of BROUGHTON et al. [1997].
Cumulative dose of methacholine (units) to cause a 20% reduction
 Baseline Low dose fish oil               High dose fish oil 
Outcome (n = 19) (n = 19) Responders Non-responders
   (n = 9) (n = 10)
FVC 24.1 11.8 > 68 3.7
PEF 17.1 5.9 > 68 3.5
FEV1 16.9 1.9 > 68 4.9
FEF25-75 9.0 0.7 > 68 9.9 
Adult asthmatics consumed fish oil capsules for 4 weeks such that the n-6 to n-3 PUFA ratio of their 
diet was 10 (low dose fish oil) or 2 (high dose fish oil). At baseline, after consuming the low dose fish oil 
and after consuming the high dose fish oil, subjects underwent challenge with increasing amounts of 
methacholine to give cumulative doses up to 68 units. Data are the mean cumulative dose of 
methacholine required to cause a 20% reduction in each indicator of lung function.
Abbreviations used:  FEV1, forced expiratory volume at one second; FEF25-75, maximum 
forced expiratory flow; FVC, forced vital capacity; PEF, peak 
expiratory flow.
the subjects when on high n-3 PUFA intakes. In fact in the other 60% of 
subjects, lung function was again worsened from baseline by a high n-3 PUFA 
intake.  The difference between responders and non-responders to n-3 PUFAs 
appeared to relate to an alteration in production of 5-series LTs from EPA; 
those subjects who had a urinary ratio of 4- to 5-series LTs less than 1 after high 
n-3 PUFA ingestion were those whose lung function improved. In the study by 
NAGAKURA et al. [2000] asthmatic Japanese children benefited significantly from 
fish oil supplementation in terms of improved asthma score and better lung 
function. Clearly more and better studies need to be done in this area, the 
effects of n-3 PUFAs in children and adults need to be discriminated, and the 
possibility of responder populations needs to be confirmed.
5-7 Conclusions
Inflammation is a part of normal host defense but is also a component of 
a range of acute and chronic human diseases. Inflammation is characterized by 
the production of inflammatory cytokines, arachidonic acid-derived eicosanoids, 
other inflammatory mediators (e.g. platelet activating factor) and adhesion 
molecules. n-3 PUFAs decrease the production of many inflammatory mediators 
and the expression of some adhesion molecules. They act both directly (e.g. by 
replacing arachidonic acid as an eicosanoid substrate and inhibiting arachidonic 
acid metabolism) and indirectly (e.g. by altering the expression of inflammatory 
genes through effects on transcription factor activation). Long chain n-3 PUFAs 
also give rise to anti-inflammatory mediators (resolvins). Thus, n-3 PUFAs are 
potentially potent anti-inflammatory agents. As such, they may be of therapeutic 
use in a variety of acute and chronic inflammatory settings. Evidence of their 
clinical efficacy is strong in some settings (e.g. in rheumatoid arthritis) but weak 
in others (e.g. in asthma). More, better designed and larger trials are required in 
inflammatory diseases to assess the therapeutic potential of long chain n-3 
PUFAs in these conditions.
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  6 –  Strategies to increase
 long chain n-3 PUFA 
status in humans
6-1  Recommendations for long chain
n-3 PUFA intake and possible 
strategies to achieve these
Long chain n-3 PUFAs exert a range of physiological functions that result in 
real or potential benefits to human health (Table 6.1). These benefits have long 
been recognized and have resulted in a series of recommendations to increase 
the intake of long chain n-3 PUFAs by various government and professional 
bodies (Table 6.2). Current intakes of long chain n-3 PUFAs in the United Kingdom 
are < 0.25 g/day [Scientific Advisory Committee, 2004] and these are likely 
representative of many Western countries. Thus, to meet even the most 
conservative of recommendations will require a doubling of intake, while a six-
fold increase intake will be required to meet the less conservative recommendations 
[British Nutrition Foundation, 1999]. A limited number of strategies is currently 
available to increase the intake of long chain n-3 PUFAs. It is evident that frequent 
consumption of oily fish could substantially increase long chain n-3 PUFA intake 
(and so status) in all subgroups of the population. However there has been an 
unwillingness for many consumers to eat fish. The latest figures for the United 
Kingdom indicate that about 20% of adults and < 10% of adolescents and children 
consume fish (excluding battered fish etc.) [Scientific Advisory Committee, 2004], 
although it is encouraging that average fish consumption has increased in the 
United Kingdom over the last 10 years. Reasons for this may be publicity about the 
health benefits of eating fish, a greater appreciation of the importance of healthy 
eating amongst some sections of the population, the proliferation of popular 
cooking programmes on television, a temporary move away from eating meat in 
some places, and increased availability and lower cost of some types of fish. In the 
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future, fish farming will make fish more readily available and at a lower cost. 
However, changes in feeding regimens of farmed fish may impact on the long 
chain n-3 PUFA content of the flesh (Section 1-3). An alternative way of meeting 
recommendations that would not require dietary change is the consumption of 
fish oil capsules (or liquid); consumption of a single typical one gram fish oil 
capsule per day would allow the majority of consumers to meet the most 
conservative of recommendations for long chain n-3 PUFA intake. 
Table 6.1  —   Summary of the physiological roles and potential clinical benefits of long chain 
n-3 PUFAs.
Physiological role of long Potential clinical benefit Target
chain n-3 PUFAs   
Regulation of blood pressure Decreased blood pressure Hypertension; CVD 
Regulation of platelet  Decreased likelihood of  CVD 
function thrombosis
Regulation of blood Decreased likelihood of  CVD
coagulation thrombosis 
Regulation of plasma  Decreased plasma  Hypertriacylglycerolemia; 
triacylglycerol concentrations triacylglycerol concentrations CVD
Regulation of vascular function Improved vascular reactivity CVD 
Regulation of cardiac rhythmn Decreased arrhythmias CVD 
Regulation of inflammation Decreased inflammation Inflammatory diseases
  (see Table 5.3); CVD 
Regulation of immune Improved immune function  Compromised immunity?
function 
Regulation of bone turnover Maintained bone mass Osteoporosis 
Regulation of insulin  Improved insulin sensitivity Type-2 diabetes
sensitivity 
Regulation of tumour  Decreased tumour cell  Some cancers
cell growth growth & survival
Regulation of visual  Optimised visual  Poor infant visual 
signalling (rhodopsin) signalling development (especially
  pre-term)
Structural component of  Optimised brain  Poor infant and childhood 
brain and central nervous development – cognitive  cognitive processes 
system and learning processes and learning
Abbreviation used:   CVD, cardiovascular disease.
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A third strategy to increase long chain n-3 PUFA intake would be to increase 
the content of those fatty acids in habitually consumed foods that normally lack 
these fatty acids (e.g. spreads, milk, meat, bread, eggs). Such enrichment could 
occur through fortification, through altered poultry or animal feeding practices, 
or, ultimately, through the application of biotechnology in crops [SAYANOVA, 
NAPIER, 2004]. FINNEGAN et al. [2003] were able to use a spread modified to include 
long chain n-3 PUFAs such that consumption of 25 g/day of the spread as part of 
a typical diet (in the United Kingdom) would increase intake of those fatty acids 
to 0.7 g/day. This resulted in significant enrichment of plasma phospholipids in 
EPA and DHA [FINNEGAN et al., 2003]. Thus it is possible to fortify some food 
products such that they can deliver sufficiently increased amounts of long chain 
n-3 PUFAs to increase the long chain n-3 PUFA content of at least some body lipid 
pools. However, altered feeding practices in farms may be the key to population 
wide increases in long chain n-3 PUFA intake. Feeding flaxseed to laying hens 
increases the long chain n-3 PUFA content of the eggs produced, such that one 
egg can provide 115-140 mg EPA+DPA+DHA. Various strategies have been used to 
increase the long chain n-3 PUFA content of chicken meat and of goat’s, sheep 
and cow’s milks, the most successful being the inclusion of fish meal, fish oil or 
n-3 PUFA-rich algal oil in the diet [CANT et al., 1997; FRANKLIN et al., 1999; OFFER et al., 
1999; DONOVAN et al., 2000; KEADY et al., 2000; BAER et al., 2001; GULATI et al., 2003]. In 
a recent study, dairy cows were fed on a diet containing rumen-protected tuna oil 
[KITESSA et al., 2004]. EPA and DHA appeared in the milk from 36 hours after the 
start of feeding and plateaued at day 6. At this stage EPA and DHA contributed 0.6 
and 1.1% of milk fatty acids, respectively. This is equivalent to 25 and 45 mg per 
100 ml milk, respectively. Thus one 250 ml glass of this milk could provide between 
35 and 40% of the current UK recommended intake of long chain n-3 PUFAs. 
Table 6.2  —   Some recommendations for the intake of long chain n-3 PUFAs
in adult humans.
Recommended intake of  Reference
long chain n-3 PUFAs (g/day)  
0.2 DE DECKERE et al. [1998] 
0.45 SCI. ADVISORY COMMITTEE ON NUTR. [2004] 
0.65 SIMOPOLOUS et al. [1999] 
1.0* KRIS-ETHERTON et al. [2002] 
1.0* VAN DE WERF et al. [2003] 
1.2 to 1.6 BRITISH NUTRITION FOUNDATION [1999] 
2 to 4** KRIS-ETHERTON et al. [2002] 
* for secondary prevention of myocardial infarction; **for hypertriacylglycerolemia.
Feeding fish oil to pigs results in increased contents of EPA, DPA and DHA in 
edible muscle and fat, in edible offal such as liver and kidney, and in meat 
products such as sausages [IRIE, SAKIMOTO, 1992; LESKANICH et al., 1997]. In another 
study pigs were fed two levels of flaxseed providing 6 and 10-times more dietary 
α-linolenic acid (αLNA) than the control animals received [MATTHEWS et al., 2000]. 
This dietary strategy resulted in greatly enhanced amounts of αLNA, EPA and DPA 
in the meat, liver and kidney. 
An alternative to the strategy of increasing intake of preformed long 
chain n-3 PUFAs is to increase consumption of precursor fatty acids such as 
α-linolenic acid (αLNA) in order to promote their endogenous synthesis using 
the pathway shown in figure 1.5 (Table 6.3). The potential for this strategy to 
be successful is discussed in Section 6-2. 
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Table 6.3  —   Strategies to increase the status of long chain n-3 PUFAs in human plasma, cells 
and tissues.
Metabolic strategy Dietary strategy
Provide pre-formed long chain n-3 PUFAs Eat oily fish
 Supplement diet with fish oil capsules
 Eat enriched or fortified foods
Provide precursor fatty acids Use α-linolenic acid containining
(mainly α-linolenic acid) vegetable oils
 Supplement diet with flaxseeds
 Eat enriched or fortified foods
6-2  Is α-linolenic acid a suitable 
substitute for long chain n-3 PUFAs?
6-2-1  Introductory comments
The major dietary sources of αLNA are green leaves, and oils used in cooking 
such as rapeseed oil and soybean oil where it accounts for up to 10% of total fatty 
acids.  Flaxseed (also known as linseed) oil is particularly rich in αLNA (> 50% total 
fatty acids). Typical consumption of αLNA in Europe, Australia and North America 
ranges between 0.6 to 2.2 g/day in men and 0.5 to 2.1 g/day in women (see Table 1.4). 
αLNA can be converted to the long chain n-3 PUFAs using the pathway outlined in 
figure 1.5. Thus, the question of whether αLNA is a suitable substitute for long chain 
n-3 PUFAs actually has two components. The first is whether αLNA in its own right 
can elicit the physiological effects of long chain n-3 PUFAs, as outlined in Sections 
3, 4 and 5. If this is the case then αLNA could be used as a genuine substitute for its 
longer chain derivatives. The second component to the question is whether αLNA 
can be converted in humans to long chain n-3 PUFAs in sufficient amounts for the 
latter to elicit their effects. In other words, this is a passive role for αLNA of being 
the substrate for the synthesis of physiologically active products. In practice, it has 
proved difficult to separate these two components of the question: in cell culture, 
animal feeding and human experiments a proportion of αLNA provided is 
converted to long chain n-3 PUFAs, and so it is difficult to ascribe with great certainty 
any biological effects seen to αLNA per se or to its derivatives. However attempts to 
answer this question in humans have used one of two approaches: acute stable-
isotope studies or chronic intervention studies.
6-2-2 Stable isotope studies
A number of studies using αLNA labeled with either [13C] or deuterium have 
provided estimates of the extent of conversion to long chain PUFAs in humans 
[EMKEN et al., 1994; 1999; SALEM et al., 1999; VERMONT et al., 2000; PAWLOSKY et al., 2001; 
2003a,b; BURDGE et al., 2002; 2003]. The general consensus of these studies is that the 
proportion of αLNA entering the desaturation/elongation pathway and converted 
to EPA and DPA is low. The extent of conversion of αLNA to DHA is even lower.  The 
highest estimated fractional conversion is 4% [EMKEN et al., 1994], while most other 
studies have reported lower estimates of conversion (0.05% or less) [VERMUNT et al., 
2000; PAWLOSKY et al., 2001; 2003a,b; BURDGE et al., 2003] and one study failed to detect 
significant incorporation of stable isotope into DHA in men [BURDGE et al., 2002]. 
PAWLOSKY et al. [2001] have suggested estimates for the efficiency of conversion of 
individual steps in the desaturation/elongation pathway from kinetic analysis based 
on the concentrations of individual deuterated fatty acids in plasma from a mixed 
group of men and women.  The findings of this study were that the efficiency of 
conversion of αLNA to EPA was 0.2%, of EPA to DPA 65% and of DPA to DHA 37%. 
Thus producing an overall efficiency of conversion from αLNA is 0.2% to EPA, 0.13% 
to DPA and 0.05% to DHA (Figure 6.1). However, BURDGE AND WOOTTON [2002] 
showed that conversion of αLNA to EPA and DHA in women aged about 28 years 
was substantially greater (2.5-fold and >200-fold, respectively) than in a comparable 
study of men of similar age [BURDGE et al., 2002]. This finding is strongly supported 
by kinetic analysis which showed that the rate constant coefficient for the 
conversion of DPA to DHA was approximately 4-fold greater in women compared 
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to men [PAWLOSKY et al., 2003b]. This may reflect greater availability of αLNA for 
conversion in women than in men perhaps, in part, due to lower partitioning 
towards β-oxidation. One possible explanation for the greater synthesis of EPA and 
DHA from αLNA in women compared to men is the action of estrogen, since DHA 
synthesis was almost 3-fold greater in women using an oral contraceptive pill 
containing 17α-ethynyloestradiol than in those who did not [BURDGE, WOOTTON, 
2002]. One possible biological role for greater capacity for αLNA conversion in 
women may be in meeting the demands of the fetus and neonate for DHA.  Since 
circulating estrogen concentration rises during pregnancy due to synthesis and 
secretion by the placenta, one possibility is that αLNA conversion may increase 
during gestation.  
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Figure 6.1  —   Estimated efficiency of the different steps of the pathway of conversion of 
α-linolenic acid to its longer chain more unsaturated derivatives in humans. Data 
are from PAWLOSKY et al. [2001].
6-2-3  Effects of chronically increased α-linolenic
acid consumption
A number of studies have reported the effects of consuming increased 
amounts of αLNA, usually via consumption of oils with a high αLNA content or of 
products made with those oils (for example spreads), on the fatty acid composition 
of plasma [1] or cell lipids [2]. These studies were conducted either in men or in 
[1] SANDERS, YOUNGER, 1981; KELLEY et al., 1993; MANTZIORIS et al., 1994; CUNNANE et al., 1995; LI et al., 1999; 
BEMELMANS et al., 2002; FINNEGAN et al., 2003; JAMES et al., 2003; WALLACE et al., 2003.
[2] SANDERS, YOUNGER, 1981; SANDERS, ROSHANAI, 1983; WEAVER et al., 1990; KWON et al., 1991; MUTANEN 
et al., 1992; KELLEY et al., 1993; MANTZIORIS et al., 1994; CAUGHEY et al., 1996; ALLMAN-FARINELLI et 
al., 1999; LI et al., 1999; HEALY et al., 2000; BEMELMANS et al., 2002; JAMES et al., 2003; KEW et al., 2003; 
WALLACE et al., 2003
mixed groups of men and women, used intakes of αLNA ranging from less than one 
to 20 g/day, and were of a few weeks to many months duration. Despite differences 
in the study design, physical form in which the αLNA was presented and the 
duration of the studies, overall they consistently demonstrate increased proportions 
of EPA in both plasma and cell lipids when αLNA intake is increased (e.g. Figures 6.2 
and 6.3).  Using such data it is clear that the relationship between increased αLNA 
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Figure 6.2  —   Effect of increased α-linolenic acid consumption on the long chain n-3 PUFA 
contents of human plasma phospholipids and platelets. 
Healthy volunteers consumed 6.5 (A), 9 (B), 9.4 (C) or 18 (D) g/day α-linolenic acid 
for 2 (A, C), 3 (D) or 4 (B) weeks. The fatty acid compositions of plasma 
phosphatidylcholine (A), plasma phospholipids (B), or platelets (C, D) were 
determined. Data are from SANDERS, YOUNGER [1981] (A), CUNNANE et al. [1995] (B), 
SANDERS, ROSHANAI [1983] (C), and ALLMAN et al. [1995] (D).
intake and increased EPA concentration in plasma phospholipids is a significant 
linear one (r = 0.846, P = 0.004). The relationship for cell phospholipids is also likely 
to be linear, but there are insufficient data for a single cell type to allow this to be 
clearly identified at this stage. Several studies also demonstrate increased 
proportions of DPA in plasma and cell lipids when αLNA consumption is increased 
(e.g. Figure 6.2D). The studies also consistently demonstrate that increased 
consumption of αLNA does not result in increased proportions of DHA in plasma 
or cell lipids (e.g. Figures 6.2 and 6.3). Indeed many studies report a tendency for 
DHA to decline when αLNA consumption is markedly increased, although few 
studies have identified this as a statistically significant effect.
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Figure 6.3  —   Effect of increased α-linolenic acid or long chain n-3 PUFA consumption on the 
long chain n-3 PUFA content of human plasma phospholipids. 
Healthy volunteers consumed diets providing 4.5 or 9 g/day α-linolenic acid or 
0.7 or 1.5 g/day EPA+DHA for 3 months. The fatty acid composition of plasma 
phospholipids was determined. Data are from FINNEGAN et al. [2003].
Consumption of 10.7 g αLNA/day by lactating women for 4 weeks 
increased maternal plasma, erythrocyte and breast-milk αLNA concentration 
[FRANÇOIS et al., 2003].  Breast milk EPA increased by about 35% while DPA 
concentration did not change. Increased consumption of αLNA did not alter 
breast-milk DHA concentration, which tended to decrease at 4 weeks. 
Because of competition for metabolism between linoleic acid and αLNA, 
the linoleic acid content of the diet may influence conversion of αLNA to longer 
chain derivatives.  If this is so then the EPA content of blood and cell lipids should 
be greater at a given intake of αLNA if linoleic acid intake is decreased. A study by 
CHAN et al. [1993] demonstrated that this is indeed the case.  Subjects consumed 
diets providing 7 g αLNA/day for 18 days against a background of either 21 or 50 
g linoleic/day. The proportion of EPA was greater in plasma and platelets after the 
low compared with the high linoleic acid background (Figure 6.4).
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Figure 6.4  —   Effect of linoleic acid consumption on human plasma phospholipid and platelet 
contents of eicosapentaenoic acid after consumption of a diet rich in α-linolenic 
acid. 
Healthy volunteers consumed a diet containing 7 g/d α-linolenic acid and either 
21 or 50 g/day linoleic acid for 18 days. The fatty acid compositions of plasma 
phosphatidylcholine (PC), plasma phosphatidylethanolamine (PE), or platelets 
(PC) were determined. Data are from CHAN et al. [1993].
Overall, these studies demonstrate that chronically increased 
consumption of αLNA results in conversion to EPA resulting in increases in 
EPA concentration in plasma and cell pools, while the extent of conversion to 
DHA is insufficient to increase the concentration of this fatty acid. One limit 
on the conversion of αLNA to EPA may be Δ6-desaturase activity. If this is so 
then the product of Δ6-desaturase (stearidonic acid; 18:4n-3) should be 
converted to EPA more efficiently than αLNA is. JAMES et al. [2003] compared 
the appearance of EPA in plasma and cell phospholipids after supplementation 
of the diet with 0.75 g/d for 4 weeks and then 1.5 g/day for 4 weeks of αLNA, 
stearidonic acid and EPA. They found that stearidonic acid resulted in greater 
appearance of EPA than αLNA did (Figure 6.5), thus supporting the notion that 
Δ6-destaturase is a limit to αLNA conversion.
6-2-4  α-Linolenic acid and human
health-related outcomes
•  α-Linolenic acid and cardiovascular disease
A population based case-control study in Costa Rica reported that high 
adipose tissue αLNA content, a marker for intake, was associated with lower 
risk of myocardial infarction [BAYLIN et al., 2003].  Dietary αLNA intake was 
significantly inversely associated with mortality from coronary heart disease 
in the Multiple Risk Factor Intervention Trial [DOLECEK, 1992].  The highest 
quintile of αLNA intake (1.36 g/day) was associated with 45% fewer coronary 
deaths in women compared with the lowest quintile (0.71 g/day) [HU et al., 
1992]. Dietary αLNA intake was inversely associated with risk of myocardial 
infarction among men [ASCHERIO et al., 1996]; there was a relative risk of 0.41 for 
each 1% increase in energy intake as αLNA. In a study of over 4400 men and 
women the highest quintile of αLNA intake (1.1 g/day) was associated with 
40% lower mortality from coronary artery disease compared with the lowest 
quintile of intake (0.5 g/day) [DJOUSSE et al., 2001].  In addition, dietary αLNA 
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Figure 6.5  —   Plasma phospholipid eicosapentaenoic acid content after consumption of 
increased amounts of α-linolenic acid (αLNA), stearidonic acid (STA) or 
eicosapentaenoic acid (EPA). 
Healthy volunteers consumed 0.75 g/day α-linolenic acid, or stearidonic acid or 
eicosapentaenoic acid for three weeks and then 1.5 g/day of the same fatty acid 
for 3 weeks. The fatty acid composition of plasma phospholipids was determined. 
Data are from JAMES et al. [2003].
intake was inversely related to carotid atherosclerosis [DJOUSSE et al., 2003].  In 
contrast to these findings, other epidemiological studies found no association 
between αLNA intake and coronary heart disease risk [SIMON et al., 1995; 
OOMEN et al., 2001] or mortality [PIETINEN et al., 1997; OOMEN et al., 2001].  A 
recent meta-analysis of five prospective cohort studies [DOLECEK et al., 1992; 
ASCHERIO et al., 1996; PIETINEN et al., 1997; HU et al., 1999; OOMEN et al., 2001] 
concluded that high αLNA intake is associated with decreased risk of fatal 
coronary heart disease [BROUWER et al., 2004].
The well-known Lyon Heart Study reported a substantial reduction in 
coronary events and deaths among myocardial infarction-survivors following 
a Mediterranean style diet which included an αLNA rich margarine providing 
1.5 g αLNA/day [DE LORGERIL et al., 1994]. However, this intervention also 
involved several other dietary changes and so the contribution, if any, of 
increased αLNA intake to the positive outcomes cannot be identified. 
•  α-Linolenic acid and cardiovascular risk factors
•  Blood lipids
A number of studies have investigated the effect of increased αLNA 
consumption of blood cholesterol, LDL and HDL concentrations. While some 
of these studies report little effect of αLNA intervention, several indicate that 
αLNA is similar to linoleic acid with respect to blood cholesterol concentration 
[KESTIN et al., 1990; CHAN et al., 1991; MANTZIORIS et al., 1994; ARJMANDI et al., 1998; 
PANG et al., 1998; SODERGREN et al., 2001; BEMELMANS et al., 2002; FINNEGAN et al., 2003; 
ZHAO et al., 2004]. Likewise some of these studies indicate similar effects of αLNA 
and linoleic acid on LDL and HDL cholesterol concentrations [KESTIN et al., 1990; 
CHAN et al., 1991; ARJMANDI et al., 1998; SODERGREN et al., 2001; BEMELMANS et al., 2002; 
FINNEGAN et al., 2003; ZHAO et al., 2004]. However two studies [MANTZIORIS et al., 
1994; PANG et al., 1998] suggest that αLNA is not as effective as linoleic acid in 
lowering LDL cholesterol concentrations. Furthermore, studies reporting that 
αLNA decreased HDL concentration [NESTEL et al., 1997; RALLIDIS et al., 2003] did 
not see this effect with linoleic acid, while BEMELMANS et al. [2002] found that HDL 
concentration was significantly lower (by 4% or 0.05 mM) after αLNA than after 
linoleic acid. Taken together these data would suggest that, while αLNA is 
cholesterol and LDL lowering, it is less effective than linoleic acid, and that 
αLNA, unlike linoleic acid, may decrease HDL concentration.
Studies investigating the effect of αLNA on fasting plasma TAG 
concentrations are contradictory, with most reporting no change from baseline, 
several reporting an increase or a tendency to an increase, and two reporting a 
decrease. These differences in outcome may relate to the fat content of the 
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background diet, to habitual dietary fat composition, to whether subjects were 
placed on a standardized diet prior to the αLNA intervention, to the amount of 
αLNA and of other fatty acids supplied, and to the degree of triacylglycerolemia 
at baseline. It is interesting that the two studies reporting decreased plasma 
TAG concentrations used very high αLNA intakes [SINGER et al., 1986; ZHAO et al., 
2004]. Some studies permit the effect of αLNA on fasting TAG concentrations to 
be directly compared with that of linoleic acid. Several found that the effects of 
a high αLNA diet were not different from those of linoleic acid-rich diet [KESTIN 
et al., 1990; NESTEL et al., 1997; PANG et al., 1998; RALLIDIS et al., 2003; ZHAO et al., 
2004]. However, ARJMANDI et al. [1998] and FINNEGAN et al. [2003] who found that 
αLNA tended to increase TAG concentration, did not see this effect with a high 
linoleic acid diet, while BEMELMANS et al. [2002] reported that plasma TAG 
concentration was significantly higher (12% or 0.24 mM) after αLNA than after 
linoleic acid. These studies are suggestive that αLNA has a TAG raising effect 
compared with linoleic acid. FINNEGAN et al. [2003] compared diets with high 
αLNA content to those with modest long chain n-3 PUFA content; long chain n-3 
PUFAs tended to lower plasma TAG concentration in contrast to αLNA, which 
tended to be TAG raising.
•  Post-prandial lipemia
FINNEGAN et al. [2003] found no effect of diets containing 4.5 or 9 g αLNA/
day on the post-prandial TAG response to a test meal, compared with study 
entry or with a linoleic acid rich diet.    
•  LDL oxidation
NESTEL et al. [1997] found that the lag time of copper-induced oxidation 
of LDL was significantly lower (by 14 minutes; about 22%) after consumption 
of an αLNA rich (20 g/day) low fat (26% energy) diet compared with a 
monounsaturated fat rich low fat diet. In addition, the content of thiobarbituric 
acid reactive substances in the oxidised LDL was higher if the LDL came from 
subjects on the αLNA rich diet [NESTEL et al., 1997]. However, FINNEGAN et al. 
[2003] reported no effect of diets containing 4.5 or 9 g αLNA/day on lag time 
of LDL oxidation, compared with study entry or with a linoleic acid rich diet. 
EZAKI et al. [1999] found no effect of 4.2 g αLNA/day on plasma lipid peroxide 
or oxidized LDL concentrations in elderly Japanese subjects.
•  Blood pressure
BERRY and HIRSCH [1986] noted that a 1% increase in adipose tissue αLNA 
content was associated with a 5 mm Hg decrease in systolic and diastolic blood 
pressure. SALONEN et al. [1988] reported an inverse association between αLNA 
consumption and blood pressure in a large prospective study. However, 38 g 
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αLNA/day for 2 weeks did not affect systolic or diastolic blood pressure in 
normotensive or hypertensive subjects [SINGER et al., 1986]. Likewise, 9.2 g αLNA/
day did not affect systolic or diastolic blood pressure in a 6 week intervention 
study in normotensive hypercholesterolemic subjects [KESTIN et al., 1990]. 
Furthermore, 6.3 g αLNA/day for 2 years did not affect systolic or diastolic blood 
pressure in subjects with multiple cardiovascular risk factors [BEMELMANS et al., 
2002], although some of these subjects were under antihypertensive therapy. 
•  Vascular reactivity
NESTEL et al. [1997] found increased arterial compliance (aortic flow 
velocity and aortic root driving pressure) after four weeks of 20 g αLNA /day (9% 
energy and 2.7% energy as LA) in exchange for oleic acid in obese subjects. 
•  Haemostasis and platelet aggregation
Increased consumption of αLNA results in an increased content of EPA and 
DPA in platelets (see Figure 6.3) in parallel with a decreased content of arachidonic 
acid. This might be expected to affect platelet aggregation, since this is regulated 
in part by arachidonic acid- and EPA-derived eicosanoids. Indeed healthy men 
consuming a high αLNA diet (8.5% energy from αLNA; approx. 18 g/day) had 
decreased collagen-induced platelet aggregation compared with those on a 
linoleic acid-rich diet (12% energy) [ALLMAN et al., 1995]. FREESE et al. [1994] reported 
a decrease in ADP-induced platelet aggregation in hyperlipemic subjects 
consuming 2.1% energy as αLNA (and 6.5% energy as linoleic acid) compared 
with a low αLNA diet (0.3% energy from αLNA and 8% energy from linoleic acid). 
However there are reports that substantially increased consumption of αLNA (3.7, 
5.9 or 15.4 g/day) does not affect platelet aggregation induced by collagen [FREESE 
et al., 1997; LI et al., 1999]. Furthermore, there was no effect of 6.8 or 10 g/day αLNA 
on ADP-induced platelet aggregation [JUNKER et al., 1991; WENSING et al., 1999]. 
A number of intervention studies report little effect of αLNA on 
coagulation and fibrinolytic factors, including factor VII, factor XII, fibrinogen, 
plasminogen activator inhibitor (PAI)-1 or tissue plasminogen activator (t-PA) 
concentration or factor VII, PAI-1 or t-PA activity. Intakes of αLNA studied have 
been in the range of 3.7 to 15.4 g/day.
•  Inflammation
Increased consumption of αLNA results in an increased content of EPA and 
DPA in the membranes of inflammatory cells like neutrophils and monocytes 
[KELLEY et al., 1993; MANTZIORIS et al., 1994; CAUGHEY et al., 1996; HEALY et al., 2000; KEW 
et al., 2003] in parallel with a decreased content of arachidonic acid. This might be 
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expected to affect inflammation, since this is regulated in part by arachidonic 
acid- and EPA-derived eicosanoids. Studies investigating the effect of αLNA on 
inflammatory outcomes in humans have examined the circulating concentrations 
of inflammatory markers such as CRP, soluble adhesion molecules or cytokines 
[JUNKER et al., 1991; THIES et al., 2001; RALLIDIS et al., 2003; 2004; BEMELMANS et al., 2004; 
ZHAO et al., 2004], while other studies have examined inflammatory cell responses 
ex vivo [CAUGHEY et al., 1996; HEALY et al., 2000; THIES et al., 2001; KEW et al., 2003; 
WALLACE et al., 2003]. CAUGHEY et al. [1996] reported that 13.7 g αLNA/day for 4 weeks 
resulted in a decrease in ex vivo production of prostaglandin E2, TNF-α and IL-1β 
by endotoxin-stimulated mononuclear cells by 33, 27 and 30%, respectively. By 
comparison fish oil providing 2.7 g EPA+DHA/day decreased production of these 
inflammatory mediators by 55, 70 and 78% respectively. Thus on a g/day basis, 
long chain n-3 PUFAs are about 8 to 14-times more potent than αLNA with respect 
to this outcome in healthy subjects. In contrast to the observations of Caughey et 
al. [44], several studies using lower intakes of αLNA (2 to 9.5 g/day) did not find 
effects on neutrophil chemotaxis, neutrophil respiratory burst, monocyte 
respiratory burst, TNF-α, IL-1β and IL-6 production by endotoxin stimulated 
mononuclear cells, all studied ex vivo, or on soluble adhesion molecule 
concentrations [JUNKER et al., 1991; HEALY et al., 2000; THIES et al., 2001; KEW et al., 2003; 
WALLACE et al., 2003]. Furthermore, a study by RALLIDIS et al. [2004] reported no 
effect of 8 g αLNA/day on sICAM-1 or sE-selectin concentrations and a similar 
decrease in sVCAM-1 concentration in both αLNA and control groups. Likewise 
BEMELMANS et al. [2004] found no effect of 6.3 g αLNA/day on sICAM-1 concentration 
at one and two years of intervention. Taken together, these data suggest that 
increasing αLNA intake to > 9 g/d is required in order for marked anti-inflammatory 
effects to be seen. Even then the effects will be much more modest than those 
exerted by long chain n-3 PUFAs [CAUGHEY et al., 1996]. However, both RALLIDIS et 
al. [2003] and BEMELMANS et al. [2004] did find a significant decrease in CRP 
concentration, suggesting that this may be a marker that is more sensitive to 
intakes of αLNA that do not affect soluble adhesion molecule or cytokine 
concentrations or ex vivo inflammatory cell responses. One study using a very 
high intake of αLNA (approx. 17.5 g/day) reported significant decreases in both 
CRP and soluble adhesion molecule concentrations [ZHAO et al., 2004]. Interestingly, 
the authors found that the changes in these inflammatory markers were 
significantly related to changes in serum concentrations of EPA or EPA plus DPA, 
but not of αLNA. This suggests that the observed effects are due to the long chain 
n-3 PUFAs rather than to αLNA per se. Thus the likely explanation for the lack of 
anti-inflammatory effect of αLNA at modest [HEALY et al., 2000; THIES et al., 2001; KEW 
et al., 2003; WALLACE et al., 2003] and even at rather high [KEW et al., 2003] intakes, is 
that there has been insufficient conversion of αLNA to the more active EPA.
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6-2-5 To summarise
Epidemiological studies show that αLNA intake is inversely associated 
with risk of cardiovascular disease. This inverse relationship may explain the 
benefit on mortality seen in an intervention study that involve increased αLNA 
intake [DE LORGERIL et al., 1994]. Intervention studies are indicative that substantially 
increased αLNA intake can beneficially affect a range of cardiovascular risk 
factors including blood cholesterol, LDL cholesterol and TAG concentrations, 
vascular reactivity, platelet aggregation and inflammation. However, the effect 
on cholesterol concentration is similar to that of linoleic acid, while αLNA is less 
potent than linoleic acid at decreasing LDL concentration. Furthermore αLNA 
can decrease HDL concentration, which linoleic acid does not do and, in 
contrast to the effects of long chain n-3 PUFAs, may increase TAG concentration. 
More modest increases in αLNA intake do not affect blood lipid concentrations, 
post-prandial lineman, blood pressure, platelet aggregation, haemostatic 
factors, or inflammation. This was also the view reached by a workshop on this 
subject held in the United Kingdom which concluded “the studies …. suggested 
little, if any, benefit of αLNA, relative to linoleic acid, on risk factors for 
cardiovascular disease ….” [SANDERSON et al., 2002]. 
The effects of αLNA contrast with those of long chain n-3 PUFAs (see 
Sections 3 and 5) and it is apparent from studies where αLNA and long chain n-3 
PUFAs have been compared that αLNA is substantially less potent [e.g. CAUGHEY 
et al., 1996]. The reason why very high intakes of αLNA may induce qualitatively 
similar effects to those of long chain n-3 PUFAs (e.g. decreasing TAG concentration, 
platelet aggregation and inflammation) while lower intakes do not, may be that 
the high intakes allow sufficient synthesis of EPA to occur to induce biologically 
effective changes in EPA concentration. This is borne out by the observations of 
ZHAO et al. [2004] that the αLNA-induced changes in inflammatory markers were 
significantly related to changes in serum concentrations of EPA or EPA plus DPA, 
but not of αLNA. Similar to this, CAUGHEY et al. [1996] related the effects of αLNA 
on inflammatory cytokine production to the increased content of EPA in 
mononuclear cells. Thus, the likely explanation for the lack of biological effect 
of more modest intakes of αLNA is that there has been insufficient conversion 
of αLNA to the more active EPA. From this point of view increased intake of 
αLNA offers little real advantage compared with increased intake of long chain 
n-3 PUFAs, and may even be disadvantageous if αLNA does increase blood TAG 
concentration. One clear advantage of increased αLNA intake is that it seems 
unlikely to make LDL more sensitive to oxidation, a process which can be 
promoted by long chain n-3 PUFAs. Once again, the fact that one study using a 
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very high intake of αLNA reported increased susceptibility of LDL to oxidation 
[NESTEL et al., 1997] may reflect the fact that the LDL may have been significantly 
richer in EPA and DPA as a result of αLNA conversion.
6-3 Conclusions
αLNA is converted to EPA and DPA in humans. This process is promoted 
if linoleic acid intake is decreased. Stearidonic acid appears better converted 
than αLNA, indicating that poor Δ6-desaturase activity plays a role in limiting 
αLNA conversion. Conversion of αLNA to DHA, is limited in humans although 
conversion is much greater in women than men. The limited extent to which 
αLNA is converted to its longer-chain metabolites may explain, at least in part, 
the relative lack of effectiveness of increased consumption of αLNA on risk 
factors for cardiovascular disease and on inflammatory markers. However αLNA 
at sufficiently high intakes can mimic the effects of long chain n-3 PUFAs, at least 
qualitatively, probably as a result of conversion to EPA. It is important to note 
that most studies have been conducted in men or in mixed groups of men and 
middle aged or older women, in whom conversion of αLNA to long chain n-3 
PUFAs is not so good as it is in younger women. Therefore the effect of increased 
αLNA consumption, in combination with decreased linoleic acid consumption, 
on health-related outcomes in young women needs to be investigated.
The best strategy by which to increase the intake of long chain n-3 
PUFAs and to increase the content of long chain n-3 PUFAs in blood, cells and 
tissues is to eat oily fish regularly (Table 6.4). An alternative is to consume fish 
oil capsules, which is a highly effective way of increasing long chain n-3 PUFA 
status in human blood and cells (Figures 2.10 to 2.12). It is apparent that foods 
either naturally enriched or fortified with long chain n-3 PUFAs will become 
increasingly available over the next 5 years and these will represent a very 
good strategy by which to increase intakes of these fatty acids, and will 
provide greater choice for those consumers who do not eat fish and who do 
not wish to take capsules. It is also clear that greatly increased intake of αLNA 
is a viable strategy to increase the EPA and DPA content of blood, cells and 
tissues, but this appears to be very poor strategy to increase DHA content, and 
may even decrease it. In this regard αLNA is greatly inferior to either fish or 
fish oil capsules. As might be expected conversion of αLNA to EPA is improved 
if linoleic acid intake is decreased in parallel with increased αLNA intake.
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 7 –  Long chain n-3
fatty acids in artificial 
nutrition with an emphasis 
on immuno-inflammatory 
outcomes
7-1  Septic syndromes
The systemic inflammatory response syndrome is the name given to the 
uncontrolled inflammatory response to insult or injury involving excessive 
production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β, IL-6 and IL-8 [BONE et al., 1997]. Sepsis has been defined as 
“the systemic inflammatory response syndrome that occurs during infection” 
[BONE et al., 1997]. Sepsis is the leading cause of death in critically ill patients in 
Western countries. Using records from 1995 for state hospitals in the United 
States it was estimated that there were over 750,000 cases of sepsis with a 28.6% 
mortality rate (215,000 deaths) and a total cost of almost US$17 billion [ANGUS et 
al., 2001]. Death from septic shock is the result of multiple organ failures and 
represents the extreme end of a continuum of events of increasing severity and 
decreasing likelihood of survival [FRIEDMAN et al., 1998; BRUN-BUISSON, 2001] 
(Figure 7.1). The systemic inflammatory response syndrome (SIRS), sepsis and 
septic shock may together be termed as “septic syndromes”.
The involvement of inflammatory cytokines in septic syndromes has 
been long recognized and VERVLOET et al. [1998] wrote “these mediators (i.e. 
inflammatory cytokines) are largely, if not completely, responsible for the 
clinical signs and symptoms of the septic response to bacterial infection”. In 
support of this idea, patients with sepsis were found to have markedly elevated 
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circulating concentrations of TNF-α, TNF-receptor 1, IL-1β, IL-1 receptor 
antagonist (IL-1ra) and IL-6, and those patients with the highest concentrations 
were more likely to die [GIRARDIN et al., 1988; VERVLOET et al., 1998; ARNALICH et al., 
2000; HATHERILL et al., 2000]. In addition, circulating white cells from septic 
patients exhibit high levels of activated nuclear factor kappa B (NFκB), a 
transcription factor that promotes the expression of numerous genes associated 
with inflammation (see Figure 5.7), and again levels of activated NFκB were 
higher in those patients who went on to die [ARNALICH et al., 2000]. Animal 
studies also support a role for inflammatory cytokines in the septic response. 
These studies have often used bacterial endotoxin (also called lipopolysaccharide; 
LPS) as a surrogate for infection, although endotoxin is a fragment of the Gram-
negative bacterial cell wall and not a viable organism. Mice injected with 
endotoxin exhibit high circulating concentrations of TNF-α, IL-1β, IL-6 [see 
SADEGHI et al., 1999] and IL-8 and survival of these animals can be dramatically 
improved by administering anti-cytokine antibodies [BEUTLER et al., 1985; TRACEY 
et al., 1987], cytokine receptor antagonists [ALEXANDER et al., 1991], or anti-
Figure 7.1  —   The progression to septic shock and the risk of mortality at the different 
stages. 
bpm, beats per minute; SIRS, systemic inflammatory response syndrome. 
Reprinted from P.C. CALDER. n-3 fatty acids, inflammation and immunity 
– relevance to postsurgical and critically ill patients. Lipids 2004; 39: 1147-
1161, with permission from the American Oil Chemists’ Society. 
inflammatory cytokines such as IL-10 [MARCHANT et al., 1994], or by knocking out 
the TNF-α receptor [PFEFFER et al., 1993]. Despite this evidence, it is important to 
note that some studies report that many septic patients do not show detectable 
or elevated circulating concentrations of TNF-α or IL-1β [see CALDER, 2004 for 
references]. Furthermore, it appears that inflammatory cytokines do play a 
beneficial role in sepsis. For example, in some animal models blocking TNF-α 
increases mortality [ESKANDARI et al., 1992; OPAL et al., 1996; ECHTENACHER et al., 
2001], while a TNF-α antagonist increased mortality in a clinical trial [FISHER et al., 
1996]. Thus, the situation regarding the pathological role of inflammatory 
cytokines in sepsis is unclear; it may be that a little is beneficial but that excess 
is harmful and that complete blocking negates the beneficial effects. Another 
consideration is that there may be large between-individual differences in the 
generation of inflammatory cytokines, in the sensitivity to the harmful effects of 
these cytokines and in the effects of blocking these cytokines. Thus, there may 
be significant variation in the susceptibility of individuals to exhibit the systemic 
inflammatory response syndrome and to progress towards septic shock. This 
may partly relate to the extent and site of the initial injury, partly to the nature 
and site of the infection, if any, and partly to aspects of the patient’s wellbeing 
prior to receiving the injury (e.g. nutritional state). It is now recognized that 
genetics may also play a role. For example genotypes affecting TNF-α production 
appear to be of relevance with respect to sepsis mortality [STUBER et al., 1996; 
MIRA et al., 1999; KAHLKE et al., 2004]. 
Although there has been much focus on the potential detrimental role 
of inflammatory cytokines in sepsis, other mediators including arachidonic 
acid-derived eicosanoids, reactive oxygen species, nitric oxide and adhesion 
molecules are involved in the pathological processes that accompany critical 
illness. Prostaglandin (PG) E2 is implicated in sepsis, burns and critical illness 
[GRBIC et al., 1991; Ertel et al., 1992], while leukotriene (LT) B4 and oxidants 
released by neutrophils are involved in acute respiratory distress syndrome 
[see KOLLEF, SCHUSTER, 1995].
In addition to hyperinflammation, patients with sepsis also display 
immunosuppression [MEAKINS et al., 1977; LEDERER et al., 1999; KAHLKE et al., 2004]. 
There are reports that septic patients have high circulating concentrations of the 
anti-inflammatory cytokine IL-10 and that these are strongly correlated with 
mortality [O’SULLIVAN et al., 1995; OPAL, DEPALO, 2000]. Note that this is contrary to the 
predicted effect of IL-10 since this cytokine down-regulates TNF-α production and 
its early administration is protective in murine endotoxemia [GERARD et al., 1993; 
HOWARD et al., 1993; SMITH et al., 1994]. However, the apparently harmful effect of 
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IL-10 may relate to the timing of its production. Lymphocytes from patients with 
burns or trauma produce low levels of the T helper (Th) 1-type cytokines (e.g. 
interferon (IFN)-γ) associated with host defence against bacteria and viruses but 
high levels of the Th2- and Treg-type cytokines (IL-4, IL-10) associated with inhibition 
of host defence against bacteria and viruses [O’SULLIVAN et al., 1995; LEDERER et al., 
1999]. There also appears to be decreased monocyte expression of human 
leukocyte antigens (HLA) [HERSHMAN et al., 1990; WAKEFIELD et al., 1993; ASTIZ et al., 1996; 
MANJUCK et al., 2000], the proteins involved in antigen presentation to T cells, and 
this is associated with impaired ability of monocytes to stimulate T cells [MANJUCK et 
al., 2000]. Interestingly, IL-10 downregulates both Th1-type cytokine production and 
HLA expression [MUNOZ et al., 1991; BRANDTZAEG et al., 1996] and this might be the 
origin of the harmful effect of this cytokine in septic patients. Recent studies have 
revealed impaired proliferative or secretory functions of T cells from patients with 
sepsis, trauma or burns [HEIDECKE et al., 1999; PELLEGRINI et al., 2000]. 
The traditional view is that the immunosuppressed phase of septic 
syndromes lags behind the hyperinflammatory phase (Figure 7.2) i.e. initially 
sepsis is characterised by increased generation of inflammatory mediators (the 
systemic inflammatory response syndrome) but as it persists there is a shift 
towards an anti-inflammatory, immunosuppressed state sometimes called the 
compensatory anti-inflammatory response syndrome. However some recent 
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Figure 7.2  —   Hypothetical biphasic immunoinflammatory response to a traumatic insult. IL, 
interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor. 
Reprinted from P.C. CALDER. n-3 fatty acids, inflammation and immunity – 
relevance to postsurgical and critically ill patients. Lipids 2004; 39: 1147-
1161, with permission from the American Oil Chemists’ Society.
studies challenge this and suggest that the hyperinflammatory and 
immunosuppressed states co-exist. Some authors report that immunosuppression 
is present at the onset of sepsis [HEIDECKE et al., 1999; WEIGHARDT et al., 2000; 
TSCHAIKOWSKY et al., 2002], rather than being a later compensatory response. For 
example, TSCHAIKOWSKY et al. [2002] identified that significantly decreased monocyte 
expression of HLA-DR was evident at the onset of severe sepsis in post-surgical 
patients; in survivors there was some recovery of expression but in non-survivors 
there was a further decrease or even a permanent suppression of HLA-DR 
expression. These authors identified that the timing of the peak of the systemic 
inflammatory reaction (identified as the time of maximum C-reactive protein 
concentration) coincided with the timing of the lowest monocyte expression of 
HLA-DR. From this they concluded that decreases in monocyte HLA-DR expression 
occur simultaneously with “signs of hyperinflammation” and as early as the onset 
of severe sepsis [TSCHAIKOWSKY et al., 2002].
Thus, it appears that immune cells and cytokines have both detrimental and 
protective roles in patients as they move through the stages of sepsis. However, the 
traditional view that hyperinflammation precedes immunosuppression, as shown 
in Figure 7.2, may be a simplification of the real situation and this increases the 
challenge to finding interventions that might benefit high risk patients.
7-2  Potential relevance
of long chain n-3 fatty acids
to immuno-inflammatory responses 
in post-surgical and critically
ill patients
The anti-inflammatory actions of long chain n-3 fatty acids (Section 5; 
Table 5.1) may be of benefit in sepsis, particularly during the “early” 
hyperinflammatory phase. For example, studies using the isolated, perfused 
rabbit lung have identified contrasting effects of arachidonic acid- and EPA-
derived eicosanoids on inflammatory responses. Infusion of Escherichia coli 
hemolysin caused hypertension mediated by thromboxane (TX) B2 and increased 
vascular leakage mediated by 4-series LTs [GRIMMINGER et al., 1997a]. Inclusion of 
arachidonic acid in the perfusate increased TXB2 and 4-series LT generation, 
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arterial pressure and vascular leakage [GRIMMINGER et al., 1997a,b]. In contrast, 
inclusion of EPA in the perfusate decreased TXB2 and 4-series LT generation, 
decreased arterial pressure and vascular leakage and increased generation of 
TXB3 and 5-series LTs [GRIMMINGER et al., 1997a]. Perfusion with fish oil attenuated 
the hypertension induced by calcium ionophore [BREIL et al., 1996]. Compared 
with soybean oil infusion, fish oil decreased the concentration of LTC4 by 50% 
and increased the concentration of LTC5 from barely detectable to very similar 
to that of LTC4 [BREIL et al., 1996]. A number of benefits of fish oil in animal 
models of experimental endotoxemia have also been demonstrated, including 
diminished metabolic perturbations [POMPOSELLI et al., 1990, 1991; TEO et al., 1991], 
improved heart and lung function and decreased lung oedema [MURRAY et al., 
1993, 1995, 2000; MANCUSO et al., 1997a,b; SANE et al., 2000] (Table 7.1). These 
metabolic improvements and maintenance of organ function may relate to the 
reported decreased circulating concentrations of inflammatory eicosanoids 
(PGE2, TXB2, 6-keto-PGF1α) [UTSUNOMIYA et al., 1994; SANE et al., 2000] and cytokines 
[SADEGHI et al., 1999]. The real evidence of benefit comes from mortality studies 
that show that dietary fish oil or fish oil infused intravenously significantly 
enhances survival of guinea pigs to intraperitoneal endotoxin compared with 
safflower oil [MASCIOLI et al., 1988, 1989] (Figure 7.3). 
In addition to effects on production of inflammatory eicosanoids and 
inflammatory cytokines, long chain n-3 PUFAs also exert effects on cell-mediated 
immunity [see CALDER, 2001; CALDER et al., 2002 for reviews]. Large amounts of fish oil 
in the diet of laboratory animals have been reported to exert immunosuppressive 
effects [e.g. YAQOOB et al., 1994a,b; SANDERSON et al., 1995, 1997]. Clearly such effects 
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Table 7.1  —   Summary of the effects of dietary fish oil on  responses to endotoxin in 
experimental animals.
Response Effect of fish oil
Fever Decrease
Anorexia Decrease
Weight loss Decrease
Acidosis Decrease
Hypotension Decrease
Impaired heart function Improve 
Impaired lung function Improve 
Lung oedema Decrease 
Circulating inflammatory mediators Decrease 
Impaired bacterial killing Improve 
Death Decrease
are to be avoided in patients with, or at risk of, sepsis. However it is the effects of 
lower amounts of long chain n-3 fatty acids that are of relevance to that setting and 
these effects appear to be limited. In fact a recent study reported that enhanced T 
cell responses (proliferation and IFN-γ production) occur at modest doses so long 
as antioxidants are also given [TREBBLE et al., 2003]. In terms of sepsis, the true test of 
immunocompetence occurs when live pathogens are administered. This is a 
different situation from using endotoxin which is not living and which therefore 
does not require a robust cell-mediated immune response to eliminate it. As 
indicated above, it is clear that long chain n-3 fatty acids protect against the 
deleterious effects of endotoxin. The same appears to be true for many live 
pathogens. Infusion of fish oil into rats also receiving low-dose endotoxin decreased 
the number of viable bacteria in mesenteric lymph nodes and liver [PSCHEIDL et al., 
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Figure 7.3  —   Effect of intravenous fish oil on survival to endotoxin in guinea pigs. 
Male Hartley guinea pigs received infusions of either safflower oil or fish oil (10% 
vol) for two days. Then endotoxin (0.35 mg/100 g body weight) was given 
intraperitoneally. Survival was monitored over 4 days. 
Data are redrawn from E.A. MASCIOLI, L. LEADER, E. FLORES, S. TRIMBO,
B. BISTRIAN, G. BLACKBURN. Enhanced survival to endotoxin in guinea pigs fed iv fish 
oil emulsion, Lipids 1988; 23: 623-625, with permission from the American Oil 
Chemists’ Society.
2000]. Fish oil did not decrease bacterial translocation across the gut and so the 
authors concluded that fish oil must have improved bacterial killing. Compared 
with linoleic acid-rich vegetable oils, fish oil fed to rats prior to exposure to live 
bacteria [BARTON et al., 1991; RAYON et al., 1997] resulted in increased survival, which 
was associated with decreased production of PGE2. More recently infusion of fish 
oil after induction of sepsis by cecal ligation and puncture decreased mortality (and 
PGE2 production) compared with vegetable oil [LANZA-JACOBY et al., 2001]. Intragastric 
administration of fish oil into chow-fed rats prior to cecal ligation and puncture 
improved survival compared with saline or vegetable oil infusion [JOHNSON et al., 
1993]. Thus, the picture that emerges from a range of animal studies is that 
administration of long chain n-3 fatty acids in the form of fish oil increases survival 
upon exposure to live pathogens. From this it can be inferred that host immune 
defences are likely to have been improved by long chain n-3 fatty acids. Interestingly 
several studies have focussed upon the fish oil-induced decrease in PGE2 production 
as being a key mechanistic effect, suggesting that the immunosuppressive effect of 
PGE2 generated in response to infection might be deleterious to host survival.   
7-3  Studies of long chain n-3 fatty 
acids in surgical patients
7-3-1  Introductory comments
Surgery is typically accompanied by an inflammatory response that may be 
exaggerated in some patients, especially if the surgery is major. If the patient is 
exposed to pathogenic organisms and is unable to cope with these, then sepsis may 
develop. Artificial nutrition is frequently used post-surgery and this may involve 
parenteral (i.e. intravenous) infusions, especially where the gastrointestinal tract is 
not fully functional (e.g. post abdominal surgery). Lipids are included in parenteral 
nutrition to provide an alternative source of calories to glucose and the lipid source 
used most frequently has been soybean oil, which is rich in the n-6 fatty acid linoleic 
acid, although it also contains a proportion of α-linolenic acid. A meta-analysis of 
total parenteral nutrition suggested that inclusion of lipids might be detrimental (P 
= 0.09 for lipids vs. no lipids) [HEYLAND et al., 1998], at least in very ill patients. It is not 
clear why this is, although a number of in vitro experiments have shown that 
soybean oil-based lipid emulsions can exert immunosuppressive effects [see 
CALDER et al., 1994 for references], which would clearly be detrimental in patients at 
risk of infection and sepsis. Clinical trials provide conflicting evidence some 
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showing some immunosuppressive effects [BATTISTELLA et al., 1997; FURUKAWA et al., 
2002] and others not [GOGOS et al., 1990; SEDMAN et al., 1991; LENSSEN et al., 1998], at 
least in some patient groups. The concern about potential harm, the view of sepsis 
as a hyperinflammatory state followed by an immunosuppressed state (Figure 7.2), 
and the idea that n-6 fatty acids might be “pro-inflammatory and immunosuppressive” 
has lead to the development of alternative lipid emulsions for parenteral 
applications. Emulsions using a mix of medium-chain triglycerides and soybean oil 
or based upon olive oil instead of soybean oil have been developed, but these will 
not be discussed here. However, of relevance to the present discussion is the 
development of emulsions that include fish oil as a partial replacement for soybean 
oil. Several such emulsions have been tested in surgical patients.
7-3-2  Parenteral n-3 fatty acids
Intravenous infusion of a lipid emulsion containing fish oil for 5 days into 
patients who had undergone major abdominal surgery resulted in much higher 
LTC5 production by blood leukocytes stimulated ex vivo at 6 days postoperation 
[MORLION et al., 1996]. In another study, patients who had undergone abdominal 
surgery received soybean oil or a mix of medium-chain triglycerides, soybean 
oil and fish oil (50:40:10 vol:vol:vol) for 5 days post-surgery [KOLLER et al., 2003]. 
Leukocytes from these patients produced more LTB5 and LTB5-isomers at 
postoperative days 6 and 8. Patients who had undergone major gastrointestinal 
surgery received a medium-chain triglyceride-soybean oil mix (50:50 vol:vol) or 
a mix of medium-chain triglycerides, soybean oil and fish oil (50:30:20 vol:vol:vol) 
for 5 days post-surgery [WACHTLER et al., 1997]. Patients receiving fish oil got 3 g 
(days 1 and 2) and 6 g (days 3, 4 and 5) long chain n-3 fatty acids per day. 
Neutrophils from these patients produced less LTB4 and more LTB5 at 
postoperative days 6 and 10. Plasma TNF-α concentrations were lower in the fish 
oil group at day 6, while plasma IL-6 concentrations were lower at day 10. The 
study did not report clinical outcomes. A more recent study infused a fish oil-
rich formula on the day before abdominal surgery and on days 1 to 5 following 
abdominal surgery [WEISS et al., 2002]. On days 4 and 5 the patients also received 
standard total parenteral nutrition which included 50 g fat/day. TNF-α production 
by endotoxin-stimulated whole blood tended to be lower at postoperative day 
5 in the fish oil group, but this was not significant. Serum IL-6 concentrations 
were significantly lower at days 0, 1 and 3 in the fish oil group. Monocyte 
expression of HLA-DR was preserved in the fish oil group but declined at 
postsurgery days 3 and 5 in the control group. No differences in infection rates 
or mortality were observed. However postoperative stay in intensive care 
tended to be shorter in the fish oil group (4.1 vs. 9.1 days) as did total hospital 
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stay (17.8 vs. 23.5 days), although neither of these was a significant effect. 
Postoperative stay on medical wards was significantly shorter in the fish oil 
group. Another recent study compared the effects of lipid-free total parenteral 
nutrition or parenteral nutrition including 10% soybean oil or 8.3% soybean oil 
plus 1.7% fish oil for 5 days after large bowel surgery [SCHAUDER et al., 2002]. 
There were no differences between the groups with respect to the numbers of 
circulating lymphocytes, B cells, CD4+ cells, CD8+ cells or natural killer cells 
before surgery or at days 3 and 6 postsurgery, although these were affected by 
surgery itself. There were no differences between groups with respect to T 
lymphocyte proliferation, but IL-2 production was increased in the fish oil 
group and the postsurgery decline in IFN-γ production was prevented by fish 
oil. These studies indicate that inclusion of fish oil in parenteral nutrition 
regimens for gastrointestinal surgical patients modulates generation of 
inflammatory eicosanoids [MORLION et al., 1996; WACHTLER et al., 1997; KOLLER et al., 
2003] and cytokines [WACHTLER et al., 1997; WEISS et al., 2002] and may help to 
counter the surgery-induced declines in antigen presenting cell activity [WEISS 
et al., 2002] and T cell cytokine production [SCHAUDER et al., 2002]. Importantly 
these studies do not reveal deleterious immunologic effects of fish oil infusion 
in these patients. Furthermore, the only one of these fairly small studies to have 
examined hard endpoints like length of hospital stay suggests some clinical 
benefit from fish oil infusion in these patients [WEISS et al., 2002]. However, 
larger studies are required to evaluate the effects of this approach on 
complication rates, hospital stay and mortality. A very recent report from a 
larger cohort of patients receiving parenteral nutrition post-surgery does 
indicate benefit of inclusion of fish oil in the regimen [TSEKOS et al., 2004]. 
Patients received fish oil post-operatively and controls received a 50:50 medium-
chain triglyceride-soybean oil mix. There were no differences between the two 
groups with respect to the proportions of patients who died or developed 
wound infections or with respect to length of hospital stay. However the 
proportion of patients who were readmitted to intensive care was significantly 
lower in the fish oil than in the control group. A group of patients also received 
the fish oil containing emulsion for two days preoperatively. Here there were a 
number of significant benefits, including decreased need for mechanical 
ventilation, a shorter length of hospital stay, less need for readmission to 
intensive care and lower mortality. This study demonstrates a benefit from the 
inclusion of long chain n-3 fatty acids in parenteral nutrition regimens used in 
abdominal surgery patients. However it also demonstrates a much greater 
benefit if the fatty acids are additionally provided pre-surgery, which, of course, 
is only possible in elective surgery. The greater benefit of preoperative infusion 
of long chain n-3 fatty acids may relate to better incorporation of the fatty acids 
into leukocytes and other tissues.  
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7-3-3  Enteral n-3 fatty acids
Enteral nutrition is an alternative form of artificial nutrition. It describes 
provision of nutrients directly into the gastrointestinal tract via a tube and is 
sometimes referred to as “tube feeding”. Enteral nutrition is used in patients with 
a functional gastrointestinal tract and is considered preferential to parenteral 
nutrition. The influence of enteral feeds including long chain n-3 fatty acids in 
their composition has been examined in surgical patients, generally in those who 
have undergone surgery to remove cancerous regions of the intestine. These 
studies have frequently used an enteral formula named Impact® which contains 
arginine, long chain n-3 fatty acids, and nucleotides, each of which is lacking from 
control formulas. Thus, any effects observed cannot be ascribed to a particular 
component of Impact®. The effects of Impact® on immuno-inflammatory outcomes 
in surgical patients have been widely examined [DALY et al., 1992; 1995; KEMEN et al., 
1995; SENKAL et al., 1995; SCHILLING et al., 1996; BRAGA et al., 1996; 1999; GIANOTTI et al., 
1999]. Overall it appears that Impact® exerts anti-inflammatory and immune 
enhancing effects in surgical (or at least gastrointestinal surgical) patients. Several 
of these studies report significantly improved clinical outcomes related to lower 
infection rate [DALY et al., 1992; 1995; BRAGA et al., 1996; 1999] and decreased length 
of hospital say [DALY et al., 1995; BRAGA et al., 1996; 1999]. Studies of Impact® and 
similar enteral formulas investigating clinical outcomes in post-surgical patients 
have been subject to meta-analyses [HEYS et al., 1999; BEALE et al., 1999; HEYLAND et 
al., 2001], which conclude that this approach to enteral nutrition significantly 
decreases infectious complications and length of hospital stay in elective surgery 
patients. It is possible that the modulation of inflammation and the improvements 
in immune function reported in these patients receiving Impact® contribute to the 
improved clinical outcomes. However, it is not possible to ascribe these benefits 
to long chain n-3 fatty acids. 
7-4  Studies of long chain n-3 fatty acids
in critically ill patients
Critically ill patients frequently require artificial support depending 
upon the extent of organ damage or failure and this will include nutritional 
support. The influence of enteral feeds including long chain n-3 fatty acids has 
been examined in critically ill patients; again many of these studies have 
involved Impact®. A study in intensive care unit patients (a mix of trauma, 
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sepsis and major surgery patients) reported that Impact® resulted in higher T 
cell proliferation at days 3 and 7 [CERRA et al., 1990], while a study of severe 
trauma patients reported greater HLA-DR expression at day 7 [WEIMANN et al., 
1998]. These studies did not report improvements in clinical outcomes. 
However, other such studies have reported on clinical outcomes and have 
been subject to meta-analysis [HEYS et al., 1999; BEALE et al., 1999; HEYLAND et al., 
2001]. The most recent of these concluded that this approach to enteral 
nutrition decreases length of hospital stay but has no effect on infectious 
complications or mortality in critically ill patients [HEYLAND et al., 2001]. 
A trial performed in patients with moderate and severe acute respiratory 
distress syndrome used an enteral preparation that differed mainly in lipid source 
from the control [GADEK et al., 1999]. The control group of patients received a 
formula where the lipid source was 97% corn oil plus 3% soy lecithin. The 
experimental group received a lipid source that was 32% canola oil, 25% medium-
chain triglycerides, 20% borage oil, 20% fish oil and 3% soy lecithin. The 
experimental formula also contained more vitamin C and vitamin E than the 
control and it contained β-carotene, taurine and carnitine, which the control 
formula did not. Patients receiving the experimental formula got about 7 g EPA, 3 
g DHA, 6 g γ-linolenic acid, 1.1 g vitamin C, 400 IU vitamin E and 6.6 mg β-carotene 
per day for 6 days. By 4 days the numbers of total leukocytes and of neutrophils 
in the alveolar fluid declined significantly in the experimental group and were 
lower than in the control group. Arterial oxygenation and gas exchange were 
improved in the experimental group. Clinical outcomes from the study are shown 
in Table 7.2. It is clear that there was substantial clinical improvement with a trend 
towards decreased mortality with the n-3 PUFA containing formula. More recently, 
new data from this study have become available [PACHT et al., 2003]. Patients 
receiving the experimental formula had significantly lower concentrations of IL-8 
in their alveolar fluid and tended to have lower concentrations of LTB4 and TNF-α. 
It is possible that the lower concentrations of LTB4 and IL-8, both of which are 
potent leukocyte chemoattractants, may have been responsible for the lower 
neutrophil infiltration reported in the experimental group, and indeed neutrophil 
counts were significantly associated with these concentrations. This study 
establishes that the experimental treatment decreases production of inflammatory 
mediators and infiltration of inflammatory leukocytes and that this can result in 
significant clinical improvement in extremely ill patients. Because of the many 
differences in composition between the experimental and control formulas used 
it is not possible to ascribe the effects and benefits to any particular nutrient. 
However the effects upon LTB4, IL-8 and TNF-α concentrations are consistent with 
effects of long chain n-3 fatty acids reported elsewhere (see Section 5).
164
OMEGA-3 FATTY ACIDS: THE GOOD OIL?
Recently data from studies using parenteral nutrition with fish oil in sepsis 
patients have become available. Patients received a standard soybean oil-based 
emulsion or an emulsion containing fish oil for 5 [MAYER et al., 2003a] or 10 [MAYER 
et al., 2003b] days. Blood leukocyte counts and serum C-reactive protein 
concentration tended to be lower and production of LTB5 by stimulated 
neutrophils was significantly higher in patients receiving long chain n-3 fatty 
acids [MAYER et al., 2003]. Production of TNF-α, IL-1β, IL-6, IL-8 and IL-10 by 
endotoxin-stimulated mononuclear cells did not increase during infusion of the 
fish oil containing emulsion whereas production of the four pro-inflammatory 
cytokines was markedly elevated during the first two days of soybean oil infusion 
[MAYER et al., 2003a]. These studies establish that infusion of long chain n-3 fatty 
acids into patients with sepsis can modulate inflammatory mediator production 
and related inflammatory processes. However, the impact of this on hard clinical 
outcomes in these patients is not yet clear.
7-5 Conclusions
Because long chain n-3 PUFAs are potentially useful anti-inflammatory 
agents they may be of benefit in patients at risk of developing sepsis. An 
emerging application of n-3 PUFAs is in surgical or critically ill patients where 
they may be added to parenteral or enteral formulas. There appear to be no 
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Table 7.2  —   Effect of an enteral formula containing long chain n-3 PUFAs on clinical 
outcomes in adults with acute respiratory distress syndrome.
Outcome Control formula n-3 PUFA   
  containing formula
Number of patients evaluated 47 51 
Time on supplemental oxygen (days) 20.2 15.8
Time on ventilator (days) 16.3 11.0 
Length of ICU stay (days) 17.5 12.8 
Length of hospital stay (days) 34.6 29.4 
New organ failures (%) 28 8 
Mortality (%) 19 12 
Adults with acute respiratory distress syndrome received a standard enteral formula or an 
experimental formula containing long chain n-3 PUFAs and a number of other ingredients 
(see text) for 4 to 7 days. 
Data are from GADEK et al. [1997]. Abbreviations used: ICU, intensive care unit; PUFA, 
polyunsaturated fatty acid.
adverse effects of inclusion of long chain n-3 PUFAs in such formulas. Indeed, 
parenteral or enteral nutrition including n-3 PUFAs preserves immune function 
better than standard formulas and partly prevents some aspects of the 
inflammatory response. Studies to date are suggestive of clinical benefits from 
these approaches, especially in post-surgical patients. However, more and 
bigger studies are required before the clinical benefit of n-3 PUFAs in these 
settings can be accepted with certainty. The contribution that n-3 PUFAs make 
to the benefits of enteral nutrition will remain unclear because experimental 
formulas have several important differences from control formulas. 
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